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Abstract 
 
ATP-sensitive potassium channels (KATP) open in response to metabolic 
challenge. They form of pore subunits (Kir6.1 or Kir6.2) and modulatory 
subunits (SUR1, SUR2A or SUR2B) and are ubiquitously expressed. 
Differential subunit composition between cardiac chambers was investigated, 
as were atrial anti-arrhythmic effects of KATP modulation. 
 
Selective pharmacology of KATP openers and inhibitors was confirmed in a 
heterologous expression system through whole-cell patch clamp. Isolated HL-1 
cells (a murine atrial cardiomyocyte model) and murine atrial cardiomyocytes 
showed identical KATP pharmacological responses representing Kir6.2/SUR1 
channels. Relative quantification of murine whole atrial RNA concurred, and 
was distinct from the ventricles (Kir6.2/SUR2). Human whole heart RNA from 
normal hearts exhibited a different pattern with no obvious chamber specificity. 
 
Kir6.1-/- and Kir6.2-/- mice demonstrated that both pore types contribute to 
electrophysiological parameters in isolated atrial cardiomyocytes, but Kir6.2 
appears more important. In atrial tissue (Langendorff hearts), Kir6.2-/- more 
than Kir6.1-/- mice demonstrated increased effective refractory periods and 
reduced conduction velocity at baseline, and during hypoxia, compared to 
wildtype. A trend to reduced arrhythmogenicity was observed during 
programmed electrical stimulation in the Kir6.2-/- mouse. 
 
In syncytia of spontaneously beating HL-1 cells, KATP activation with diazoxide 
was met with rotational to uniform wavefront organisation and silencing of 
electrical activity in a dose-dependent manner, reversed with channel blockade. 
In Langendorff mouse hearts KATP inhibition reversed hypoxia induced slowing 
of spontaneous sinus node activation, but pharmacological activation alone did 
not, suggesting different mechanisms with hypoxic channel activation. 
 
Thus, both pore subunits contribute to the cardiac electrophysiology of murine 
atria, but Kir6.2 appears more important. HL-1 cells exhibit identical KATP 
pharmacology to murine atrial myocytes, which have a differential subunit 
composition compared to the ventricle. Any human cardiac KATP differential 
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subunit expression needs further exploration. KATP activation and inhibition have 
anti-arrhythmic effects and this might be explored further clinically. 
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PIP2 Phosphatidylinositol-4,5-bisphosphate 
PKA Protein Kinase A 
PKC Protein Kinase C 
PNU PNU37883A 
PP-1 Protein-phosphatase 1 
PV Pulmonary vein 
PVI Pulmonary vein isolation 
qRT-PCR Quantitative real-time reverse transcriptase polymerase chain 
reaction 
RA Right atrium 
RV Right ventricle 
RyR Ryanodine receptor 
SAN Sino-atrial node 
SCN1B Gene encoding the sodium channel auxiliary subunit β1 
SCN2B Gene encoding the sodium channel auxiliary subunit β2 
SCN3B Gene encoding the sodium channel auxiliary subunit β3 
SCN5A Gene encoding the sodium channel pore-forming subunit 
Nav1.5 
SERCA Sarcoplasmic reticulum calcium transport ATPase 
SR Sarcoplasmic reticulum 
SUR1 Adenosine triphosphate-sensitive potassium channel 
sulphonylurea receptor subunit 1 
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SUR2A Adenosine triphosphate-sensitive potassium channel 
sulphonylurea receptor subunit 2 splice variant 2A 
SUR2B Adenosine triphosphate-sensitive potassium channel 
sulphonylurea receptor subunit 2 splice variant 2B 
t1/2 Time to half maximum activation 
TASK-1 Suggested inward leak potassium channel 
TdP Torsades de Pointes 
TMD Transmembrane domain 
TOLB Tolbutamide 
UEGM Unipolar electrogram 
V1/2 Potential at which activation reaches half-maximum 
VF Ventricular fibrillation 
Vh0.5 Membrane potential at which 50% of channels are inactivated 
Vj1/2 Transjunctional voltage gradient of half maximal 
activation/inactivation  
Vm Membrane potential 
Vmax Action potential phase 0 maximum upstroke velocity 
VT Threshold voltage for activation 
WFPL Minimum wavefront path length 
WT Wild-type mouse 
α1 Alpha adrenergic receptor 1 
β1 Beta adrenergic receptor 1 
τa Exponential time constant of activation 
τd Exponential time constant of deactivation 
τ i Exponential time constant of inactivation 
τ rec Exponential time constant of recovery from inactivation 
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Section 1: Introduction 
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1.1 The Human Cardiac Action Potential and Excitation-
Contraction Coupling 
 
1.1.1 The Action Potential 
 
Contraction of the myocardium and the action of the heart as a pump requires 
the flow of various ionic currents in and out of cardiomyocytes. The rhythmic 
beating of the heart requires the propagation of these currents from groups of 
cells in one region, conducted to groups of cells in neighbouring and distant 
regions. The currents are carried by sodium (Na+), calcium (Ca2+) and 
potassium (K+) ions through pores called ion channels in the membranes of 
cardiomyocytes. Ionic flow is dependent on an electrochemical gradient defined 
by their concentrations on either side of the cell membrane (diffusion) and the 
potential difference across the membrane at any particular moment, exerting an 
electromotive force on the ion. The equilibrium potential (or reversal potential) 
for an ion (Ei), is the potential difference across the membrane, that results in 
no flow of that particular ion given the concentrations of it either side of the 
membrane (discussed in more detail in section 2.7.1 on patch clamp 
electrophysiology). If the membrane potential of the cell (Vm) is more positive to 
Ei for a given cation, then that cation will carry outward current (assuming a 
permeable ion channel is open) and the opposite is true if the membrane 
potential of the cell is more negative to Ei. Ultimately, it is the depolarisation of a 
cardiomyocyte where the cytoplasmic face of the cell membrane is transformed 
at rest from a negative potential difference relative to the extracellular face, to 
that of a positive one by inward Na+ and Ca2+ ions, and the binding of Ca2+ to 
intracellular myofilaments, that cause the cell to contract. The cell must then be 
able to relax again and repolarise ready for the next beat and this requires the 
extrusion of Na+ and Ca2+ ions, the re-sequestration of Ca2+ ions back into the 
sarcoplasmic reticulum (SR), and the outward flow of potassium ions. This 
process is what constitutes the action potential and excitation-contraction 
coupling. The classic cardiac action potential in large mammals consists of 4 
phases (see Figure 1.1). 
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Action Potential Phase 0 
 
The upstroke of the action potential is produced by the inward sodium current 
(INa). Cardiac sodium channels are voltage-gated and composed of an α pore-
forming subunit and either 1 or 2 β (regulatory) subunits (Nerbonne & Kass, 
 
Figure 1.1 The human cardiac action potential (taken from Nerbonne & 
Kass, 2005). Schematic showing a comparison of action potentials of human 
ventricular (left) and atrial (right) myocytes, and the ionic currents that 
produce them. Downward shading denotes inward current, and upward 
shading outward current. INa, inward sodium current; ICa,L, L-type inward 
calcium current; Ito,f, transient outward potassium current fast recovery 
component; Ito,s, transient outward potassium current slow recovery 
component; IKs, slowly activating delayed rectifier potassium current; IKr, 
rapidly activating delayed rectifier potassium current; IKur, ultra-rapidly 
activating delayed rectifier potassium current; IK1, inward rectifier potassium 
current; IKATP, ATP-sensitive potassium channel current; IK,slow1, IK,slow2, Iss are 
delayed recifier currents expressed in murine cardiomyocytes that are absent 
in human cardiomyocytes. See also figure 1.13 for comparison with murine 
currents. 
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2005). The α subunit consists of four domains each with six transmembrane-
spanning regions and the predominant cardiac α subunit across species is 
Nav1.5 encoded by the SCN5A gene (Fozzard, 2002; Nerbonne & Kass, 2005). 
Three β subunits Navβ1, Navβ2 and Navβ3 encoded by SCN1B, SCN2B and 
SCN3B respectively contribute to the expression and trafficking of the channel 
to the sarcolemma and its voltage-gating (Nerbonne & Kass, 2005). Based on 
Hodgkin and Huxley's original model of ion channel gating it can be said that 
sodium channels have both activation and inactivation gates (Hodgkin & 
Huxley, 1952). Nav1.5 containing channels have very fast activation kinetics 
with a time to half maximal activation at 20oC (t1/2) of ~0.8ms, a threshold 
voltage for activation (VT) of ~-55mV and a voltage producing half maximal 
conductance (V1/2) of ~-50mV (Ulbricht, 2005). This is followed by fast voltage-
dependent inactivation with an exponential time constant (τi) of the rapid 
component of inactivation at Vm=+20mV of ~0.4ms, before fast recovery from 
this inactivation with a time constant (τrec) at Vm=-100mV of ~40ms and 
deactivation at Vm=-60mV back to the resting state of both gates during 
repolarisation (Nerbonne & Kass, 2005; Ulbricht, 2005; Armstrong, 2006; 
Mangold et al., 2017). Estimates suggest that at membrane potentials 
corresponding to the plateau phase ~+10mV (phase 2) of the action potential in 
ventricular myocytes, ~99% of the sodium channels are inactivated (Nerbonne 
& Kass, 2005). Recovery from inactivation requires that the membrane potential 
becomes repolarised and the probability of recovery from inactivation increases 
as the membrane potential drops from the plateau potential (Ulbricht, 2005). 
Loss of function mutations in the Nav1.5 channel are thought to underpin, in 
part, the mechanisms behind the Brugada syndrome (Wilde et al., 2010; 
Kusano, 2013). Changes in ventricular depolarisation (slower phase 0, reduced 
peak amplitude in phase 0) and repolarisation and subsequent accentuated 
heterogeneous dispersion of action potential duration (APD) predisposes to 
triggered and re-entrant arrhythmia leading to polymorphic VT/VF and sudden 
death (Wilde et al., 2010; Kusano, 2013). 
 
Action Potential Phase 1 
 
The transient outward potassium currents (Ito) produce the “notch” and the early 
initial repolarisation of the action potential (Liu et al., 1993; Wettwer et al., 
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1994). These currents are part of a family of voltage-gated potassium channels 
activated by the depolarisation of the cell. Voltage-gated potassium channels in 
general, consist of a pore-forming α subunit composed of tetramers of six 
transmembrane domain proteins and associate with β subunits which contribute 
to the expression and trafficking of the channel to the sarcolemma and its 
voltage-gating (Nerbonne & Kass, 2005). Voltage-gated potassium channels 
are outwardly rectifying whereby pore opening on depolarisation of the 
cardiomyocyte leads to outward potassium current. The transient outward 
potassium current activates and inactivates quickly at membrane potentials 
positive to ~-30mV (Wettwer et al., 1994; Nerbonne & Kass, 2005). Two types 
of transient outward potassium current exist namely Ito,f (fast activation with time 
to peak activation ~10ms, fast inactivation τi ~60ms at Vm=+60mV, fast recovery 
kinetics τrec ~25ms at Vm=-100mV) and Ito,s  (fast activation and moderately fast 
inactivation with similar time constants to Ito,f, but slower recovery kinetics τrec 
~340ms) (Liu et al., 1993; Wettwer et al., 1994; Nerbonne & Kass, 2005). Ito has 
a narrow window current with a steady-state voltage dependence of inactivation 
such that the potential at which 50% of channels are inactivated (Vh0.5) is of the 
order of ~-30mV. Ito,f appears to consist of Kv4.3 α subunits encoded by KCND3 
and KChIP2 β subunits encoded by KCNIP2 probably in a 4:4 stoichiometry 
(Nerbonne & Kass, 2005). The α subunit of Ito,s is Kv1.4 encoded by KCNA4 but 
the β subunit is not well defined (Nerbonne & Kass, 2005). 
 
The voltage-gated IKur (ultra-rapid) current also contributes to phase 1 
repolarisation with very fast activation at VT ~-30mV and a time constant of 
activation (τa) of ~2ms at Vm=+50mV, but very slow inactivation kinetics and, 
essentially, does not functionally inactivate. For example current is reduced by 
only ~16% moving from Vm=-80mV to +40mV via a 1000ms pre-pulse to  -20mV 
(Wang et al., 1993; Ravens & Wettwer, 2011). It consists of Kv1.5 α subunits 
encoded by KCNA5 and associates with Kvβ1.2 and Kvβ1.3 β subunits 
encoded by splice variants of KCNAB1, and Kvβ2.1 subunits encoded by 
KCNAB2 (Nerbonne & Kass, 2005; Ravens & Wettwer, 2011). IKur appears to 
be expressed specifically in the atria (Ravens & Wettwer, 2011). 
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The sodium/potassium-ATPase pump (INa/K) extrudes Na+ and imports K+ with a 
stoichiometry of three Na+ ions to two K+ ions (Glitsch, 2001). It is activated by a 
high intracellular sodium concentration ([Na+]i) and/or a high extracellular 
potassium concentration ([K+]o) and given the stoichiometry of flux, produces an 
outward pump current of positive ions (Ip) (Glitsch, 2001). It contributes to 
repolarisation, the maintenance of a negative resting membrane potential and 
the maintenance of intra- and extracellular ion concentrations necessary for 
normal cellular function. It is constitutively active throughout the action potential.  
 
Action Potential Phase 2 
 
A balance of inward calcium and sodium currents, and outward potassium 
currents, produces the plateau phase. The depolarisation caused by INa 
activates voltage-gated calcium channels. Calcium channels, like sodium 
channels, are formed from an α subunit comprising 4 domains each with six 
transmembrane-spanning regions. Long-acting (L-type) calcium channels (ICaL) 
are high-voltage activating (HVA) opening rapidly (τa~2.3ms) at VT ~-20mV and 
are long-acting owing to a slow time-course of inactivation (τi~1s). They recover 
from inactivation over ~400ms at Vm=-80mV. They are the predominant current 
contributing to the classic atrial and ventricular myocyte action potential (Bean, 
1985; Hirano et al., 1989; Koschak et al., 2001; Nerbonne & Kass, 2005; 
Catterall, 2011). In the atria and ventricle they are formed of a Cav1.2 α subunit 
encoded by CACNA1C and the predominant cardiac accessory subunits 
Cavβ2, encoded by CACNB2, and Cavα2δ, encoded by CACNA2D1 which both 
contribute to the expression and trafficking of the channel to the sarcolemma 
and its voltage-gating (Nerbonne & Kass, 2005). ICaL in the sinus node is 
produced predominantly by channels with Cav1.3 subunits encoded by 
CACNA1D (Mangoni et al., 2003). They activate at more negative membrane 
potentials (VT~-45mV), more rapidly (τa~0.8ms), and inactivate more slowly 
(τi~1.7s) than Cav1.2 channels (Koschak et al., 2001). Cav1.3 channels also 
undergo the phenomenon of voltage dependent facilitation during recovery from 
inactivation at hyperpolarised potentials, post a depolarising pulse (Christel et 
al., 2012). These properties owing to Cav1.3 channels serve function to a 
pacemaking role in the sinus node as is discussed below. L-type calcium 
channels also undergo calcium-dependent-inactivation whereby their opening 
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and subsequent influx of calcium also promotes their inactivation (Bers, 2002; 
Catterall, 2011). 
 
Transient-acting (T-type) calcium channels (ICaT) are low-voltage activating 
(LVA) and open rapidly at VT ~-50mV. They are more densely expressed in the 
atria and pacemaker/nodal tissues contributing to automaticity, particularly in 
nodal tissues, and inactivate more rapidly than L-type channels with τi ~20ms at 
Vm=+10mV (Bean, 1985; Perez-Reyes, 2003; Nerbonne & Kass, 2005; 
Catterall, 2011). They recover from inactivation more slowly than L-type calcium 
channels ~800ms at Vm=-80mV (Hirano et al., 1989). They are formed of 
Cav3.1 and Cav3.2 α subunits encoded by CACNA1G and CACNA1H 
respectively and it appears that they are expressed at the sarcolemma in the 
absence of a β subunit (Perez-Reyes, 2003; Nerbonne & Kass, 2005). 
 
A small population of Nav1.5 sodium channels is slow to inactivate during 
phase 1 and phase 2 and this contributes a persistent late sodium current (INaL) 
to the plateau phase (Liu et al., 1993; Sakmann et al., 2000; Nerbonne & Kass, 
2005). The kinetics and voltage-dependency of inactivation and the degree of 
INaL are governed in part by the associated Nav β-subunit (Nerbonne & Kass, 
2005; Ulbricht, 2005). Mutations in Nav1.5 channels leading to increased INaL 
underpin heterogeneous action potential duration (APD) prolongation in Long-
QT syndrome 3 (LQT3) leading to triggered polymorphic VT/VF and sudden 
death (Schwartz et al., 2012). 
 
The sodium/calcium (Na/Ca) exchanger is constitutively active and is reversible 
with a stoichiometry of moving three Na+ ions to one Ca2+ ion (Blaustein & 
Lederer, 1999; Bers, 2002; Eisner & Sipido, 2004). As such when calcium is 
extruded from the cell there is a net inward positive current (INa/Ca), and the 
opposite is true when calcium enters the cell when INa/Ca is outward (reverse 
mode). The equilibrium potential of the Na/Ca exchanger is given by ENa/Ca = 
3ENa - 2ECa. During the early part of phase 2 the concentration of intracellular 
Na+ ([Na+]i) is high and the membrane potential is more positive to ENa/Ca and so 
INa/Ca is outward and calcium enters the cell in reverse mode (Bers, 2002). 
During the end of phase 2 the membrane potential drops below ENa/Ca and 
 31 
intracellular Ca2+ ([Ca2+]i) is high and so INa/Ca is inward and calcium is extruded 
(Bers, 2002). This is forward mode. 
 
Intracellular Ca2+ activates the ryanodine receptor (RyR) located in the 
sarcoplasmic reticulum (SR) membrane. In turn Ca2+ is released from the SR 
through the RyR in a process called calcium-induced-calcium-release (CICR) 
(Bers, 2002). Thus, whilst the Na/Ca exchanger may be in reverse mode with 
outward INa/Ca, the inward flow of Ca2+ through the exchanger can prolong the 
plateau phase through CICR at the SR (Bers, 2002). 
 
It is during phase 2 that there is high [Ca2+]i and Ca2+ binding to Troponin C 
causing the tropomyosin complex to move off the actin active site and allow the 
myosin head to bind actin. With ATP hydrolysis the myosin head then pulls the 
actin filament closer in towards the sarcomere for contraction (Bers, 2002; de 
Tombe, 2003; Gordan et al., 2015) (see Figure 1.2). 
 
Figure 1.2. Excitation-contraction coupling (taken from Bers, 2002). 
Schematic demonstrating the processes of excitation-contraction coupling 
and Ca2+ extrusion from the cytosol. The inset shows the time course of an 
action potential , Ca2+ transient and contraction measured, in this case, from 
a rabbit ventricular myocyte at 37oC. NCX, sodium-calcium exchanger; ATP, 
ATPase pump; PLB, phospholamban; SR, sarcoplasmic reticulum. 
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Outward potassium currents have been described for phase 1 namely the 
transient outward currents and IKur. Late in phase 2 activation of the rapid 
delayed rectifier potassium current IKr contributes to repolarisation. This current 
is produced by an outwardly rectifying voltage-gated potassium channel made 
up of hERG1 α subunits encoded by KCNH2 and, most likely, a MiRP1 β 
subunit encoded by KCNE2 (Nerbonne & Guo, 2002; Schram et al., 2002; 
Nerbonne & Kass, 2005). It activates moderately fast with a τa ~127ms whilst 
also inactivating and recovering from inactivation with fast kinetics (τi  ~4ms at 
Vm=0mV ; τrec ~8ms at Vm=-80mV) (Nerbonne & Kass, 2005; Vandenberg et al., 
2012). It deactivates very slowly with a time constant of deactivation (τd) of 
~300ms at Vm=-70mV (Vandenberg et al., 2012). Loss of function mutations in 
hERG underpin heterogeneous action potential duration (APD) prolongation in 
Long QT syndrome 2 (LQT2) leading to triggered polymorphic ventricular 
tachycardia (VT) / ventricular fibrillation (VF) and sudden death (Schwartz et al., 
2012). 
 
Action Potential Phase 3 
 
Repolarisation occurs when outward potassium currents predominate after 
inactivation of voltage-gated inward cation currents. In addition to IKur and IKr the 
slow delayed rectifier potassium current IKs contributes. This current is produced 
by an outwardly rectifying voltage-gated potassium channel made up of Kv7.1 α 
subunits encoded by KCNQ1 and a β subunit encoded by KCNE1 (Nerbonne & 
Kass, 2005; Tinker & Harmer, 2010). It activates very slowly over the order of 
seconds at positive membrane potentials (τa ~800ms) with no inactivation and 
deactivates slowly τd ~150ms (Gintant, 1995; Nerbonne & Kass, 2005; Tinker & 
Harmer, 2010). In the absence of KCNE1, activation is not attenuated and is 
fast (Nerbonne & Kass, 2005; Tinker & Harmer, 2010). Owing to slow activation 
kinetics and a lack of inactivation, IKs accumulates at higher heart rates and 
contributes to action potential shortening at short diastolic intervals (Volders et 
al., 2003). Loss of function mutations in KCNQ1 underpin heterogeneous action 
potential duration (APD) prolongation in Long-QT syndrome 1 (LQT1) leading to 
triggered polymorphic VT/VF and sudden death (Schwartz et al., 2012). 
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During phase 3 the Na/Ca exchanger is in its calcium extrusion mode owing to 
high [Ca+]i. The inward INa/Ca is unable to overcome the large repolarising 
potassium currents and the cell repolarises. Ca2+ dissociates from myofilaments 
and undergoes uptake back into the SR via the sarcoendoplasmic reticulum 
calcium transport ATPase (SERCA), an ATPase pump associated with the SR 
membrane protein phospholamban (Bers, 2002; de Tombe, 2003; Gordan et 
al., 2015). Ca2+ is also extruded via a Ca2+-ATPase pump at the sarcolemma 
and via uptake into mitochondria via the mitochondrial Ca2+ uniport (Bers, 
2002). In doing so the myofilaments relax back to their original Ca2+ unbound 
state. 
 
An inward rectifier potassium channel (see below 'Other Potassium Currents' for 
description) formed by a tetramer of Kir2.1 pore subunits encoded by KCNJ2 
produces the IK1 current (Nerbonne & Kass, 2005). It is constitutively active and 
non-voltage-gated as per the inward rectifier family (Hibino et al., 2010). It 
undergoes strong inward rectification (see below 'Other potassium currents') 
and contributes only a small outward potassium current between membrane 
potentials of ~-70mV and -30mV, and a larger inward potassium current at 
membrane potentials more negative to the equilibrium potential of potassium 
(EK) ~-80mV (Nerbonne & Kass, 2005; Hibino et al., 2010). It thus contributes to 
the end of repolarisation in phase 3 and helps set the resting membrane 
potential. 
 
Action Potential Phase 4 
 
Inward leak K+ currents which might represent TASK-1 channels encoded by 
KCNK3 cause very slow depolarisation of membrane potential in phase 4 of 
atrial and ventricular myocytes (Nerbonne & Kass, 2005; Tinker & Harmer, 
2010). Otherwise phase 4 is largely quiescent in these cells and the overall 
permeability to K+ ions, driven in large part by IK1, sets the resting membrane 
potential, and where the Na+/K+-ATPase pump ensures a chemical gradient for 
K+ ions. The hyperpolarisation-activated cyclic nucleotide-gated cation channel 
(HCN), encoded by HCN4, is expressed at high levels in sinoatrial nodal (SAN) 
and atrioventricular nodal (AVN) cells, and to a lesser degree in Purkinje fibre 
cells (Schram et al., 2002; Nerbonne & Kass, 2005; DiFrancesco, 2010). It is a 
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non-specific cation channel permeable to both sodium and potassium ions and 
activates at membrane potentials below ~-40mV (DiFrancesco, 2010). Owing to 
its permeability to sodium and potassium its reversal potential is ~-10mV and 
therefore carries inward current If where "f" denotes the "funny" current. It is 
named so given its activation at hyperpolarised membrane potentials, which 
was in stark difference to other ion channels known at the time of discovery in 
the late 1970s (DiFrancesco, 2010). The "funny" current is physiologically 
highest in density in SAN cells and therefore the rate of rise of the 
depolarisation slope is largest in SAN cells making them the predominant 
pacemaking cells in the heart (Schram et al., 2002; Lakatta & DiFrancesco, 
2009; DiFrancesco, 2010; Park & Fishman, 2011). 
 
Other Potassium Currents 
 
Two other members of the inward rectifier potassium channel family (along with 
Kir2.1, IK1) contribute to the cardiac action potential, namely the G-protein linked 
acetylcholine/adenosine activated potassium channel (GIRK), and ATP-
sensitive potassium channels (KATP). Inward rectifier potassium channels are 
characterised by a tetramer of pore-forming subunit proteins each with two 
transmembrane-spanning regions and a connecting H5 region homologous to 
that of the voltage-gated potassium channels that provides the K+-selectivity 
filter (see schematic for KATP channel Figure 1.10) (Hibino et al., 2010). Inward 
rectification is provided by a degree of block from the intracellular side of the 
pore by magnesium ions (Mg2+) and polyamines at membrane potentials more 
positive to their respective reversal potentials (Hibino et al., 2010). This serves 
to produce an overall greater inward channel conductance. However, given the 
channel selectivity for potassium, and that the membrane potential does not 
deviate grossly negative to EK, functionally these channels contribute more to 
repolarisation and membrane hyperpolarisation (Nerbonne & Kass, 2005; 
Hibino et al., 2010; Tinker & Harmer, 2010). GIRK and Kir2.1 channels show 
strong inward rectification and KATP channels weak inward rectification (Hibino 
et al., 2010). KATP channels therefore will produce relatively larger outward 
currents at more positive membrane potentials. Inward rectifier channels are not 
voltage-gated and are either constitutively open as in Kir2.1 channels, or open 
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in response to receptor-linked activation (GIRK) or changes in the metabolic 
environment (KATP) (Hibino et al., 2010). 
 
GIRK channels in the heart are formed by a tetramer of two Kir3.1 subunits, 
encoded by KCNJ3, and two Kir3.4 subunits, encoded by KCNJ5, and are 
expressed largely in the atria and sinus node (Nerbonne & Kass, 2005; Hibino 
et al., 2010; Tinker & Harmer, 2010). They are linked to G-inhibitory proteins 
(Gi) that are activated by M2 muscarinic receptors in the heart in response to 
the binding of acetylcholine, and A1 adenosine receptors activated by 
adenosine (Lerman & Belardinelli, 1991; Hibino et al., 2010). When activated, 
guanosine diphosphate (GDP) bound by the Gi-protein Coupled Receptor α 
subunit (Gαi) is released owing to confirmational change, and guanosine 
triphosphate (GTP), present in high concentration binds instead. This causes 
separation and activation of the two subunits Gαi and Gβγ of the G-inhibitory 
protein (Hibino et al., 2010). The Gβγ subunit then activates a linked potassium 
channel increasing its open probability (Hibino et al., 2010). Inactivation of Gi is 
through GTP hydrolysis to GDP. Owing to activation by acetylcholine and 
adenosine the current has been denoted IKACh,Ado. 
 
Kir2.1 channels (IK1) have been discussed previously and KATP channels will be 
discussed in greater detail in later sections. 
 
1.1.2 Depolarisation Propagation and Gap Junctions 
 
In a normal heart beat the rhythm is initiated in the sinus node located in the 
roof of the right atrium (RA) between the vena cavae. The depolarisation wave 
exits into the RA and propagates first through the RA. Propagation then moves 
to the left atrium (LA) and occurs directly via a collection of parallel fibres known 
as Bachmann's bundle which traverses from the RA superiorly and posteriorly 
across the interatrial roof and groove over to the LA and inserts into the lateral 
wall between the left atrial appendage (LAA) and the orifice of the left upper 
pulmonary vein (LUPV) (Ariyarajah & Spodick, 2006; van Campenhout et al., 
2013). The LAA is the last area of the atria to activate (Durrer et al., 1970; 
Ramanathan et al., 2006). The depolarisation wave then reaches the AV node 
that exerts a delay in conduction down through the His-Purkinje system that in 
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turn depolarises the ventricles. In this manner blood is first pumped from the 
atria into the ventricles during ventricular diastole and then from ventricles into 
the arterial circulation during ventricular systole. 
 
For heart rhythm and synchronisation to be under the control of pacemaker 
tissue, cardiomyocytes need to be coupled to allow propagation of waves of 
depolarisation through the heart. As cells in one region depolarise, this needs to 
initiate activation of the next group of cells. Cardiomyocytes are coupled at the 
intercalated disc by gap junctions that allow the flow of ions from one cell 
directly to another. This speeds up the propagation of the wave of 
depolarisation from one cell to another, and from one region to another. 
Evidence exists that gap junctions co-localise with Nav1.5 channels at the 
intercalated disc. This facilitates conduction as Na+ entry in one cell can then 
diffuse down its electrochemical gradient into a neighbouring cell thereby 
activating it (Rohr, 2004). Each cell contributes hemichannels or connexons to 
the junction and connexons are made up of 6 subunit connexins (Grant, 2009) 
(see Figure 1.3).  
 
 
Connexins have 4 transmembrane-spanning regions, cytosolic N- and C- 
termini and 2 extracellular loops making up the pore (Kanno & Saffitz, 2001).  
 
 
Figure 1.3. Connexon channel structure (taken from Kanno & Saffitz, 
2001). 6 subunit connexins make up a hemichannel connexon and 2 
connexons make up a gap junction channel. Various combinations of 
connexins are possible as indicated. 
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There are three major types connexin 40 (Cx40), connexin 43 (Cx43) and 
connexin 45 (Cx45) (Kanno & Saffitz, 2001). They each have different gating 
mechanisms being sensitive to changes in pH, voltage and Ca2+ and each have 
different unitary conductance (Ahir & Pratten, 2014). Cx43 is the most widely 
expressed in the heart and is relatively voltage insensitive with a transjunctional 
voltage gradient of half maximal activation/inactivation (Vj1/2) of ~+/-60mV and 
single channel conductance of ~50pS (Kanno & Saffitz, 2001; van Veen et al., 
2001). Cx40 is more voltage-sensitive, Vj1/2  ~+/-50mV, and has a larger unitary 
conductance ~100pS (van Veen et al., 2001; Ahir & Pratten, 2014). Cx45 has a 
lower unitary conductance ~30pS and is steeply voltage sensitive Vj1/2~+/-20mV 
(van Veen et al., 2001; Ahir & Pratten, 2014). Connexins contribute to 
anisotropy whereby conduction is favoured in a certain direction. This can be in 
part because of preferential voltage-sensitive gating. For example, connexins 
can form heterotypic channels at cell junctions (eg. a connexon made up of 
Cx40 followed in series by a connexon made up of Cx43 both embedded either 
side in the sarcolemma of separate cells). In such heterotypic channels it has 
been shown that Cx40 gates preferentially with positive polarity and Cx43 with 
negative polarity (Valiunas et al., 2000; Kanno & Saffitz, 2001). Conduction is 
facilitated when the Cx40 cell is depolarised and the Cx43 cell not (Valiunas et 
al., 2000; Kanno & Saffitz, 2001). Physiologically this can facilitate anterograde 
conduction from Purkinje fibres, with a predominant expression of Cx40, to 
ventricular myocytes with predominant expression of Cx43, and inhibiting 
retrograde conduction (Valiunas et al., 2000). Anisotropy also develops in the 
context of source-sink mismatch. If a smaller mass of excited tissue connects 
with a larger mass, and connexin expression is high between all the cells in that 
3D structure, then crudely, the current load from each tissue mass is distributed 
evenly to the other. If a depolarisation wave is travelling from smaller to larger 
tissue mass, the probability that there will be enough current to bring all the 
cells of the larger tissue mass to threshold will be low and there is likely to be 
conduction block which would constitute a low safety factor (Rohr, 2004). This is 
not true for the opposite direction (larger tissue mass to smaller tissue mass). 
However, if connexin expression in the larger tissue mass is low, then the 
current load from the smaller tissue mass might be preferentially distributed only 
to cells in the larger tissue mass coupled by connexins, and there will effectively 
be more current load per cell. The probability of threshold being reached is 
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much higher and conduction is more likely to ensue (high safety factor), albeit 
that conduction velocity might be slow (Rohr, 2004). 
 
1.1.3 Ion Channel / Connexin Expression and Regional Specialisation 
 
Ion channels are differentially expressed throughout heart regions providing 
different action potential morphologies that serve the function of that particular 
region. KATP channels are ubiquitously expressed throughout the body and this 
goes too for the different regions of the heart. It is suggested though that KATP 
subunit expression could itself have cardiac chamber specificity. This will be 
discussed in greater depth in later sections and KATP is not included in the 
following overview. 
 
Sinoatrial Node 
 
The SA node consists of a central chief pacemaking region and towards the 
periphery a transitional zone where ionic properties gradually become more 
"atrial-like". The central pacemaking cells have a high density of HCN channels 
and If is large and contributes to the prominent phase 4 depolarisation in these 
cells. Phase 0 upstroke is relatively slow owing to a lack of fast activating 
sodium current. There is a high density of Cav3.1, Cav3.2, Cav1.2 and Cav1.3 
containing channels reflecting important contributions of the ICaT and ICaL 
currents respectively to the upstroke of the action potential (Boyett et al., 2000; 
Mangoni et al., 2003; Park & Fishman, 2011). The delayed rectifier KV currents 
are both expressed in the central node but there is a smaller IKr current relative 
to the periphery and atria. IKs is also present (Schram et al., 2002). There is also 
a small Ito current but a lack of IK1. This all translates into a more prolonged 
action potential duration (APD) in the central node with a more positive 
maximum diastolic potential (MDP) ~-50mV. Kir3.1/3.4 containing channels are 
also expressed providing modulation by the parasympathetic nervous system 
(Park & Fishman, 2011). Controversy exists as to the driving mechanisms 
behind pacemaker activity (Lakatta & DiFrancesco, 2009). Some are 
proponents that If drives diastolic depolarisation in phase 4, and others that 
there is rhythmic release of Ca2+ from RyRs at the SR that causes inward INa/Ca 
and depolarisation, a phenomenon known as the "calcium clock" (Park & 
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Fishman, 2011). The "calcium clock" has been reported to be more important in 
smaller mammals (Bogdanov et al., 2001; Lakatta & DiFrancesco, 2009). 
Cav1.3 channels are reported to be the predominant carrier of ICaL in the sinus 
node and their activation at more negative membrane potentials with faster 
activation and slower inactivation than Cav1.2 channels supports automaticity 
(Mangoni et al., 2003; Christel et al., 2012). Cav1.3 channels have also been 
shown to localise with ryanodine receptors in sarcomeric structures and 
produce a greater frequency of spontaneous local calcium induced calcium 
release events from RyRs that increase the frequency of automaticity (Torrente 
et al., 2016). This frequency is also sensitive to the direct effects of β-
adrenergic stimulation on Cav1.3 channels (Torrente et al., 2016). Loss of 
function mutations affecting Cav1.3 strongly impact on pacemaking function 
both in the sinus node and the AV node (Mesirca et al., 2015). The If current 
may be more sensitive to parasympathetic inhibition and slowing of heart rate 
and the "calcium clock" more sensitive to β-adrenergic stimulation and 
increases in heart rate (DiFrancesco, 2010). In order to maintain a more 
positive MDP the central node needs to be insulated from the periphery and 
atria but such that depolarisation can still propagate to the atria. This is served 
by SAN anatomy and connexin expression. The central node has a low 
expression of small conductance Cx45 containing connexons and a lack of 
Cx40/Cx43. At the periphery the expression of Cx45 increases along with Cx40 
and Cx43 and atrial fibres extend into the node with finger-like projections 
minimising connecting surface area (Coppen et al., 1999; Verheijck et al., 
2001). In this manner source-sink mismatch is reduced and the smaller tissue 
mass of the sinus node is able to conduct and propagate into a smaller proximal 
mass of atrial fibres. As connexin expression then increases the increasing 
activated atrial mass is able to depolarise with high conduction velocity. 
Similarly, due to low conductance, the more central regions are shielded from 
the hyperpolarising effects of the atria (Joyner & van Capelle, 1986; Coppen et 
al., 1999; Verheijck et al., 2001). There is a significant degree of connective 
tissue between the central node and crista terminalis which also minimises the 
surface area of SAN in contact with the atria (Coppen et al., 1999). Heterotypic 
connexons containing Cx43/Cx45 might exist at the periphery connecting nodal 
and atrial cells and such connexons could have rectifying properties (White et 
al., 1994). If inserted into the membrane in the correct orientation they would 
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facilitate current to flow from SAN to atria and not in a retrograde fashion that 
also helps to insulate the SAN from the hyperpolarising effects of the atria 
(Verheijck et al., 2001). Expression of Nav1.5 channels increases towards the 
SAN periphery, which also aids to overcome source-sink mismatch with the 
larger mass of the atria (Unudurthi et al., 2014). 
 
Atria 
 
Atrial cells show much lower expression of If current and have little or no phase 
4 depolarisation (Porciatti et al., 1997; Schram et al., 2002). They exhibit a large 
INa current and have a fast upstroke translating to rapid tissue conduction 
(Sakakibara et al., 1992). T-type calcium current is present to a higher degree in 
atria than ventricle and Cav1.2 channels are also abundant (Schram et al., 
2002). The IK1 current is smaller in the atria than ventricle leading to a more 
positive MDP ~-70mV than ventricle (Li et al., 2001). The IKr current is larger in 
LA than RA leading to shorter APD and shorter effective refractory period (ERP) 
in the LA (Li et al., 2001). The IKur current appears to be atrial specific (Ravens 
& Wettwer, 2011). There is a much larger inducible IKACh,Ado current in the atria 
than the ventricle (Schram et al., 2002; Tinker & Harmer, 2010). An Ito,f current 
exists likely of the Kv4.3 molecular correlate (Wang et al., 1999). There appear 
to be no differences between RA and LA for the IKur, Ito or IK1 densities (Schram 
et al., 2002). Evidence exists suggesting that IKACh density is greater in the LA 
compared to the RA (Sarmast et al., 2003). Cx43 is the major atrial connexin 
though close to the SAN there is co-expression with Cx40 (Vozzi et al., 1999; 
Schram et al., 2002). 
 
Atrioventricular Node 
 
The AVN, like the SAN, has distinct regions of cellular function. Rod-shaped 
cells predominate at the junction of the atria and node that have ionic 
mechanisms more akin to atrial cells. Ovoid-shaped cells are present towards 
the compact central AVN and towards the His bundle (Munk et al., 1996; 
Schram et al., 2002). Ovoid cells express a significant If current providing their 
automatic pacemaker capability but no INa and the action potential upstroke is 
provided by ICaT and ICaL though ICaL predominates (Hancox & Mitcheson, 1997). 
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Similar to SAN cells there is a small Ito current, however, repolarisation is reliant 
on IKr with little or no IKs and thus APD is longer than in the SAN (Schram et al., 
2002). AVN cells exhibit post-repolarisation refractoriness (Munk et al., 1996) 
most likely secondary to reliance on ICaL for the upstroke with its slower 
activation, longer recovery time and more positive activation voltage to that of 
INa. The MDP is also more positive than the atria and ventricle ~-60mV, owing to 
a lack of IK1 (Hancox & Mitcheson, 1997). IKACh is present and enables 
modulation by the parasympathetic nervous system (Harvey & Belevych, 2003). 
Like the SAN the predominant gap junction protein is Cx45 and conduction is 
slow in the AVN compared to non-nodal tissues (Schram et al., 2002). 
 
His-Purkinje System 
 
These cells exhibit a fast upstroke owing to Nav1.5, Cav3.1 and Cav3.2 
channel expression (Schram et al., 2002; Nerbonne & Kass, 2005). The plateau 
phase is less depolarised than in ventricular cells owing to less ICaL current 
(Tseng & Boyden, 1989; Schram et al., 2002). The action potential is longer 
than in ventricular muscle that might be explained by reduced expresson of 
delayed rectifier potassium channel mRNA, though IKr and IKs are detectable 
(Schram et al., 2002). APD might also be prolonged due to a smaller Ito,f  current 
and a larger INaL than in ventricular myocytes but the presence of Ito still gives 
rise to a "spike and dome" morphology of the action potential (Carmeliet, 1987; 
Schram et al., 2002; Niwa & Nerbonne, 2010). IK1 is present and governs a 
negative MDP of ~-80mV akin to ventricular myocytes but there is also a low 
expression of HCN4 and If current that enables phase 4 diastolic depolarisation 
and automaticity (Kus & Sasyniuk, 1975; Schram et al., 2002; Nerbonne & 
Kass, 2005). IKACh is also expressed albeit to a much lesser degree than the 
nodal and atrial tissues (Nerbonne & Kass, 2005). The His-Purkinje system 
appears to contain abundant amounts of all three connexins and this 
contributes to the rapid conduction of these tissues (Davis et al., 1995). 
 
Ventricle 
 
Ventricular cardiomyocytes have little or no phase 4 depolarisation owing to 
very low expression of an If current (Hoppe et al., 1998; DiFrancesco, 2010). 
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The MDP is ~-85 to -90mV secondary to a large IK1 current and this also 
renders any residual If expression defunct (Davis & Temte, 1969; Wettwer et al., 
1994; Konarzewska et al., 1995; DiFrancesco, 2010). The upstroke is fast 
secondary to a large INa (Fozzard, 2002; Nerbonne & Kass, 2005; Rook et al., 
2012). The plateau phase is driven largely by L-type calcium current and late 
persistent sodium current INaL as previously described for the typical phase 2 of 
the action potential. Repolarisation is governed by Ito and IK1, and to a lesser 
extent by IKr and IKs (Wettwer et al., 1994; Konarzewska et al., 1995; Nerbonne 
& Guo, 2002). As will be described in later sections IKATP also contributes 
significantly to repolarisation during ischaemia. The predominant connexon in 
the ventricle is Cx43 (Vozzi et al., 1999; Schram et al., 2002). 
 
In the ventricle, transmural and regional heterogeneity in expression and 
function of these currents determines variations in action potential duration and 
repolarisation times and it is heterogeneity of repolarisation that is 
mechanistically important in arrhythmogenesis. Increased heterogeneity of 
repolarisation makes re-entry and/or fibrillatory conduction more likely. A large 
body of evidence from canine wedge preparations suggests the presence of 3 
layers of cell types endocardial, midmyocardial (M-cell) and epicardial 
(Antzelevitch et al., 1991). M-cells appear to have longer action potentials than 
endocardial myocytes, which in turn have longer action potentials than 
epicardial myocytes. This is thought to arise due to a lower expression of IKs, a 
larger INaL and larger INa/Ca current in M-cells as compared to epicardial or 
endocardial myocytes (Viswanathan et al., 1999; Zygmunt et al., 2001; 
Nerbonne & Guo, 2002). Epicardial myocytes and M-cells have a larger Ito 
current than endocardial myocytes with a particularly large Ito,f in epicardial cells 
contributing to a shorter action potential than M-cells and endocardial myocytes 
(Antzelevitch et al., 1991). Expression of Ito is contingent on expression of both 
the pore-forming subunit and the β-subunit KChIP2 and evidence suggests it is 
varied transmural expression of KChIP2 that governs differences in transmural 
current density of Ito (Nerbonne & Guo, 2002). Given the kinetics of recovery 
from inactivation are faster for Ito,f and M-cells appear to have a greater Ito,s 
density, M-cells have a steep slope of restitution of action potential duration, 
epicardial myocytes less steep and endocardial myocytes a lesser rate-
dependence of action potential duration still. With longer diastolic intervals there 
 43 
is greater Ito recovery between beats. This may then seem paradoxical but the 
existing theory is that as less IKs is recruited at slower rates, the greater degree 
of notch produced in phase 1 actually slows the activation of IKr and ICaL which 
in turn prolongs the action potential phases 2 and 3. At shorter diastolic 
intervals IKs is recruited and less Ito recovers between beats, especially Ito,s, 
leading to restitution and shortening of action potential duration (Antzelevitch et 
al., 1991; Viswanathan et al., 1999). On top of transmural heterogeneity in 
action potential duration (APD), evidence across species suggests that in 
general, APD is shorter in the right ventricle (RV) than the left ventricle (LV) 
largely owing to greater expression of Ito and IKs (Molina et al., 2016). In canine 
hearts evidence suggests greater expression of these two currents at the apex 
compared to the base in both current measured from isolated cells and protein 
quantification via western blot (Szentadrassy et al., 2005). Results of protein 
study for human heart were similar (Szentadrassy et al., 2005). This would 
suggest shorter APD at the apex compared to the base. In the dog this then 
follows that the sequence of repolarisation crudely follows that of activation (ie. 
anterior septum through apex and free wall and up to base) and would explain 
discordant T wave polarity to that of the QRS complex on the surface ECG. In 
human, however, there is concordance between T wave polarity and that of the 
QRS. Given local repolarisation time is contingent on the activation time 
together with the action potential duration, evidence exists that T wave/QRS 
concordance exists in humans due to an inverse relationship between activation 
time and repolarisation time and that repolarisation proceeds from base to apex 
(Opthof et al., 2009; Janse et al., 2012).  In silico modelling suggests that all 
three of transmural, apico-basal and interventricular gradients of repolarisation 
are involved in the inscription of the T wave on the ECG (Zheng et al., 2016). 
Above all these gradients of repolarisation and the heterogeneity of action 
potential duration are critical in arrhythmogenesis and increased heterogeneity 
in disease states makes tissue more arrhythmogenic. Mapping and targeting of 
susceptible areas of tissue is important for therapeutic aim both by 
surgical/catheter-based and pharmacological means, and further delineation of 
species specific gradients of ion channel expression in health and disease will 
aid the search for new therapeutic approaches. 
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1.1.4 Autonomic and G-protein Linked Regulation 
 
Fine-tuning of the underlying properties of action potential generation, 
propagation and excitation-contraction coupling are afforded by a balance of the 
effects of the sympathetic and parasympathetic nervous systems. Both 
circulating adrenaline and noradrenaline released from penetrating post-
ganglionic sympathetic nerve fibres, are responsible for activating β-adrenergic 
Gs-protein coupled receptors (stimulatory G-proteins) throughout the 
myocardium and conduction system (Salazar et al., 2007; Gordan et al., 2015) 
(see Figure 1.4). 
 
  
 
 
Figure 1.4. Autonomic inputs to the heart (taken from Gordan et al., 
2015). Parasympathetic control is through pre-ganglionic cholinergic 
neurons of the vagus nerve and short post-ganglionic cholinergic neurons. 
This is in balance with sympathetic control through short pre-ganglionic 
cholinergic neurons and longer post-ganglionic adrenergic neurons. RA, 
right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle; SA, sino-
atrial node; AV, atrio-ventricular node; NE, norepinephrine; ACh, 
acetylcholine. 
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On activation by receptor-ligand binding, the heterotrimeric G-protein complex 
separates through exchange of GDP to GTP releasing the Gαs subunit 
(Lymperopoulos et al., 2013) (see Figure 1.5). 
 
 
Figure 1.5. Autonomic regulation of cardiomyocytes (taken from 
Gordan et al., 2015). Acetylcholine from parasympathetic post-ganglionic 
neurons activates at muscarinic M2 receptors through inhibitory G-protein 
leading to reduced cAMP production and an increase in outward potassium 
currents linked to these G-proteins. Noradrenaline from sympathetic post-
ganglionic neurons has the opposite effect through activation of β1 receptors 
and stimulatory G-protein leading to increased cAMP production. cAMP 
leads to protein kinase A activation and phosphorylation of various 
downstream targets including the inward calcium current and 
phospholamban leading to increased sarcoplasmic calcium uptake and 
release. NE, norepinephrine; β1, beta1-adrenergic receptor; Gs, stimulatory 
G-protein; Ach, acetylcholine; M2, muscarinic receptor type 2; Gi, inhibitory 
G-protein; AC, adenylate cyclase; PKA, protein kinase A; ICa,L, L-type 
calcium channel; RyR2, ryanodine receptor 2; SERCA, sarcoplasmic 
reticulum Ca2+-ATPase2a; PLB, phospholamban. 
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This activates adenylate cyclase converting ATP to cyclic AMP (cAMP), which 
in turn activates Protein Kinase A (PKA) (Lymperopoulos et al., 2013). Through 
phosphorylation by PKA of T-type and L-type calcium channels there is 
increased inward calcium that leads to a positive inotropic effect. In SAN tissue 
this leads to increased calcium uptake into the SR that in turn leads to an 
increased likelihood, and therefore rate of, calcium release and forward mode 
INa/Ca current leading to increased automaticity (Lakatta & DiFrancesco, 2009). 
PKA signalling also positively modulates ryanodine receptor (RyR) calcium 
release increasing automaticity (Vinogradova et al., 2002). This is coupled to a 
direct positive effect of cAMP on the If current shifting the open state to more 
depolarised potentials and thus shortening the cycle length of automaticity in 
the SAN (DiFrancesco & Tortora, 1991). PKA phosphorylation of 
phospholamban and Troponin I induces a positive lusitropic effect by way of 
enhanced release of calcium from myofilaments and increased re-uptake into 
the SR through release of phospholamban-inhibition of SERCA (Bers, 2002). 
This in turn enhances SR calcium content leading to a positive inotropic effect. 
PKA phosphorylation increases IKs current leading to accelerated repolarisation 
to counter the action potential prolonging effects of an increased inward calcium 
current and allow for higher heart rates (Volders et al., 2003). There is also a 
positive dromotropic effect that may be due to an increased gap junction 
conductance particularly with respect to Cx40 and Cx45 in nodal tissue, and 
also an increased INa expression and conductance (Abriel, 2007; Salameh & 
Dhein, 2011; Rook et al., 2012). β-adrenergic modulation occurs throughout the 
myocardium and conduction system. 
 
Acetylcholine release at post-ganglionic parasympathetic nerve fibres and the 
effects of adenosine lead to opening of inhibitory G-protein (Gi) linked 
potassium channels (GIRK) and an increased outward potassium current as 
previously described (see also Figure 1.5). IKACh,Ado is a hyperpolarising current 
opposing the effects of If and slowing automaticity in nodal tissue, and also 
reduces calcium load and automaticity through the "calcium clock" (Brodde & 
Michel, 1999). The Gαi subunit released on activation also reduces adenylate 
cyclase activity having an inhibitory effect on PKA activation. GIRK channels 
and parasympathetic innervation is abundant in sinoatrial tissue but not so in 
the ventricle (Brodde & Michel, 1999). 
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The endothelin-1 receptor ETA, angiotensin II receptor AT-1, adrenergic α1 
receptor and muscarinic acetylcholine receptor M3 are all coupled to Gq-
proteins. Activation leads to heterotrimeric separation of the Gαq subunit via 
exchange of GDP for GTP, which in turn activates phospholipase C leading to 
generation of diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) from 
phosphatidylinositol-4,5-bisphosphate (PIP2) (Tinker et al., 2016). IP3 release 
leads to sustained calcium release from the SR. Whilst this calcium release 
might initially be positively inotropic, it also enables calcium-dependent DAG 
activation of protein kinase C (PKC) groups through which phosphorylation 
pathways mediate myocardial apoptosis, necrosis and hypertrophy pathways 
(Salazar et al., 2007).  PKC signalling pathways also activate protein 
phosphatase-1 (PP-1), which dephosphorylates phospholamban causing 
inhibition of SERCA, reduced SR calcium uptake and an ensuing negative 
inotropic effect (Braz et al., 2004). IP3 itself also has a nuclear envelope 
receptor, which is involved with nuclear calcium signalling and coupled gene 
expression through a calcineurin pathway leading to hypertrophy (Salazar et al., 
2007; Nakayama et al., 2010). As such the neurohumoral stress agonists 
mentioned above, through the IP3 / DAG pathway linked to Gq-protein-coupled 
receptors, play an important role in the pathophysiology and tissue remodelling 
in heart failure. 
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1.2 Atrial Fibrillation 
 
1.2.1 Definition and Proposed Mechanisms 
 
Atrial Fibrillation (AF) is the most common sustained arrhythmia (Lip & Tse, 
2007). It has an estimated prevalence in the developed world of 1.5-2% of the 
general population, and is associated with a five-fold risk of stroke and a three-
fold incidence of congestive heart failure, and higher mortality (Camm et al., 
2012). The current European Society of Cardiology (ESC) guidelines for the 
management of AF, declare that “...this arrhythmia remains one of the major 
causes of stroke, heart failure, sudden death, and cardiovascular morbidity in 
the world. Furthermore, the number of patients with AF is predicted to rise 
steeply in the coming years" (Kirchhof et al., 2016). 
 
Fibrillation is defined by rapid, disorganised and chaotic activation of excitable 
tissue. The random chaotic impulses propagating through the atria activate the 
AV node in a random pattern thus causing a completely irregularly irregular 
depolarisation of the ventricles. Where the AV node functions well it can 
conduct these random impulses at high rates and thus the ventricular rate can 
be very rapid causing symptoms of palpitations, light-headedness and 
breathlessness. Atrial systole is effectively lost and the absence of active atrial 
transport of blood to the ventricles during ventricular diastole can worsen heart 
function, contributing to symptoms, and can cause heart failure. The increased 
residual volume in the atria leads to volume overload and increased atrial 
pressure, which in turn can promote the pathophysiological changes that cause 
perpetuation of the arrhythmia. A prothrombotic state is produced by an 
inflammatory response to the increased atrial stretch and fibrosis caused by 
volume overload, and by the stasis of blood that ensues in the atria whilst they 
are fibrillating (Kirchhof et al., 2016). This is particularly apparent in the left atrial 
appendage where the velocity of blood can be very low. Clot can then embolise 
causing various sequelae including devastating stroke, ischaemic gut and 
limbs. As such the arrhythmia can cause a large degree of morbidity and 
associated mortality. 
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All arrhythmogenic mechanisms of automaticity, triggered and re-entry (see 
Figure 1.6) have been implicated in AF whether with regards the initiation or 
perseveration of the arrhythmia. Atrial ionic remodelling appears to ensue 
whereby prolonged bouts serve to further potentiate the arrhythmia (Hobbs et 
al., 1999; Nattel, 2002). 
 
Classical postulated mechanisms of AF involve rapidly firing ectopic foci 
(particularly in the pulmonary veins, superior vena cava and ligament of 
marshall), single circuit re-entry and multiple circuit re-entry (Moe et al., 1964; 
          
 
 
 
Figure 1.6. Mechanisms of arrhythmia. Automaticity upper left panel, 
increased in black, whereby the phase 4 slope of depolarisation is steeper 
creating a greater frequency of firing rate, and decreased in red. Continuous 
rotational activity through re-entry upper right panel, of a depolarising wave 
front around an anatomical obstacle like inexcitable scar (left), and functional 
re-entry owing to centripetal wave front collision at the centre of the 
rotational wave front (right). Re-entry is contingent on recovered excitable 
tissue at the tail of the wave front ready to be reactivated. Triggered activity 
lower panel owing to abnormalities of calcium handling leading to forward 
mode INa/Ca and premature reactivation, including EADs, early after-
depolarisations through action potential prolongation and initial reactivation 
of ICaL and DADs, delayed after-depolarisations through calcium loading and 
subsequent leak from the SR in diastole. 
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Allessie et al., 1977; 1985; Haïssaguerre et al., 1998; Doshi et al., 1999; Tsai et 
al., 2000) (see Figure 1.7). It remains to be confirmed whether AF drivers are 
due in part to automatic, triggered or re-entrant foci and all mechanisms may be 
in play (Schotten et al., 2011). 
 
Classical Re-entry 
 
The work of Allessie and colleagues promoted the concept of the leading circle 
theory, re-entry around a functional rather than anatomical obstacle, and that of 
the minimum wavefront path length (WFPL) to sustain a re-entrant arrhythmia 
as a product of the effective refractory period (ERP) and the conduction velocity 
(CV) in the tissue (see Figure 1.8). 
 
 
 
 
Figure 1.7. Proposed AF mechanisms (taken from Nattel, 2002). 
Schematic demonstrating an area of focal ectopic activity (left), single circuit 
re-entry (middle) and multiple circuit re-entry (right). 
 
            
 
Figure 1.8. Schematic of functional re-entry (taken from Nattel, 2002). 
Centripetal activation with wavefront collision at the centre of the re-entrant 
wave leads to a functional obstacle for this re-entry. 
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The shorter this path length, the more likely a re-entrant wave to set up in a 
tissue of given mass, and the more likely for multiple re-entrant circuits. This 
idea underpins one proposed mechanism of anti-arrhythmic drug action. That 
their effects on ERP and CV combine to a product of a longer minimum WFPL, 
that reduces the likelihood of single or multiple re-entrant waves (Wang et al., 
1990; 1994; 1995). 
 
Atrial electrophysiology remodels as a consequence of chronic AF with changes 
in ion channel expression and/or regulation and gating. The inward calcium 
current ICa is reduced in density (Workman et al., 2008; Heijman et al., 2014) 
and this corresponds with a shorter action potential duration and loss of rate 
adaptation of APD (Van Wagoner et al., 1999). Potassium channel functional 
remodelling also occurs. For example, Kir2.1 expression, basal IK1 density and 
open probability is higher in right atrial appendage myocytes from patients with 
chronic AF compared to those in sinus rhythm (Dobrev et al., 2005). IKACh 
appears to be constitutively active when investigated in the same myocytes in 
an agonist-independent manner with a greater open probability and this is 
thought to be driven by abnormalities in protein kinase C (PKC) channel 
phosphorylation (Dobrev et al., 2005). On the other hand transient outward and 
ultra-rapid delayed-rectifier potassium current densities appear to be reduced 
(Workman et al., 2008; Heijman et al., 2014). Cholinergic activation of IKACh at 
times of high vagal tone, and reductions in APD particularly in the left atrium, 
has been implicated as a mechanistic step to the initiation of AF by ectopic foci 
(Wakimoto et al., 2001; Kneller et al., 2002; Sarmast et al., 2003).  The 
proposed overall effect is a reduction in APD that translates to a shorter 
effective refractory period that contributes to perseveration and increased 
burden of arrhythmia. 
 
Gap junction expression and distribution is also affected by chronic AF with an 
enhanced Cx40 expression and a shift of distribution to the lateral membrane 
from the polar membrane of both Cx43 and Cx40 in atrial cardiomyocytes 
(Polontchouk et al., 2001). This is associated with a functional reduction in the 
physiological anisotropy of the atrial tissue promoting conduction perpendicular 
to the fibre axis as well as in parallel (Polontchouk et al., 2001). This reduction 
in anisotropy promotes re-entry due to multiple directions of impulse 
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propagation and for the fact that there is an increase in source-sink mismatch 
for depolarising current being distributed to a greater number of adjacent cells. 
This reduces conduction velocity and shortens the minimum wavefront path 
length. 
 
The myocardial sleeve extensions into the pulmonary veins from the left atrium 
show histological features of fibrosis, akin to that produced by ischaemia, and 
slow conduction would lend itself as a fertile substrate for re-entry (Saito et al., 
2000; Ho et al., 2001). Stable micro-reentry has been shown within the 
pulmonary veins particularly under the influence of acetylcholine (Po et al., 
2005). 
 
Automaticity and Triggered Activity 
 
Ectopy arising from areas such as the pulmonary veins, superior vena cava and 
ligament of Marshall, can initiate the arrhythmia and there is a body of evidence 
to suggest that automaticity, triggered activity and micro-reentrant circuits could 
all be responsible for ectopy arising from these sites (Schotten et al., 2011). 
Pulmonary vein myocytes at the LA-PV junction have been seen to have a 
morphology akin to nodal cells, exhibit a current resembling If, and in patients 
with AF, gene expression at the LA-PV junction favours a nodal phenotype that 
would lend itself to automatic activity (Schotten et al., 2011; Yeh et al., 2013). 
 
Delayed after-depolarisations (DADs) are caused by leak of calcium either from 
an overloaded SR or leaky RyRs. The calcium sparks cause forward mode 
INa/Ca current leading to depolarisations that, if propagate to surrounding tissue, 
can initiate ectopic activity. In atrial cardiomyocytes from both patients with 
paroxysmal and chronic AF there appears to be a greater diastolic calcium leak 
and incidence of triggered activity via DADs because of increased SERCA 
uptake in the former, and increased RyR and INa/Ca  activity in the latter (Voigt et 
al., 2012; 2014). 
 
Early after-depolarisations (EADs) occur classically with action potential 
prolongation whereby a prolonged phase 2 leads to activation of an inward 
calcium window current and subsequent forward mode INa/Ca leading to a new 
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upstroke and action potential in phase 2 (Antzelevitch & Burashnikov, 2011). 
Late phase 3 EADs occur when there is a combined sympathovagal tone 
causing both calcium loading and action potential shortening respectively. This 
leads to strong calcium release from the SR that persists long into phase 3 of 
the action potential by which time the membrane potential is repolarised enough 
beyond the equilibrium potential of INa/Ca to allow forward mode current and lead 
to a new action potential (Burashnikov & Antzelevitch, 2006). Late phase 3 
EADs are suggested to play a role in immediate recurrences of AF 
(Burashnikov & Antzelevitch, 2003). 
  
Whilst vagotonically induced AF is commonly explained by APD shortening due 
to increased IKACh, acetylcholine also activates muscarinic M3 receptors and the 
Gq linked IP3 / DAG pathway as previously discussed and IP3 release causes 
sustained SR calcium release that could induce after-depolarisations and 
triggered activity (Tinker et al., 2016). 
 
Spiral Wave Theory 
 
A developing hypothesis for rotational wavefront generation are spiral waves or 
rotors with a constantly excitable core, termed a phase singularity owing to this 
core displaying no definable cyclical presence of activity and where all other 
markers of the spatiotemporal phase of the rotor converge (Beaumont et al., 
1998; Pandit & Jalife, 2013). Aspects of spiral wave theory lend themselves to 
explaining why anti-arrhythmic drugs that block sodium (Na+) channels, 
reducing excitability and slowing conduction, but not necessarily increasing 
minimum wavefront path length, can terminate AF (Wijffels et al., 2000; Kawase 
et al., 2003). Evidence has shown reducing excitability through Na+ channel 
blockade, can enlarge the excitable core of rotors through "source-sink" 
mismatch and increase the radius of rotation (Wijffels et al., 2000; Cosío & 
Delpón, 2002; Kawase et al., 2003). Enlarging the excitable gap at the centre of 
these rotors increases the chance of fusion of wavefronts and extinguishing the 
rotor (Wijffels et al., 2000; Nattel, 2002; Cosío & Delpón, 2002; Kawase et al., 
2003) (see Figure 1.9). 
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1.2.2 Management and Therapies 
 
Reducing the risk of stroke in the context of AF is enabled by the use of anti-
coagulation strategies using drugs such as warfarin or the novel oral 
anticoagulants. At present, reducing the morbidity associated with the 
arrhythmia is mainly via the use of anti-arrhythmic drugs and/or catheter 
ablation. 
 
Anti-arrhythmic drugs 
 
The classical mechanism of action of anti-arrhythmic drugs is via prolongation 
of the action potential duration and effective refractory period to reduce the 
likelihood of sustained re-entry by prolonging the wavefront path length. 
Potassium channel blockade prolongs phase 3 of the action potential. 
 
Class Ia and Ic sodium channel blockers reduce the maximum upstroke velocity 
of phase 0 of the action potential (Vmax) due to slow offset kinetics. This in turn 
slows conduction velocity and excitability of the tissue (Osadchii, 2017). This 
might be seen as paradoxical as the WFPL would be shortened and might 
 
 
 
Figure 1.9. Spiral waves. Schematic demonstrating propagation outwards 
from a spiral wave. Where tissue has low excitability, the central core will be 
enlarged and the radius of arc of activation larger. 
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promote re-entrant arrhythmias and indeed in some instances, particularly 
ischaemic hearts and those with high scar burden from previous infarct, this is 
the case as was demonstrated in the CAST study (Echt et al., 1991). However, 
most are not pure sodium channel blockers and have some potassium channel 
blocking effects on Ito and hERG also prolonging phase 3 and APD (Wang et 
al., 1990; 1995; Melgari et al., 2015). Sodium channel blockers also cause post-
repolarisation refractoriness due to delaying recovery from inactivation of the 
sodium channel and this in turn prolongs the ERP (Coronel et al., 2012; 
Osadchii, 2017). Sodium channel blockade causing reduction of tissue 
excitability and AF termination is in support of spiral waves as a mechanism of 
AF given the angle of curvature at the centre of a spiral wave is contingent on 
tissue excitability. With reduced excitability the angle of curvature that can be 
maintained is less acute. The more acute the angle of curvature of the rotor, the 
greater the volume of tissue directly in front of the curving wavefront, and the 
greater the sink of tissue that must be activated by the rotor wavefront. It follows 
that greater tissue excitability is required for greater curvature (Pandit & Jalife, 
2013). Sodium channel blockade, thus, reduces the acuteness of the angle of 
curvature of the rotor and in turn increases the rotor wavefront path length, and 
also increases the excitable gap at the centre of the rotor. All this makes 
wavefront collision and rotor extinction more likely. 
 
Beta-blockers serve to block sympathetically driven recruitment of potassium 
currents such as IKs thus prolonging APD and also reduce inward calcium 
reducing the SR calcium load and probability of triggered and automatic activity 
(Chen et al., 1999; Kühlkamp et al., 2000). 
 
In a meta-analysis of randomised controlled trials comparing anti-arrhythmics 
vs. placebo or no treatment after cardioversion, sodium channel blockers 
(disopyramide, quinidine, flecainide and propafenone), pure potassium channel 
blockade (dofetilide), potassium channel blockade plus beta-blockade class 3 
(sotalol), or mixed ion channel blockade plus anti-sympathetic effects class 3 
(amiodarone, dronedarone) significantly reduced the recurrence rate of AF at 1 
year (OR 0.19 to 0.7) (Lafuente-Lafuente et al., 2015). However, given the 
recurrence rate in the control arms was as high as 84% at 1 year, most would 
agree this is only a modest practical reduction, and side effects were frequent in 
 56 
all groups.  This is also in the context that all but amiodarone and propafenone 
were associated with pro-arrhythmia. Amiodarone and standard beta-blockers 
(eg. bisoprolol, metoprolol succinate) are the only anti-arrhythmics with an 
adequate safety profile to use in those with depressed LV function, though 
success rates at rhythm control with standard beta-blockers are limited (OR 
0.62), and amiodarone in particular is associated with side effects, most notably 
abnormal liver and thyroid function, pulmonary fibrosis and corneal deposits 
(Camm et al., 2010; Lafuente-Lafuente et al., 2015). All Class I and III anti-
arrhythmics are prone to prolonging the QT interval and predisposing to 
Torsades de Points (TdP) (Camm et al., 2010). Thus, there is a desire to 
develop new anti-arrhythmics with higher specificity for the atria compared to 
the ventricle, or those that have desirable effects in the atria with the same or 
neutral effects in the ventricle. 
 
Catheter ablation 
 
Catheter ablation for AF has developed significantly as a treatment strategy 
over the past 15 years. The empirical strategy is to produce lines of block 
around the pulmonary vein (PV) ostia (pulmonary vein isolation; PVI) to prevent 
ectopic firing from the PVs into the left atrium (Haïssaguerre et al., 1998). The 
PVs appear to have a tissue architechture distinct from the LA with myocardial 
sleeve projections from the LA inter-digitating with fibrotic areas with slow 
conduction providing a substrate for re-entry (Nattel, 2003; Chard & Tabrizchi, 
2009). This is coupled with the fact that PV myocytes have been shown to have 
a shorter APD than the LA owing to a smaller ICa and larger delayed recifier 
potassium currents (Nattel, 2003). PV myocytes also appear to have a 
phenotype displaying automatic behaviour and a propensity to triggered activity 
through differences in calcium handling where SR loading capability is less and 
open to leak (Chard & Tabrizchi, 2009). Postganglionic autonomic nerve fibres, 
particularly cholinergic, also richly innervate the PVs that might cause 
autonomically driven pro-arrhythmic effects as previously described in section 
1.1.4 (Chard & Tabrizchi, 2009). 
 
Success rates from PVI for an AF-free 1 year period can be as high as ~90% in 
skilled hands and taking into account the need for multiple procedures (Jaïs et 
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al., 2008). It appears to be a successful treatment modality in most patients with 
paroxysmal AF. One recent large randomised controlled trial has now also 
demonstrated a survival/hospitalisation benefit at 1.5 years in patients with 
persistent or paroxysmal AF. This was in the context of severely impaired LV 
systolic dysfunction with an implantable cardioverter defibrillator (ICD), who 
were largely intolerant of anti-arrhythmic drugs, undergoing pulmonary vein 
isolation as compared to medical therapy (ventricular rate control or pursued 
attempts at chemical rhythm control) (Marrouche et al., 2018). The primary 
outcome measure correlated with better maintenance of sinus rhythm. 
 
Nevertheless catheter ablation is not without risk of major complication. In one 
survey reporting the outcome of more than 1000 AF ablation procedures, acute 
severe complication rates were 0.6% for stroke, 1.3% for tamponade, 1.3% for 
peripheral vascular complications and 2% for pericarditis (Arbelo et al., 2012; 
Camm et al., 2012). These data were from high volume centres with 
experienced operators and thus rates are likely to be higher globally. 
 
Most studies thus far have been in those with no or minimal structural heart 
disease and success rates are not as high in those with persistent AF where 
episodes last greater than 7 days. Where persistent AF has developed, this 
may derive from a completely different mechanism to the paroxysmal form, or 
this mechanism may even be a progression based on remodelling of the atria to 
frequent paroxysms (Hobbs et al., 1999; Camm et al., 2010). Current proposed 
mechanistic approaches suggest areas of slow conduction in the LA body due 
to fibrosis that promote re-entry, but attempts to improve outcomes beyond 
those with PVI alone, by targeting complex fractionated electrograms thought to 
be emanating from areas of scar in persistent AF have been met with mixed 
results (Verma et al., 2010; 2015). 
 
Similarly attempts to use software capable of defining rotor activity through 
mapping phase singularities at the rotor core, and ablating areas with rotors of 
dominant frequency, has also been met with mixed results (Narayan et al., 
2012; 2014; Buch et al., 2016; Steinberg et al., 2017). 
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Whilst it appears PVI with catheter ablation is superior to medical therapy alone 
in the heart failure population with severely impaired LV systolic dysfunction, 
certainly men aged below 70 years of age where the LV ejection fraction was 
still over 25%, this is the cohort that had the largest benefit and no obvious 
harm in the aforementioned study (Marrouche et al., 2018), results of an even 
larger randomised controlled trial comparing catheter ablation to PVI in all-
comers with all types of AF, appears to demonstrate no clear hard outcome 
primary endpoint benefit in an intention-to-treat analysis. The results of the 
CABANA trial have been presented through a conference, but the study data 
are yet to be formally published. The authors have stipulated a large crossover 
from the medical to the ablation arm and that in an on-treatment analysis a 
benefit of ablation can be seen, but there was inadequate powering of the trial 
for such an analysis and it is open to confounding. Thus far it can only be seen 
as hypothesis generating. Another qualm with all trials comparing ablation and 
medical therapy to date is that the control medical arm contains no "sham" 
methodology. A placebo effect of ablation cannot be discounted. 
 
A large growing body of evidence has shown that obesity is an independent risk 
factor for incidence and increasing burden of AF (Lavie et al., 2017). Apart from 
links with atherosclerosis and hypertension that are themselves associated with 
an increased burden of AF, haemodynamic effects of obesity are such that 
circulating blood volume increases as does a demand for greater cardiac 
output. This leads to left ventricular hypertrophy and at least diastolic if not 
systolic LV dysfunction and subsequent atrial stretch and fibrosis (Lavie et al., 
2017). Obesity is also associated with a greater volume of epicardial and 
pericardial fat, particularly around the posterior left atrium and pulmonary veins. 
Fat here is secretory of various pro-inflammatory cytokines (eg. IL-6) and 
growth factors (eg. TGF-β1) amongst other metabolic, angiogenic and 
neurohumoural factors. This all serves to increase fibrotic changes around the 
pulmonary vein ostia and left atrium which in turn has detrimental effects on 
calcium handling and reduces conduction velocity promoting the substrate for 
re-entry and AF triggers (Wong et al., 2017). Epicardial adipose tissue (EAT) 
itself also interdigitates the atrial myocardium adding to conduction slowing 
(Lavie et al., 2017). 
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Direct correlation has been shown between volume or thickness of epicardial fat 
and AF burden via Computed Tomography (CT) / Magnetic Resonance Imaging 
(MRI) studies (Gaeta et al., 2017). However, a large heterogeneity exists with 
regards the absolute volumes reported in the separate studies suggesting it is 
hard to label any cut-off value to risk. Structured cardiovascular risk factor and 
weight loss management programmes have been shown in both randomised 
controlled trials and observational studies to reduce the burden of AF and 
improve outcomes following catheter ablation (Abed et al., 2013; Pathak et al., 
2014; 2015). 
 
1.2.3 Drug Development for AF 
 
The search continues for an effective atrial specific drug that does not produce 
pro-arrhythmia in the ventricle. 
 
Blocking potassium channels has the effect of prolonging the APD and ERP 
and blocking sodium channels reduces excitability and also prolongs the ERP. 
As previously explained this in turn increases the minimum wavefront path 
length for re-entry and reduces the likelihood of fibrillatory conduction. A 
corollary to this is that without atrial specificity of these drugs, they also increase 
APD and ERP in a very heterogeneous manner in the ventricle. Sotalol, for 
example, is highly specific for IKr block and preferentially prolongs APD in the 
mid-myocardial layer of the ventricle (Nerbonne & Guo, 2002). This in turn 
increases the likelihood of early after-depolarisations (EADs), spontaneous 
depolarisations occurring prior to full repolarisation because of excess 
intracellular calcium during a prolonged phase 3 of the action potential, that in 
turn cause forward mode of the INa/Ca exchanger with net inward current (Priori & 
Corr, 1990). If EADs propagate to tissue no longer refractory, this can set up re-
entry and/or fibrillatory conduction and constitutes a risk of sudden death of 
malignant ventricular arrhythmias. 
 
Work has been performed to test the efficacy of blockers of IKur (such as 
vernakalant) and IKACh given the suggested atrial specificity of these currents. 
Vernakalant has been shown to terminate AF when given intravenously but this 
is probably due to its Na+ blocking effect for it is not a specific blocker of IKur 
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(Ravens & Wettwer, 2011). Pure IKur block has not yet been demonstrated to 
suppress AF, its block actually shortens APD in atrial cardiomyocytes in sinus 
rhythm and IKur is downregulated in chronic AF all questioning how useful a drug 
target it will be (Ravens & Odening, 2016). Despite promising results of IKACh 
blockers in dogs, a recent clinical trial of the agent BMS 914392 failed to show 
a reduction in AF burden in patients with paroxysmal AF (Podd et al., 2016). 
 
Another atrial specific target has been the late persistent sodium current INaL. 
The inactivation curve of the atrial Nav1.5 channel appears to be left shifted 
towards more negative potentials and given the resting membrane potential of 
atrial cardiomyocytes is more positive than ventricular cardiomyocytes, for any 
particular resting state there is a greater population of Nav1.5 channels in an 
inactivated state in the atria compared to the ventricle (Maier & Sossalla, 2013). 
Ranolazine is a drug licensed for use as an anti-anginal whereby its mechanism 
of action is suggested to inhibit the late sodium current thereby reducing [Na]i 
and consequently reducing reverse mode of the INa/Ca exchange current and 
reducing calcium load on the cell. This in turn reduces energy requirements and 
improves LV diastolic function reducing supply/demand mismatches during 
ischaemia. It exhibits use-dependent block with a selectivity for Nav1.5 
channels but can also block in a pre-open state when only a limited number of 
activation gates are open at less positive membrane potentials (Zygmunt et al., 
2011). It has fast release from block but only when the channel has recovered 
from inactivation and as such at short diastolic intervals, such as during an atrial 
arrhythmia, there will ensue a high degree of block in the atria given the 
differences in the inactivation curves of the sodium channel between the atria 
and ventricle. Thus, its effect on the peak sodium current, INaPeak, is more 
pronounced in the atria and presumably reduces excitability either causing a 
source-sink mismatch at the centre of rotors, or prolonging post-repolarisation 
refractoriness (Zygmunt et al., 2011; Vizzardi et al., 2012). Its anti-arrhythmic 
properties are accentuated by its, albeit weaker, IKr blocking effect and the 
favourable metabolic sequelae from inhibiting INaL (Vizzardi et al., 2012). The 
MERLIN-TIMI 36 trial randomised 6500 acute coronary syndrome patients to 
ranolazine in addition to standard therapy or standard therapy alone (Scirica et 
al., 2007). Although no difference in the combined primary outcome of 
cardiovascular death, myocardial infarction or recurrent ischaemia, further 
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analysis did show a trend towards a reduced AF and supraventricular 
tachycardia burden. A more recent trial looked at use of ranolazine alone and in 
combination with dronedarone in patients with pAF, found no benefit with either 
drug alone, but significantly reduced AF burden compared to placebo when the 
drugs were used in combination (Reiffel et al., 2015). No safety concerns were 
raised from the trial but we know that dronedarone has a significant negatively 
inotropic effect and is contraindicated in patients with structural heart disease 
thus putting up a barrier to the widespread use of this drug combination.  
 
Other avenues explored include upstream therapies. Angiotensin converting 
enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) have 
shown mixed results. A randomised controlled trial examining the effect of 
olmesartan in patients with lone paroxysmal AF (no AF risk factors) 
demonstrated no benefit on AF burden (Goette et al., 2012) whilst a 
retrospective matched case-control study in hypertensive patients with no other 
AF risk factors demonstrated a benefit for reduced AF burden amongst patients 
on an ACEi or ARB as compared with β-blockers or diuretics, but not calcium 
channel antagonists (Marott et al., 2014). The suggestion is such therapy is 
useful in conjunction with reducing other AF risk factors, and in line with general 
cardiovascular disease prevention reducing AF burden rather than being an 
independent modifier of AF risk. This too can be said for statin therapy whereby 
any signal for their effect on AF burden reduction is most likely due to reduced 
burden of vascular disease as an associated AF risk factor (Fang et al., 2012; 
Alves-Cabratosa et al., 2017).  
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1.3 ATP-sensitive Potassium Channels 
 
1.3.1 ATP-sensitive Potassium Channel Structure, Function and 
Modulation 
 
ATP-sensitive potassium channels (KATP) are weak inwardly-rectifying 
potassium (K+) channels displaying no voltage-dependent gating and instead 
link cellular excitability to the cell’s metabolic state. Inward rectification is 
produced by block of the cytosolic side of the pore by magnesium and 
polyamines but this block is weak affording still a strong outward current when 
the membrane potential is more positive to EK. Their structure consists of a 
hetero-octamer of subunits. The pore forming subunits are designated Kir6.1 
and Kir6.2, and regulatory sulphonylurea receptor (SUR) subunits SUR1, 
SUR2A and SUR2B (Inagaki et al., 1996). Four of each make up the channel 
(Clement et al., 1997; Inagaki et al., 1997; Shyng & Nichols, 1997) (see Figure 
1.10). 
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In native cells, transport of the Kir subunit to the sarcolemma is contingent on 
co-expression with SUR, which covers up an ER-retention motif (Neagoe & 
Schwappach, 2005). The genes KCNJ8 and KCNJ11 encode the two isoforms 
of the pore forming subunit Kir6.1 and Kir6.2 respectively (Inagaki et al., 1995b; 
1995a). SUR1 is encoded by ABCC8 and SUR2 encoded by ABCC9, with two 
RNA splice variants of SUR2 namely SUR2A and SUR2B (Inagaki et al., 1995a; 
Chutkow et al., 1996). KCNJ8 and ABCC9 are adjacent to each other on 
chromosome 12p12.1 and KCNJ11 and ABCC8 likewise on chromosome 
11p15.1 (Inagaki et al., 1995a; Chutkow et al., 1996). 
 
The Kir subunits have two trans-membrane domains (TMDs) with cytosolic N 
and C termini and an H5 segment with homology of the voltage gated K+ 
channels and which is responsible for the channel’s K+ selectivity (Flagg et al., 
2010). In addition, running parallel to the cytoplasmic surface of the cell 
 
Figure 1.10. KATP structure. Schematic of KATP structure. Kir6x pore-
forming subunits consist of two transmembrane domains. SURx subunits 
consist of 3 transmembrane domains, (TMD0 5 helices, TMD1 6 helices, 
TMD2 6 helices) with linking loops, together with nucleotide binding fold 
domains responsible for MgATP hydrolysis. Four Kir6x and four SURx make 
up a channel. 
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membrane, there is an amphipathic "interfacial" or “slide” helix thought to 
provide part of the physical link with adenosine triphosphate (ATP) gating 
(Ribalet et al., 2006; Enkvetchakul et al., 2007; Flagg et al., 2010). 
Conductances between the two isoforms differs, Kir6.2 ~80pS and Kir6.1 
~35pS (Inagaki et al., 1995a; 1996; Yamada et al., 1997; Kondo et al., 1998). 
There is direct magnesium (Mg2+) independent nucleotide tri-phosphate, and to 
a lesser extent nucleotide di-phosphate inhibition at the Kir subunits (Tucker et 
al., 1998; Babenko & Bryan, 2001). 
 
The SUR subunits consist of 3 TMDs (17 helices) and nucleotide binding folds 
(NBFs) associated with TMD2 that have Walker A and B motifs responsible for 
Mg2+ dependent binding of nucleotide di- and tri-phosphates on the cytoplasmic 
side of the membrane (Gribble et al., 1997a; Shyng et al., 1997; Flagg et al., 
2010). Such Mg2+ dependent binding allosterically regulates activity of the Kir 
subunit via interaction with cytoplasmic TMD0 and linker (or lasso) L0 regions 
(Lederer & Nichols, 1989; Smith et al., 2002; Babenko & Bryan, 2003).       
Mg2+-dependent hydrolysis of ATP to adenosine diphosphate (ADP), or a 
lowering of the intracellular MgATP/MgADP ratio, leads to NBF dimerisation and 
confers an increase in Kir opening by allosterically releasing the Kir subunit 
from nucleotide di- or tri-phosphate inhibition (Hopkins et al., 1992; Ueda et al., 
1999; Matsuo et al., 2000). 
 
When expressed in the absence of SUR by deletion of the ER-retention motif, 
the pore-forming subunits display differing effects to the influence of adenine 
nucleotides. Kir6.2 is directly inhibited (IC50 ~100µmol/L) whereas Kir6.1 not 
(Tucker et al., 1997; Farzaneh & Tinker, 2008). When either Kir6x are 
expressed along with SUR both have been shown to display adenine nucleotide 
inhibition even in Mg2+-free solution and the presence of SUR1 with Kir6.2, for 
example, decreases the IC50 to ~10µmol/L (Babenko & Bryan, 2001). R50, 
K185, I182, F333, G334, Y330, L205 are key residues implicated in ATP 
binding and gating of Kir6.2 (Tucker et al., 1998; Drain et al., 1998; Li et al., 
2000a; Ribalet et al., 2003; John et al., 2003; Antcliff et al., 2005; Tammaro et 
al., 2006). They have been delineated to a pocket associated with the 
"interfacial" helix and region of interaction of the L0 linker region to the pore in 
the area parallel to the submembrane space in a recently described cryo-EM 
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crystal structure of the Kir6.2/SUR1 channel (Martin et al., 2017). Most if not all 
residues have demonstrated importance of ATP binding via mutant studies 
owing to charged side chains important in phosphate species binding of ATP 
(Tucker et al., 1998; Drain et al., 1998; Li et al., 2000a; Ribalet et al., 2003; 
Antcliff et al., 2005). Kir6.1 does not share all of these residues. However, it 
may be that co-expression with SUR produces subsequent subtle folding of the 
pore that enables binding of ATP that can reconcile the findings that a truncated 
Kir6.1 expressed in the absence of SUR displays no direct ATP inhibition, but 
that expressed with SUR, does display ATP inhibition despite the absence of 
magnesium (Babenko & Bryan, 2001; Farzaneh & Tinker, 2008). Another 
specific feature of Kir6.1-containing species is their dependence on ADP for 
activation (Beech et al., 1993; Yamada et al., 1997; Satoh et al., 1998).  
 
Activation and inhibition is in fine balance. With co-expression of SUR the pore-
forming subunits appear sensitised to Mg2+-free adenine nucleotide inhibition 
but also the SUR subunit confers the ability to allosterically free the Kir subunit 
from this inihibition on Mg2+-dependent hydrolysis of ATP to ADP at the NBFs 
that lead to their dimerisation (Babenko & Bryan, 2001; Flagg et al., 2010). In 
the physiological setting cytosolic concentrations of ATP nearly always saturate 
inhibition at either pore type. In turn the activation/inhibition balance is largely 
driven by the MgATP/MgADP ratio at the SUR subunit (Babenko & Bryan, 
2001). Sensitising effects of co-expressed SUR on either pore type appear to 
be in a hierarchy with   SUR1 ~ SUR2B > SUR2A and Kir6.1 appears more 
sensitive to the effects of co-expressed SUR (Isomoto et al., 1996; Babenko et 
al., 1998; 1999). Kir6.1 species, thus, tend to display an intrinsically greater 
open probability. 
 
Phosphatidylinositol 4,5-bisphosphate (PIP2) interaction at the membrane is 
crucial to maintain channel activation and with its depletion there is channel 
inhibition (Tinker et al., 2014). PIP2 binding directly competes or at least inhibits 
ATP binding at the pore. In the recently described cryo-EM structures of the 
Kir6.2/SUR1 channel, the PIP2 binding site is delineated and in one case PIP2 
appears to be seen bound to the pore at the cytosolic domain close to the 
"interfacial" helix and in very close proximity to the ATP binding site just below 
(Li et al., 2017; Martin et al., 2017). All of these structures surround the area of 
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the inner helix gate on the pore and it is easy to reconcile that allosteric 
pressure from these species can alter the aperture of this gate. The structures 
are in keeping with previous homology modelling of the channel that has 
described the association and stoichiometry of Kir6x and SURx subunits (see 
Figure 1.10) (Clement et al., 1997; Antcliff et al., 2005). The structures have 
given further insight into the molecular mechanics governing channel gating. 
Rotation of TMDs 1 and 2 during NBF dimerisation from a "propeller" shape to a 
"quatrefoil" shape appears to release pressure from the TMD0, and crucially, 
the lasso L0 structure on the region of ATP binding preventing buttressing of 
the ATP molecule and promoting its release, thus causing increased aperture of 
the inner helix gate and opening of the pore (Lee et al., 2017). Figure 1.11 
demonstrates 2D class averages, EM density maps and ribbon representations 
depicted from the recent publications of the cryo-EM structure of Kir6.2/SUR1 
channels. 
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Figure 1.11. Cryo-EM structure of a Kir6.2/SUR1 channel. A. 2D class 
averages of channels in top view and side view from a cryo-EM micrograph 
(taken from Martin et al., 2017). B. Side view and view from below of (top) 
quatrefoil and (bottom) propeller forms of the channel showing the Lasso 
abutting the inner helix gate in the propeller form (taken from Lee et al., 
2017). C. (Left) Ribbons representation of two Kir6.2/SUR1 fusion protomers 
in the quatrefoil form, (Right) EM density and ribbons representations of the 
Kir6.2 tetramer with EM density of the bound ATP molecule in yellow (taken 
from Lee et al., 2017). 
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Changes in the ATP/ADP ratio at different compartments in the subcellular 
space are transmitted via diffusion through the 2 phosphotransfer pathways 
controlled by creatine kinase (CK) and adenylate kinase (AK) (Carrasco et al., 
2001; Crawford et al., 2002; Selivanov et al., 2004; Flagg et al., 2010). The CK 
pathway is able to amplify subtle changes in ATP concentration from one 
compartment to another such that small reductions in the bulk cellular 
concentration of ATP are amplified at the submembrane space and can be 
sensed by KATP (Selivanov et al., 2004). This occurs as the stoichiometry of flux 
of submembrane creatine phosphate (CrP) required to correct for reductions in 
bulk ATP concentration is much larger than that required for the reverse 
process (Selivanov et al., 2004). The AK pathway is able to fine-tune this to 
avoid large oscillations in ATP and ADP at the submembrane (Selivanov et al., 
2004). 
 
There is also modulation by downstream effects of G-protein linked protein 
kinase A (PKA) phosphorylation with subsequent phosphorylation of both the 
Kir and SUR subunits. In vascular smooth muscle (VSM) for example this 
activates the channel (Tinker et al., 2014). In cardiac myocyte channels this is 
less well examined but also appears to have the same effect (Zingman et al., 
2002; Flagg et al., 2010; Kim et al., 2012). Apart from β-adrenergic activation 
via PKA, adenosine also activates the channel via this pathway in the 
vasculature through stimulatory G protein coupled adenosine A2 receptors 
(Kleppisch & Nelson, 1995). 
 
The modulation by phosphorylation of protein kinase C (PKC) also has 
heterogeneous effects dependent on the specific subunit composition, 
activating KATP at the cardiomyocyte sarcolemma and inhibiting at the VSM cell 
membrane (Flagg et al., 2010; Tinker et al., 2014). 
 
Thus, in a metabolically challenging environment with a low intracellular 
ATP/ADP ratio and thus high MgADP/MgATP ratio, there is a tendency to 
accelerate repolarisation or hyperpolarise the membrane. In cardiac myocytes 
there is acceleration of phase 3 of the action potential through increased 
channel activity and thus action potential duration (APD) shortening (Lederer et 
al., 1989; Venkatesh et al., 1991; Kubota et al., 1993; Tinker et al., 2014). 
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The channel expressed in pancreatic β cells links cellular metabolism to insulin 
secretion. Active glucose uptake after a meal when circulating glucose levels 
are high, leads to a higher ATP/ADP ratio conferring closure of the channel, 
with reduced K+ efflux leading to depolarisation of the cell membrane and 
opening of voltage-gated calcium channels. The inward flow of calcium leads to 
exocytosis of insulin (Ashcroft, 1988; Aguilar-Bryan et al., 1995; Inagaki et al., 
1996). 
 
It is also expressed in the brain, skeletal muscle and vascular smooth muscle 
(VSM) (Flagg et al., 2010). Ablation of KATP currents in VSM cells produces 
hypertensive animals and coronary artery spasm through prolonged smooth 
muscle depolarisation and contraction (Miki et al., 2002; Chutkow et al., 2002). 
Its expression and function in the heart will be discussed further in later 
sections. 
 
1.3.2 ATP-sensitive Potassium Channel Pharmacology 
 
KATP channels involve a rich pharmacology. This has been exploited through the 
use of sulphonylureas in the treatment of diabetes. Drugs such as tolbutamide 
and glibenclamide inhibit KATP. Binding and allosteric modulation at the SUR 
subunit causes closed state stability and increased interburst closed times. This 
prolongs depolarisation of the cell (in this case the pancreatic β-cell), with 
inward Ca2+ current triggering exocytosis and increased release of insulin 
(Aguilar-Bryan et al., 1995; Sola et al., 2015). There are also a variety of KATP 
channel openers (KCOs) including diazoxide, pinacidil, nicorandil and 
cromakalim with effects mediated via Mg2+-dependent hydrolysis of ATP to ADP 
at the SUR subunit (Schwanstecher et al., 1998; Babenko et al., 2000; 
Bienengraeber et al., 2000). 
 
Inhibitors 
 
These drugs have specificity for particular SUR subunits. Tolbutamide is more 
specific to SUR1 than SUR2A with TMD2 helices 12-16 being implicated for 
high affinity binding and inhibition (Ashfield et al., 1999; Babenko et al., 1999). 
An interaction with tolbutamide and the N-terminus of the pore-forming subunit 
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also appears to be crucial to its effect whilst inhibition is also augmented by its 
interference with the action of MgADP at the NBFs promoting unbalanced Mg2+-
independent inhibition at the pore (Gribble et al., 1997b; Reimann et al., 1999; 
Babenko et al., 1999). SUR1 containing protein complexes can be inhibited by 
micromolar concentrations of tolbutamide while glibenclamide is less specific 
between SUR1 and SUR2A where its binding site in biochemical studies using 
truncated protein implicates the L0 cytosolic loop, TM helices 15/16 and the 
cytosolic loop 8 between them (Gribble et al., 1998; Ashfield et al., 1999; 
Babenko et al., 1999; Mikhailov et al., 2001). In one of the recently defined 
crystal structures it is implied that a density befitting of glibenclamide can be 
seen associated with a region involving both the above cytosolic loops that 
would support the previous putative binding site data (Lee et al., 2017). It is also 
suggested that this position would serve to keep the NBFs forced apart 
preventing dimerisation and thus maintaining the buttressing effect of the L0 
loop on the inner helix gate providing a mechanistic explanation to the inhibitory 
effect of glibenclamide on channel opening (Lee et al., 2017). However, the 
authors stipulate that further studies with greater resolution of structures will be 
needed to confirm this. 
 
HMR1883 and its sodium salt HMR1098 are sulphonylurea derivatives thought 
to have a selective inhibition of SUR2A containing channel complexes over 
SUR1 though this has also been challenged recently (Gögelein et al., 1998; 
Russ et al., 2001; Manning Fox et al., 2002; Zhang et al., 2011). PNU37883A is 
unique in that it is thought to be a direct pore blocker of the Kir subunit and it 
has been suggested exhibits selectivity for Kir6.1 containing channel complexes 
over Kir6.2 but again this is also a matter of contention (Cui et al., 2003; 
Kovalev et al., 2004). It is also implicated in blocking other ion channels with K+ 
and Ca2+ conductance (Teramoto, 2006a). 
 
Openers 
 
Diazoxide is relatively SUR1-specific at micromolar concentrations owing to 
residues at TMD1 helices 6-11 and NBF1 and pinacidil SUR2 specific at similar 
concentrations owing to residues at TMD2 helices 12-17 (Babenko et al., 2000; 
Dabrowski et al., 2002; Hambrock et al., 2004). Similar findings to pinacidil 
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relate to cromakalim and its analogues (Uhde et al., 1999; Babenko et al., 2000; 
Moreau et al., 2000; 2005b). Indeed transfer of residues at TM17 in SUR2A to 
SUR1 confers the SUR2A KCO sensitivity patterns in SUR1 (Moreau et al., 
2000; Hambrock et al., 2004). Pinacidil, cromakalim and to a lesser extent, 
diazoxide, all have opener activity on SUR2B-containing channels 
(Schwanstecher et al., 1998; Uhde et al., 1999; Matsuoka et al., 2000; Moreau 
et al., 2005b). Whilst diazoxide is thought not to activate SUR2A-containing 
channels with great efficacy, reports have shown a binding affinity and ability to 
activate dependent on the presence of MgADP (Schwanstecher et al., 1998; 
D'hahan et al., 1999; Matsuoka et al., 2000). 
 
The pharmaco-topology of drug-SUR selective binding as determined by the 
site directed mutagenesis and chimaeric studies described above, is 
summarised in Figure 1.12. 
  
 72 
 
 
Figure 1.12. Pharmaco-topology of KATP openers and inhibitors. 
Pharmaco-topology with respect to the different SUR subtypes. Colour 
coding demonstrates crudely the homology between the subtypes. SUR2A 
and SUR2B (red) share almost 100% homology. However, the terminal 42 
amino acids of the C terminus of SUR2A and SUR2B differ, and SUR1 
shares almost 100% homology with that in SUR2B as depicted by the colour 
coding in blue. Openers and their sites of action are depicted in green and 
inhibitors black. Upper case denotes binding with high affinity and lower case 
with lower affinity. The action of diazoxide on SUR2A is shown in dark green 
in that this interaction requires the presence of a high concentration of 
MgADP, and this probably results allosterically due to the differing terminal 
42 amino acids at the C terminus of SUR2A (Moreau et al., 2005b). 
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1.3.3 Cardiac ATP-sensitive Potassium Channels 
 
Cardiac protection 
 
KATP channels are expressed throughout the heart in the atria, ventricles and 
the cardiac conduction system. They appear to be closed under normal 
metabolic conditions (Noma, 1983; Zünkler et al., 1997; Babenko et al., 1998; 
Pelzmann et al., 2001). Shortening of phase 3 of the action potential, through 
KATP opening in response to metabolic stress (a reduction of intracellular ATP 
concentration [ATP]i and an increase in intracellular ADP concentration [ADP]i 
in the presence of Mg2+), is thought to provide a protective mechanism during 
these periods. In one study looking at guinea pig ventricular myocytes, action 
potential duration (APD) was reduced by as much as 50% when as little as 
0.7% of the maximum KATP conductance was active (Nichols et al., 1991). 
Excessive calcium (Ca2+) loading confers cellular toxicity (Bers, 2008). 
Shortening of APD allows for reduced calcium (Ca2+) loading together with 
conservation of cellular ATP, and this has been shown to be executed by KATP 
opening in response to ischaemia (McPherson et al., 1993; Jovanović et al., 
1998; 1999; Suzuki et al., 2002; Baumann et al., 2002). This effect can also be 
diminished with ablation of KATP current and in animal models KATP inhibition, 
both through knockout and pharmacological modulation, has been shown to 
increase infarct size after ischaemic insults (Gross & Auchampach, 1992; 
Jovanović et al., 1998; Suzuki et al., 2002; 2003; Aziz et al., 2017). 
 
There is also evidence that shortening of APD via KATP opening is important for 
exertional capacity at higher heart rates during β-adrenergically driven stress 
and the “fight/flight” response (Zingman et al., 2002). 
 
KATP channel activation appears fundamental to the process of ischaemic 
preconditioning in cardiac and skeletal muscle, where short bursts of ischaemia 
lead to conditioning of tissue and reduced injury to future, more prolonged bouts 
of ischaemia (Murry et al., 1986; Gross & Auchampach, 1992). Whether this is 
due solely to activation of sarcolemmal currents still remains to be seen and 
there is a vast amount of work, reviewed extensively by Yellon and Downey, 
supporting the theory that a mitochondrial KATP current (mitoKATP) is responsible 
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(Yellon & Downey, 2003). Opening of the mitochondrial channel and influx of K+ 
into mitochondria is thought to cause osmotic swelling altering the ability to 
phosphorylate ADP. ADP cannot enter the intermembrane space due to 
swelling. Instead creatine is phosphorylated and this is a more efficient means 
of transmitting energy to the cytoplasm (Yellon & Downey, 2003). An influx of K+ 
through mitoKATP opening also reduces toxic Ca2+ entry and prevents the 
opening of the mitochondrial transition pore through which other toxic 
substrates can enter during prolonged bouts of ischaemia (Yellon & Downey, 
2003). 
 
With increases of afterload, Ca2+ overload can lead to cardiac hypertrophy 
through activation of the calcineurin-NFAT signal transduction cascade that 
drives the expression of hypertrophy genes (Wilkins & Molkentin, 2004). 
Ablation of KATP currents in knockout animals has been shown to correlate with 
cardiac hypertrophy and heart failure phenotypes and that this is likely to be 
directly related to APD prolongation and Ca2+ overload (Kane et al., 2006; 
Yamada et al., 2006). Consistent with a role of KATP in heart failure phenotypes, 
there is convincing human evidence that a frame-shift mutation in the region 
encoding the NBF of SUR2A, which causes defective catalysis of ATP 
hydrolysis and reduced channel function, is associated with an otherwise, 
idiopathic, dilated cardiomyopathy (Bienengraeber et al., 2004). Reduced KATP 
activity is also implicated in the reduced downstream activity of peroxisome 
proliferator-activated receptor Υ coactivator (PGC)-1 α and a group of energy 
metabolism related genes at both protein and mRNA levels that leads to a heart 
failure phenotype (Hu et al., 2008; Zlatkovic et al., 2009). 
 
Arrhythmia 
 
As explained in section 1.2.1 arrhythmia mechanisms described include re-
entry (anatomical, functional and spiral wave), abnormal automaticity and 
triggered events (EADs and DADs) (Tse, 2016). In guinea pig ventricular 
myocytes action potential duration (APD) was reduced by as much as 50% 
when as little as 0.7% of the maximum KATP conductance was active (Nichols et 
al., 1991) and the opening of KATP channels leads to faster repolarisation and a 
shorter QT interval on the surface ECG, a marker of the activation-recovery 
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interval (Kubota et al., 1993; Lu et al., 2008). In turn this gives a reduced 
effective refractory period, which in principle can predispose to re-entrant 
circuits and a pro-fibrillatory state. Pro-fibrillatory effects of KATP openers have 
been shown in numerous animal models and a major factor in this is likely to 
involve heterogeneous dispersion of APD effects both in an interventricular, and 
intraventricular manner between layers of the myocardium (Wolleben et al., 
1989; Chi et al., 1990; Furukawa et al., 1991; Di Diego & Antzelevitch, 1993; 
Wolk et al., 1999; Uchida et al., 1999). In a Kir6.2 knockout (KO) mouse model 
surface ECG recordings showed absence of ST elevation in response to 
ischaemia in the knockouts that was present in the wild-type (WT) mice (Li et 
al., 2000b). In epicardially mapped dogs regional ST elevation was seen in 
response to regionally induced ischaemia by coronary ligation of the left anterior 
descending artery (LAD) that was very similar to regional injection of the KCO 
pinacidil in the same artery, and in both, ST elevation was reversed with the 
KATP inhibitor glibenclamide (Kubota et al., 1993). Similar glibenclamide reversal 
of ischaemia-induced T wave changes was seen in another canine study 
(Kondo et al., 1996). The component of ST deviation seen in response to 
ischaemia that can be attributed to KATP opening, is explained by a 
heterogeneous dispersion of transmural expression such that there is higher 
expression in the epicardium relative to the endocardium (Furukawa et al., 
1991). Increased outward K+ current in response to ischaemia in the epicardium 
thus provides a transmural voltage gradient seen on the surface ECG. 
 
The corollary is that blocking KATP would be anti-arrhythmic. Studies in rat and 
canine models have looked at ventricular fibrillatory potential in the context of 
ischaemia and shown that this is reduced in the presence of KATP blocking 
drugs (Wolleben et al., 1989; Kantor et al., 1990; Billman et al., 1998). This has 
been replicated in a Langendorff-perfused explanted cardiomyopathic human 
heart model (Farid et al., 2011). 
 
Studies have also investigated arrhythmia inducibility in atrial preparations. In a 
rat model isoproterenol-induced metabolic stress led to a reduced intracellular 
ATP concentration and an increased atrial tachyarrhythmia inducible state that 
was reversed with the KATP inhibitor glibenclamide (Kim et al., 2012). In a 
murine model with salt-induced hypertension, atrial KATP upregulation was seen 
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coinciding with shortened APD and ERP and increased atrial arrhythmia 
inducibility (Lader et al., 2011). In human hearts obtained at transplantation, 
KCOs were seen to increase atrial arrhythmia inducibility that was then 
terminated with a KATP inhibitor (Fedorov et al., 2011). Pro-fibrillatory effects of 
KATP openers have also been shown in rat, canine, rabbit and feline models 
(Wolleben et al., 1989; Chi et al., 1990; Furukawa et al., 1991; Di Diego & 
Antzelevitch, 1993; Wolk et al., 1999; Uchida et al., 1999). 
 
Perhaps paradoxically, however, in clinical trials in patients with cardiac 
ischaemia, patients using the KATP opener and nitric oxide donor nicorandil had 
improved outcomes and no increased arrhythmic risk (IONA Study Group, 
2002; Simpson & Wellington, 2004). In fact the drug was even found to reduce 
arrhythmic risk in one study (Ueda et al., 2004). This is despite its ability to 
activate both the proposed smooth muscle and classic cardiac sarcolemmal 
channel (Reimann et al., 2001). Indeed, whilst KATP opening during ischaemia 
may well be pro-fibrillatory, its pharmacological blockade during ischaemic 
insults leads to increased infarct size in animal models (Gross & Auchampach, 
1992; Suzuki et al., 2002; 2003). Thus, from a translational perspective, 
particularly with regards the ventricle, pursuit of an anti-arrhythmic mechanism 
from channel blockade in this setting may well be counter-productive. 
 
Atrial electrophysiology remodels as a consequence of changes in ion channel 
expression and/or regulation and gating with AF (Dobrev et al., 2005; Workman 
et al., 2008; Heijman et al., 2014). Conflicting evidence exists for remodelling of 
KATP current in human chronic AF. Two studies have looked at differences in 
KATP current density in isolated right atrial appendage myocytes between sinus 
rhythm and chronic AF patients and showed opposing results (Balana et al., 
2003; Wu et al., 2005). Another report looking at mRNA expression of a variety 
of potassium channel genes in AF patients demonstrated a reduced expression 
of KNCJ11 (Brundel et al., 2001). It is unclear how these findings might relate to 
the maintenance of the arrhythmia though a reduction in current might serve to 
promote re-entry through conduction slowing if diastolic membrane potential is 
more depolarised. A reduction in repolarising current might also promote 
triggered activity. 
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The early repolarisation pattern (“J wave”) on the ECG is commonly seen in 
healthy individuals. Though in documented kindreds it can represent something 
more malignant and the early repolarisation pattern (“J wave syndromes”) may 
predispose individuals to ventricular fibrillation and sudden death (Antzelevitch, 
2012). A rare variant in KCNJ8 (S422L) has been associated with early 
repolarisation and ventricular fibrillation (Haïssaguerre et al., 2009). Other 
groups have also described similar findings with the same mutation (Medeiros-
Domingo et al., 2010; Barajas-Martínez et al., 2012). This mutant Kir6.1 subunit, 
co-expressed with SUR in mammalian cells, leads to an increase in current 
density compared to wild-type, owing to a decrease in sensitivity and inhibition 
by ATP (Haïssaguerre et al., 2009; Medeiros-Domingo et al., 2010; Barajas-
Martínez et al., 2012). The mutation has also been associated with lone atrial 
fibrillation in conjunction with early repolarisation in another case study 
(Delaney et al., 2012).  
 
Whilst channel opening might open up tissue to the increased likelihood of re-
entry, in the case of abnormal automaticity or triggered activity, it is also 
possible that hyperpolarisation of the membrane will lead to the arrhythmia 
being extinguished. Effects of KATP modulation on automaticity have largely 
been investigated in isolated nodal cell or Purkinje fibre preparations and 
confirm that an increased outward potassium flux and membrane 
hyperpolarisation on channel opening slows spontaneous firing rate and 
suppresses automaticity (Yanagisawa & Taira, 1981; Satoh & Hashimoto, 1984; 
Imanishi et al., 1984; Lathrop et al., 1990). Hypoxia-induced spontaneous cycle 
length prolongation was blunted in Kir6.2 deleted Langendorff hearts 
suggesting a prominent role for KATP in sinus node automaticity (Fukuzaki et al., 
2008). Pinacidil has been shown to abolish EADs produced after drug-induced 
APD prolongation and DADs produced after ouabain induced calcium overload 
in canine ventricular myocytes (Spinelli et al., 1991). Similar effects have been 
shown using nicorandil (Lathrop et al., 1990). Indeed, nicorandil can abolish 
transmural dispersion of repolarisation and triggered activity in canine long QT 
models (Shimizu & Antzelevitch, 2000; Chinushi et al., 2002), and when given 
intravenously, has been shown to abolish EADs and ventricular fibrillation in a 
patient with long QT syndrome (Sato et al., 1995) and abolish Torsades de 
Pointes in a patient with atrio-ventricular block and bradycardia induced QTc 
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prolongation (Watanabe et al., 1999). Loss of KATP function has also been 
shown to promote triggered activity. For example, Kir6.2 deletion was met with 
defective action potential shortening and EADs in isoproterenol challenged 
Langendorff mouse hearts (Liu et al., 2004). A similar mechanism was 
proposed in a patient with lone Atrial Fibrillation (AF) emanating from the Vein 
of Marshall who was found to have a missense mutation Thr1547Ile in the 
ABCC9 gene encoding the SUR2A subunit (Olson et al., 2007). Thus, the exact 
role of KATP in arrhythmia is complex and substrate dependent. 
 
1.3.4 ATP-sensitive Potassium Channels and Cardiac Chamber Subunit 
Specificity 
 
With the notion that manipulation of KATP current might influence arrhythmia 
inducibility in the clinical setting, an attractive aspect for KATP as a potential 
pharmacological target is its subunit composition and that there might be 
differences in expression between atria and ventricle. This might lead to the 
development of novel drugs that target the atria, circumventing the problems 
discussed above of unwanted effects on the ventricle of many pre-existing 
drugs used in clinical practice today. 
 
A general picture has emerged with regards subunit expression and 
composition. The classic cardiac ventricular KATP channel comprises Kir6.2 and 
SUR2A. For example, the KATP properties of ventricular myocytes, including 
human, have been recapitulated in heterologous expression systems with this 
combination of subunits (Inagaki et al., 1996; Babenko et al., 1998). Ventricular 
myocytes of Kir6.2-/- or SUR2-/- mice lack KATP currents (Suzuki et al., 2001; 
Chutkow et al., 2001) and are unaffected in SUR1-/- mice (Elrod et al., 2008). 
The opposite is true of SUR1-/- murine atrial myocytes and in this case KATP 
currents are absent (Flagg et al., 2008). This finding was reproduced in 
experiments with SUR1-/- murine atrial and ventricular myocytes with a variety 
of SUR isotype specific KCOs and inhibitors showing ablation of atrial but not 
ventricular currents (Glukhov et al., 2010). Ablation of both atrial and ventricular 
currents in Kir6.2-/- mice has also been demonstrated (Glukhov et al., 2010). 
The importance of Kir6.2 in the mouse atria has also been established in 
another set of experiments with a mouse with global deletion (Saegusa et al., 
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2005). In a murine model, the atrial channel appears to be represented at least 
in part by Kir6.2/SUR1. 
 
In the sino-atrial node (SAN) cells of the rabbit it was shown that SUR2 specific 
openers caused hyperpolarisation of the maximum diastolic potential (MDP) 
and reduced automaticity but the single channel KATP conductance was an 
intermediate 52±8 pS suggesting both pore-forming subunits could be present 
(Han et al., 1996). KATP currents present in SAN cells of WT mice have, 
however, been ablated in Kir6.2 KO mice suggesting the importance of this 
pore-forming subunit in this model (Fukuzaki et al., 2008). Recently our lab has 
demonstrated direct electrophysiological effects on SAN cells of conduction 
system-specific knockout of Kir6.1 in the mouse heart and in the majority of 
cells KATP current was activated by diazoxide and sensitive to tolbutamide (Aziz 
et al., 2018). An ATP-sensitive K+ current that increases with metabolic 
inhibition has also been demonstrated in the atrio-ventricular nodal (AVN) cells 
of the rabbit (Kakei & Noma, 1984). The single channel conductance was in 
keeping with that of Kir6.1 as forming the pore but there has been little other 
work that demonstrates this.  
 
The presence of KATP has also been demonstrated in the Purkinje system of the 
mouse heart whereby the current was more sensitive to activation by MgADP 
when compared to ventricular myocytes, and where Kir6.1 mRNA expression 
was higher than Kir6.2 in the Purkinje system compared to the ventricle (Bao et 
al., 2011). In this study currents in the Purkinje system were responsive to 
diazoxide and levcromakalim, and only levcromakalim in the ventricle. SUR2B 
mRNA expression was higher than SUR2A in the Purkinje system compared to 
the ventricle. There were similiar findings both pharmacologically and with slope 
conductance in another study all suggesting a predominance of a Kir6.1/SUR2B 
composition (Light et al., 1999). 
 
Whilst the classic cardiac sarcolemmal channel has been described as 
Kir6.2/SUR2A and in the rodent atria Kir6.2/SUR1, mRNA encoding Kir6.1 is 
consistently detected at high levels in human heart (Erginel-Unaltuna et al., 
1998; Gaborit et al., 2007; Fedorov et al., 2011). There appears to be some 
association between gain-of-function KCNJ8 mutations and ECG 
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findings/arrhythmia (Haïssaguerre et al., 2009; Medeiros-Domingo et al., 2010; 
Delaney et al., 2012; Barajas-Martínez et al., 2013). Various studies have 
recognised the capability for heteromultimerisation of the pore-forming subunits 
that would explain intermediate single channel conductances (Baron et al., 
1999; Cui et al., 2001; Pountney et al., 2001). Expression of pore mutations in 
Kir6.1 and Kir6.2 have both caused reductions in KATP current in rat 
cardiomyocytes (van Bever et al., 2004). Heteromultimers of the SUR subunit 
have also been demonstrated (Cheng et al., 2008; Wheeler et al., 2008), 
though the likelihood of this, particularly in native cells, has been questioned 
(Giblin et al., 2002; Tricarico et al., 2006). 
 
Changes in expression patterns have also been demonstrated in response to 
hypoxia and ischaemic insults. SUR1 expression has been seen to increase 
post-infarct in the infarct border zone in the ventricles of rat hearts (Isidoro 
Tavares et al., 2007), whereas SUR2A expression was seen to increase in rat 
embryonic heart cells in response to hypoxia (Crawford et al., 2003). In another 
study in rat embryonic heart cells, hypoxia appeared to up-regulate Kir6.1 
expression and down-regulate Kir6.2 expression (Melamed-Frank et al., 2001). 
This may be co-ordinated by a Forkhead transcription factor signalling pathway 
(Philip-Couderc et al., 2008; Raeis et al., 2010). A study on human hearts 
obtained at transplantation found SUR2A to be present in both atria and 
ventricle of non-failing hearts but a signal for SUR1 only in the ventricle. Both 
SURs appeared to be present in atria and ventricles of failing hearts suggesting 
an up-regulation of SUR1 in this setting (Fedorov et al., 2011). 
 
Conflicting reports are available with regards the subunit expression in vascular 
smooth muscle though the general picture appears to be that of Kir6.1/SUR2B 
or Kir6.2/SUR2B (Flagg et al., 2010; Tinker et al., 2014). In skeletal muscle 
reports suggest Kir6.2 is expressed with either SUR1 or SUR2A depending on 
fibre type (Tricarico et al., 2006; Flagg et al., 2010). In the pancreas a more 
cemented opinion has been formed that the composition is that of Kir6.2/SUR1 
(Yokoshiki et al., 1998). 
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One approach to defining the importance of KATP subunit expression in different 
tissues is to see the effect of mutations leading to pathology and disease traits. 
A summary of this is provided in Table 1. 
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CLINICAL 
CONDITIONS 
GENE MECHANISMS AND 
OBSERVATIONS 
REFERENCES 
CARDIAC    
Brugada 
syndrome, Early 
repolarisation ("J 
wave") 
syndrome, atrial 
and ventricular 
fibrillation 
KCNJ8 S422L GOF has been 
associated with these 
conditions 
(Haïssaguerre et al., 
2009; Medeiros-
Domingo et al., 2010; 
Barajas-Martínez et 
al., 2012; Delaney et 
al., 2012) 
 ABCC9 V734I and S1402C 
GOF mutations 
implicated 
(Hu et al., 2014) 
Atrial Fibrillation ABCC9 Missense mutation 
T1547I leading to 
loss of function and 
implicated in AF 
initiating from the 
Vein of Marshall 
(Olson et al., 2007) 
Sudden Infant 
Death Syndrome 
KCNJ8 In frame deletion 
E332del and 
missense mutation 
V346I each cause 
loss of function and 
have been associated 
with this condition 
(Tester et al., 2011) 
Increased LV size 
and Heart Failure 
KCNJ11 E23K mutant appears 
over-represented in 
heart failure patients 
(Reyes et al., 2008; 
2009) 
 
 ABCC9 Missense mutation 
A1513T or frameshift 
mutation and stop 
codon introduction at 
L1524 - both impair 
nucleotide hydrolysis 
at NBF2 causing 
reduced function and 
associated with DCM 
patients 
(Bienengraeber et al., 
2004) 
Coronary spasm 
and Myocardial 
Infarction 
ABCC9 Association with 
V734I mutation which 
causes both reduced 
ATP inhibition and 
reduced MgNDP 
activation when 
mutant co-expressed 
with SUR2B 
(Smith et al., 2013) 
 
Table 1. Summary of human diseases or traits in which mutations or 
genomic variants in KATP occur. 
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INSULIN 
SECRETION 
   
Congenital 
Hyperinsulinism 
KCNJ11 Recessive mutations 
leading to loss of 
KATP channels at the 
membrane and ER 
retention eg. H259R 
(Marthinet et al., 
2005) 
 KCNJ11 Recessive mutations 
producing non-
functional protein eg. 
Y12X, L147P 
(Thomas et al., 1996; 
Nestorowicz et al., 
1997) 
 KCNJ11 Dominant mutation 
causing impaired 
pore-opening eg. in-
frame deletion 
I284del 
(Kapoor et al., 2011) 
 
 
 ABCC8 Recessive mutations 
leading to loss of 
KATP channels at the 
membrane and ER 
retention eg. 
F1388del 
(Sharma et al., 1999; 
Cartier et al., 2001; 
Yan et al., 2007; 
Taneja et al., 2009) 
 ABCC8 Recessive mutations 
causing loss of 
MgADP and drug 
sensitivity despite 
membrane resident 
channels eg. 
T1139M, R1215Q 
(Shyng et al., 1998) 
 ABCC8 Dominant mutations 
causing reduced 
sensitivity to 
metabolic inhibition 
and drug activation 
eg. V187D, E1506K 
(Otonkoski et al., 
1999; Huopio et al., 
2000; Kapoor et al., 
2011) 
Neonatal 
Diabetes 
KCNJ11 Missense mutations 
causing ATP 
insensitivity and GOF 
eg. E227K, E229K 
(Gloyn et al., 2004; 
Girard et al., 2006; 
Vedovato et al., 
2016) 
 KCNJ11 In-frame deletion 
Kir6.2-28Δ32 causing 
ATP insensitivity and 
GOF 
(Craig et al., 2009) 
 ABCC8 Missense mutations 
causing ATP 
insensitivity and GOF 
eg. L213R, I1424V 
(Babenko et al., 
2006) 
 
(Table 1 Continued)  
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Type 2 Diabetes KCNJ11 E23K mutant causing 
modest ATP 
insensitivity and GOF 
(Gloyn et al., 2003) 
 
 ABCC8 S1369A variant when 
co-expressed with 
KCNJ11 E23K variant 
causes ATP 
insensitivity and GOF 
(Hamming et al., 
2009) 
CANTÚ 
SYNDROME 
   
Hypertrichosis, 
Osteochondro-
dysplasia, 
Cardiomegaly 
and concentric 
hypertrophy 
KCNJ8 Missense non-
synonymous variant 
V65M, functional 
characteristics not 
confirmed 
(Brownstein et al., 
2013) 
 ABCC9 Missense mutations 
leading to reduced 
ATP sensitivity or 
increased MgADP 
activation and GOF 
eg. P432L, A478V, 
C1043Y 
(Harakalova et al., 
2012; van Bon et al., 
2012; Cooper et al., 
2015) 
 
(Table 1 Continued)  
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1.4 The Mouse Heart as a Model for Investigating Arrhythmia 
Mechanisms and Therapies 
 
The stark differences in body surface area to volume ratio of the mouse 
compared to larger mammals are exhibited again by differences in cardiac 
electrophysiological properties. The murine heart rate ranges from 500-700 
beats per minute (bpm) as compared to the normal human range ~40-180bpm 
 
 
Figure 1.13 Comparison of human and mouse action potentials (taken 
from Nerbonne, 2004). Schematic demonstrating differences in the 
ventricular action potential of the human (left) and mouse (right). Downward 
shading denotes inward current, and upward shading outward current. INa, 
inward sodium current; ICa,L, L-type inward calcium current; Ito,f, transient 
outward potassium current fast recovery component; Ito,s, transient outward 
potassium current slow recovery component; IKs, slowly activating delayed 
rectifier potassium current; IKr, rapidly activating delayed rectifier potassium 
current; IKATP, ATP-sensitive potassium channel current; IK,slow1, IK,slow2, Iss are 
delayed recifier currents expressed in murine cardiomyocytes that are absent 
in human cardiomyocytes. 
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and the murine action potential is markedly shorter (~50-80ms) than the human 
(~250-300ms) (Kaese & Verheule, 2012) (see Figure 1.13). 
 
Where similar ion channel expression occurs between mice and human so too 
largely does the molecular composition (Nerbonne & Kass, 2005). The only 
exception is with regards the fast recovering transient outward current, Ito,f 
where the pore-forming subunit in the mouse is made up of a heteromultimer of 
Kv4.2 and Kv4.3 subunits as opposed to a homomultimer of Kv4.3 subunits in 
human (Nerbonne, 2004). Murine nodal cells share similar ion channel and gap 
junction protein expression, together with nodal structure, to that of human but 
Ito,s is the major repolarising current (Nerbonne & Kass, 2005; Kaese & 
Verheule, 2012). In the atria and ventricles the fast depolarising phase 0 
upstroke is supplied, as in human, by the Nav1.5 sodium channel (Nerbonne, 
2004). There is, however, a much lower contribution of inward calcium current 
and late persistent sodium current in the mouse and as such there is merely a 
gradual repolarisation and no spike and notch of phase 1 and a loss of dome in 
phase 2 (Nerbonne, 2004; Kaese & Verheule, 2012). This is also compounded 
by ~90% of calcium extrusion being through SERCA at the SR and only a small 
contribution by forward mode INa/Ca current. In the human this is more like 70:30 
in favour of SERCA under steady state conditions (Bers, 2002). Calcium 
handling, is therefore, different in the mouse and this will have implications on 
arrhythmia mechanisms. The major repolarising currents in mouse atria and 
ventricle are IKslow1 (Kv1.5, the molecular correlate of which in the human 
produces the atrial specific IKur current) and IKslow2 (Kv2.1), along with Ito 
(Nerbonne, 2004). There is negligible expression of IKr and IKs. KChIP2 also 
provides the auxiliary subunit for Ito as it does in human, except regional and 
transmural expression is dependent on pore expression rather than KChIP2 
expression, as in the human ventricular wall (Nerbonne, 2004). Mice share 
molecular correlates for IKATP, IK1 and IKACh,Ado (Nerbonne & Kass, 2005). 
Connexon expression largely mirrors that of humans (Kaese & Verheule, 2012). 
Conduction velocity in the mouse is not too dissimilar to larger mammals (~50-
60cm/s) and thus surface ECG parameters and timings are much shorter given 
the shorter distances impulses must travel in the murine heart (Kaese & 
Verheule, 2012). Owing to the murine myocardial wall being much thinner than 
the human, and due to much more subtle dispersion in repolarisation times, the 
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surface T wave of the mouse is a much more subtle feature. Despite the above, 
incidence of arrhythmias still appears higher when there is increased dispersion 
of repolarisation (Nerbonne, 2004). Despite the small area and volume of 
murine atria and ventricles, and the small wavefront path length that would be 
required for re-entry, re-entrant arrhythmias have been demonstrated in murine 
hearts and cholinergic atrial fibrillation with shortening ERP has also been 
demonstrated (Wakimoto et al., 2001; Opel et al., 2015). Induced fibrosis has 
also contributed to arrhymogenicity as we see in human (Choi et al., 2012; 
Kaese & Verheule, 2012). Spiral waves too have been observed as have 
triggered induced mechanisms for both ventricular and atrial arrhythmia 
(Comtois et al., 2005; Kaese & Verheule, 2012). Transgenic mice with 
knockdown of Ito and IKslow have shown QT prolongation and a higher incidence 
of ventricular arrhythmias (Nerbonne, 2004).   
 
Transgenic models might alter gene expression in different ways in the mouse 
compared to the human, the species' do not share identical ion channel 
expression patterns and of course the mouse heart size introduces technical 
issues. However, all proposed human arrhythmia substrates are demonstrable 
in the mouse and with similar mechanisms. This together with the relative ease 
of housing smaller animals and breeding transgenic models means costs are 
also lower and logistics favourable. The mouse is still a reasonable model for 
studying cardiac arrhythmia. 
 
Other possible models with similar logistical ease might be the zebrafish, 
though it does not share the same structural cardiac similarities to human that 
the mouse affords and, thus, as a whole heart model is not as favourable 
(Verkerk & Remme, 2012). Inducible pluripotent stem cells re-programmed 
from, for example, skin cells received from patients, are an exciting area of 
development but experience from our own lab shows how early we are with this 
model. Cells are immature and do not exhibit the full array of currents and 
another disadvantage is the lack of a whole heart model, though strides are 
being made to overcome this (Tiscornia et al., 2011; Jackman et al., 2015; 
Tzatzalos et al., 2016; Lemoine et al., 2018). 
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1.5 Hypotheses 
 
A 
 
1. Kir6.1, in addition to Kir6.2, is an important pore-forming subunit in atrial 
cardiomyocytes. 
2. There is a differential KATP subunit expression between cardiac chambers 
that would make it plausible to pharmacologically manipulate KATP channels 
in the atria selectively as a drug target for atrial arrhythmias. 
 
B 
 
Manipulation of KATP channels in cardiac muscle can be anti-arrhythmic: 
1. Channel opening will hyperpolarise cardiomyocytes tending to reduce 
automaticity and/or triggered activity. 
2. Channel inhibition will prolong ERP theoretically attenuating the inducibility of 
re-entrant arrhythmias. 
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1.6 Aims 
 
1. To define the KATP subunit expression and current characteristics in the atria 
and ventricles of mouse heart and to compare this with human atria. 
2. To examine the role of KATP channels in the genesis of abnormal atrial 
rhythm using pharmacological approaches in a murine model with global 
deletion of either Kir6.1 or Kir6.2, and utilising HL-1 cells. 
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Section 2: Methods 
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2.1 Molecular Biology and Cell Culture 
 
2.1.1 HEK293 stable cell lines expressing KATP subunits 
 
My first task was to develop a system by which I could use subunit-specificity of 
KATP openers and inhibitors to delineate the KATP subunit composition of a 
population of KATP channels in a cell. 
 
KATP channels composed of all combinations of a homomultimer of pore-forming 
subunits with a homomultimer of sulphonylurea receptor subunits were stably 
overexpressed in HEK293 cells, originally acquired by the laboratory as a gift 
from Professor L. Y. Jan (University of California, San Francisco, USA). 
 
Whole-cell patch clamp would be performed on these cells in the presence of 
KATP openers and inhibitors. 
 
2.1.1.1 Materials 
 
cDNAs encoding the Kir6x pore-forming subunits were propagated in the 
pcDNA3.1/Zeo(+) mammalian expression vector (Life Technologies Ltd 
Invitrogen Division, Paisley, UK) and had been previously obtained by the 
laboratory as a gift from Professor S. Seino (Chiba University School of 
Medicine, Chiba, Japan). cDNAs encoding the SURx subunits were propagated 
in the pcDNA3 mammalian expression vector (Life Technologies Ltd Invitrogen 
Division, Paisley, UK). SUR1 cDNA had been previously obtained as a gift from 
Professor J. Bryan (Baylor College of Medicine, Houston, USA). SUR2A and 
SUR2B cDNAs had been previously obtained as a gift from Professor Y. 
Kurachi (Osaka University, Osaka, Japan). Sanger sequencing performed at the 
William Harvey Research Institute Genome Centre, confirmed the identity and 
species of the cDNAs: Kir6.1 cDNA belonged to rat; Kir6.2 cDNA belonged to 
mouse; SUR1 cDNA belonged to hamster; SUR2A and SUR2B cDNAs 
belonged to mouse (Inagaki et al., 1995a; Hambrock et al., 1999). The Qiagen® 
Plasmid Midi Kit (Qiagen, Manchester, UK) was used when required for plasmid 
amplification, G-418 disulphate from Melford Laboratories Ltd (Ipswich, UK) and 
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Zeocin from Life Technologies Ltd Invitrogen Division (Paisley, UK). Cell culture 
medium was Gibco™ MEM (+Earle's salts; +L-Glutamine) Ref 31095-029. 
 
2.1.1.2 Derivation and culture of HEK293 cell line stably overexpressing 
Kir6.1/SUR1 KATP Channels 
 
Owing to failure to derive a stable line using circular plasmids, the plasmids 
containing cDNA for Kir6.1 and SUR1 were first linearised. Restriction enzymes 
were chosen from a selection advised in the manufacturer's guidelines to cut at 
one site on the plasmid. The chosen restriction enzymes were then checked 
against the New England Biolabs database NEBcutter V2.0 (www.nc2.neb.com) 
so as to ensure they would not cut in the sequence of the gene of interest. The 
restriction enzyme MfeI (with Cutsmart Buffer) was used to linearise Kir6.1 and 
PvuI (with Buffer 3.1) to linearise SUR1. Enzymes and buffers were obtained 
from New England Biolabs (Hitchin, UK). Buffers were chosen as per the 
manufacturer's guidelines. A reaction mixture consisted of 5µg of plasmid 
cDNA, 10U of restriction enzyme, 2µl of 1X buffer and all made up to 20µl with 
double-distilled water. All reagents were kept on ice until the start of the 
reaction, which took place incubated at 37oC for 2 hours as per the 
manufacturer's guidelines. The reaction products were then purified using the 
Qiagen QIAquick PCR Purification Kit from Qiagen (Manchester, UK) as per the 
manufacturer's instructions. The concentration of DNA was analysed using a 
NanoDrop® 1000 spectrophotometer. 
 
The purified cDNA was transfected into HEK293 cells using Lipofectamine® 
2000 transfection reagent (Life Technologies Ltd Invitrogen Division, Paisley, 
UK) as per the manufacturer's guidelines. Briefly, 5µl Lipofectamine® 2000 was 
added to 195µl Opti-MEM® I (Life Technologies Ltd Invitrogen Division, Paisley, 
UK). Separately, 250ng of Kir6.1 cDNA and 1000ng SUR1 cDNA were made up 
to 200µl with Opti-MEM® I. The Lipofectamine® 2000/Opti-MEM® I mixture 
was then mixed gently with the Opti-MEM® I/cDNA mixture and left for 20 
minutes at room temperature. 
 
Wild-type HEK293 cells had been cultured in 6-well (9.62cm2 per well) plates to 
~70% confluence in each well with ~3mls of standard media (Gibco™ MEM 
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containing 10% foetal bovine serum + 1% penicillin/streptomycin). The media 
were removed and the cells washed in 1ml of Opti-MEM® I before incubating 
the cells in 1ml of Opti-MEM® I. The Lipofectamine® 2000/Opti-MEM® I/cDNA 
mixture from above was then added drop by drop to the cells and the 
cell/reagent mixture incubated at 37oC/5% CO2 for 4 hours. The Lipofectamine® 
2000/Opti-MEM® I/cDNA mixture was then removed from the cells and they 
were washed in pre-warmed (37oC) phosphate buffered saline (PBS). The cells 
were trypsinised with 400µl of trypsin and seeded at 1:100, 1:1000 and 1:10000 
dilutions in 100mm dishes and in 10mls antibiotic-free media (Gibco™ MEM + 
10% foetal bovine serum) and incubated for 24 hours at 37oC and 5% CO2. 
When cells were deemed to have seeded adequately the media were switched 
to the selection media (Gibco™ MEM containing 10% foetal bovine serum + 
1mM G418 disulphate + 350µM Zeocin). The media were then changed every 3 
to 4 days. Cell death would occur but individual "islands" of cells representing 
clones of individual transfection events conferring resistance to the antibiotics in 
the media would develop and be spatially separated. After ~3 weeks of 
continued selection, large and distinct colonies were "picked off" the bottom of 
the dishes using sterilised cotton buds, and reseeded into separate 9.62cm2 
wells of a 6-well plate with 3mls of selection media. Media were changed twice 
a week. When ~70% confluent, media were removed and cells from each well 
washed in warmed PBS, trypsinised with 400µl trypsin and reseeded in 
separate 25cm2 flasks with 5mls of selection media. Selection media were then 
changed twice a week. When ~70% confluent media were removed, the cells 
washed in warmed PBS and trypsinised with 1.5mls of trypsin. Trypsin was 
deactivated by making up to 5mls with selection media. A proportion of cells 
were reseeded onto 10mm coverslips in a 6-well plate at 10-15% confluence 
and incubated in 3mls selection media. The rest of the cells were reseeded into 
a 75cm2 flask made up to 10mls selection media. Media were always changed 
twice a week. Forty-eight hours later, cells seeded onto coverslips were suitable 
for electrophysiology experiments (30-40% confluent). Cells in 75cm2 flasks 
were passaged into new 75cm2 flasks at 70% confluence by removing media, 
washing with warmed PBS and trypsinising with 3mls trypsin. Trypsin was 
deactivated by the addition of selection media (up to 10mls) and a proportion, 
usually a 1:20 dilution, was transferred to a new 75cm2 flask and made up to 
10mls with selection media. 
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Alternatively trypsinised cells made up to 10mls with standard media could be 
frozen for future use by spinning at 800rpm for 3 minutes, discarding 
supernatant, and the pellet resuspended in 5mls of 90% foetal bovine 
serum/10% DMSO. 1ml aliquots of this were then placed in cryovials and frozen 
slowly (~ -1oC/min) in a freezing jar submerged in isopropanol in a -80oC freezer 
and stored thereafter at -80oC. When needed, aliquots were revived by fast 
thawing at 37oC in a water bath, spun at 800rpm for 3 minutes, FBS + 10% 
DMSO removed and the pellet resuspended in standard media and seeded into 
a 25cm2 flask. 24 hours later when adequately stuck down the media were 
changed to selection media and passaging could continue usually with all cells 
being first reseeded into a 75cm2 flask as previously described. When required, 
a proportion of trypsinised cells from the 75cm2 flask could always be seeded 
onto 10mm coverslips in a 9.62cm2 well at 10-15% so that in 48 hours the cells 
would be at 30-40% ready for patch clamp experiments (see section 2.7). 
 
2.1.1.3 Derivation and culture of HEK293 cell line stably overexpressing 
Kir6.1/SUR2A KATP Channels 
 
In this instance plasmid cDNAs for Kir6.1 and SUR2A (as described above) 
were used. For transfection FuGENE® HD transfection reagent (Promega Ltd, 
Southampton, UK) was used as per the manufacturer's guidelines. Briefly, 7µl 
FuGENE® HD, 500ng Kir6.1 cDNA and 2000ng SUR2A cDNA were made up to 
100µl with Opti-MEM® I, mixed gently and left for 15 minutes at room 
temperature. Wild-type HEK293 cells had been cultured on 6-well (9.62cm2 per 
well) plates at ~70% confluence in each well with ~3mls of Gibco™ MEM 
(containing 10% foetal bovine serum + 1% penicillin/streptomycin). The 
FuGENE® HD/Opti-MEM® I/cDNA mixture was then added directly to the 
media in the 9.62cm2 well and incubated at 37oC/5% CO2 for 4 hours. The 
mixture was then removed from the cells; they were washed with warmed PBS 
and trypsinised with 400µl of trypsin. All the trypsinised cells were then 
transferred to 10mls of standard media in a 100mm dish. After 24 hours when 
adequately stuck down the media were changed to selection media and this 
changed every 3 to 4 days. Cell death would occur but individual "islands" of 
cells representing clones of individual transfection events conferring resistance 
to the antibiotics in the media would develop and be spatially separated. After 
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~3 weeks of continued selection, large and distinct colonies were "picked off" 
the bottom of the dishes using sterilised cotton buds, and reseeded into 
separate 9.62cm2 wells of a 6-well plate with 3mls of selection media. The 
process thereafter as per the derivation of the Kir6.1/SUR1 stable line would 
then be repeated. 
 
2.1.1.4 Revival and culture of HEK293 cell lines stably overexpressing 
Kir6.1/SUR2B, Kir6.2/SUR2B, Kir6.2/SUR1 and Kir6.2/SUR2A KATP Channels 
 
These cell lines had been derived previously by the laboratory using the 
FuGENE® HD method as described in section 2.1.1.3. 1ml aliquots stored at     
-80oC in FBS + 10% DMSO could be fast thawed at 37oC and revived by the 
process described above for the Kir6.1/SUR1 stable line. 
 
2.1.1.5 Transforming bacteria to amplify plasmids and cDNA 
 
When required more cDNA for the KATP subunits could be produced as follows. 
Lysogeny broth (LB) is a nutritionally rich medium created by Giuseppe Bertani 
used in promoting the growth of bacteria. The pcDNA3 and pcDNA3.1/Zeo(+) 
vectors confer a resistance to various antibiotics including carbenicillin. LB-
Agar-carbenicillin plates were made from an autoclaved solution of two LB 
tablets (Sigma Aldrich Co Ltd) and 1.5g Agar (Sigma Aldrich Co Ltd) in 100ml 
double distilled water. Carbenicillin (Thermofisher Scientific) was made as a 
100mg/ml stock and 100µL added to the 100ml LB-Agar solution making 
100µg/ml solution. Plain LB was made from an autoclaved solution of two LB 
tablets in 100ml double distilled water for later use. Per transformation, 50µL of 
competent Escherichia Coli cells were thawed on ice to which 50-100ng (1µL of 
a 1:10 dilution) of cDNA-containing plasmid was added. The cell-DNA mix was 
further incubated on ice for 30 minutes. As a control 1µL of culture grade water 
(Sigma Aldrich Co Ltd) was added to a separate sample of 50µL competent 
cells and incubated on ice for 30 minutes. The cells were heat-shocked at 42oC 
for 90 seconds in a heat block to promote uptake of the exogenous plasmid and 
then placed on ice for a further 2 minutes. 800µL of pre-warmed (37oC) LB was 
then added to the cDNA-cell or H2O-cell mixture. This mixture was then 
incubated at 37oC for 1 hour in a water bath. Thereafter, 100µL of the LB-
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cDNA-cell or LB-H2O-cell mixture was plated on a LB-Agar-carbenicillin plate 
using a spreader until all had appeared to be absorbed into the plate. The plate 
was incubated at 37oC overnight in an oven to promote growth. 
 
The following morning, colonies were counted and starter cultures were initiated 
in LB containing carbenicllin (100µg/ml final concentration). Sterile pipette tips 
were used to pick off individual colonies of interest, and placed in separate 
falcon tubes containing 10ml of LB-carbenicillin (100µg/ml) mixture. The tubes 
were then placed in a shaking incubator at 37oC and at 210rpm for 5 hours to 
promote growth. 
 
In the meantime, an autoclaved conical flask containing 50ml LB-carbenicillin 
was prepared. After 5 hours the most turbid of the starter cultures was poured 
into the conical flask, the top covered with foil and incubated overnight with 
shaking (210rpm) at 37oC. 
 
The next morning the contents of the flask were emptied into a tube suitable for 
centrifugation and spun at 4000rpm at 4oC for 30 minutes and the supernatant 
removed leaving the bacterial pellet. 
 
2.1.1.6 Isolation and Purification of Plasmid DNA 
 
Plasmid DNA was isolated and purified using the Qiagen® Plasmid Midi Kit 
following the manufacturer's instructions (Qiagen, 2012). Briefly, this involves 
first resuspension of the bacterial pellet in Qiagen® resuspension buffer 
(containing 50mM Tris-Cl, pH 8.0; 10mM EDTA and 100µg/ml RNase A). Then 
lysis of the bacteria is performed using Qiagen® lysis buffer (200mM NaOH, 1% 
SDS (w/v)). Neutralisation of the lysis mixture is then achieved with Qiagen® 
neutralisation buffer (3M potassium acetate, pH 5.5). This produces a 
precipitate containing genomic DNA, proteins, cell debris, and potassium 
dodecyl sulfate. This mixture is passed through filter paper to remove the 
precipitated debris. QIAGEN-tips are a column allowing gravity flow of solution 
through a resin that binds plasmid DNA. The filtered solution is passed through 
a column where the resin has been equilibrated with Qiagen® equilibration 
buffer (750mM NaCl, 50mM MOPS, pH 7.0; 15% isopropanol (v/v); 0.15% 
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Triton® X-100 (v/v)). The plasmid DNA collected in the resin is then washed 
using Qiagen® wash buffer (1.0M NaCl, 50mM MOPS, pH 7.0; 15% isopropanol 
(v/v)) to remove contaminants including large amounts of carbohydrates. The 
plasmid DNA is then eluted from the resin using Qiagen® elution buffer (1.25M 
NaCl; 50mM Tris-Cl, pH 8.5; 15% isopropanol (v/v)) before being precipitated 
with isopropanol. The precipitated plasmid DNA is collected as a pellet via 
centrifugation and washed with 70% ethanol to remove precipitated salt. The 
70% ethanol is also more volatile than isopropanol and in replacing it, makes 
the DNA easier to redissolve. After air-drying the pellet of the 70% ethanol it 
can be re-dissolved in RNase/DNase-free water. The concentration of DNA was 
checked for purity with spectrophotometry (NanoDrop® 1000) to ensure a 
260/280 absorbance ratio of 1.8 or above. 
 
2.1.2 HL-1 Cells 
 
HL-1 cells are the first cell line established that can maintain the differentiated 
cardiomyocyte phenotype and contractile activity in vitro (Claycomb et al., 
1998). They were established by Professor William Claycomb's group (New 
Orleans, USA) by culturing AT-1 cells under specific conditions. AT-1 cells are  
murine atrial cardiomyocyte tumour cells that have been grown in a transgenic 
mouse in which expression of the simian virus 40 (SV40) large T antigen was 
targeted for expression in atrial cardiomyocytes via the atrial natriuretic factor 
(ANF) promoter (Field, 1988; Claycomb et al., 1998). These tumour cells could 
be harvested and transplanted subcutaneously as ectopic grafts in other 
syngeneic hosts such that they would propagate as new subcutaneous tumours 
(Steinhelper et al., 1990). On harvesting tumour cells after each transplantation, 
AT-1 cells would retain their cardiomyocyte phenotype in culture (Lanson et al., 
1992; Borisov & Claycomb, 1995). This included functional, biochemical and 
ultrastructural features characteristic of adult atrial myocytes. However, the 
phenotype was not sustainable during passage and thus it was necessary to 
use them as primary cells (Claycomb et al., 1998). 
 
Further investigation led to the discovery that under certain conditions, when 
AT-1 cells were cultured and passaged in specific media termed "Claycomb 
Medium" supplemented with 100µM norepinephrine, 10% FBS of a specific 
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batch, and 2mM L-glutamine, this would maintain the cell line and the mature 
cardiomyocyte phenotype even during multiple passages (Claycomb et al., 
1998). This cell line has been termed the HL-1 cell line. The Claycomb Medium 
formula remains proprietary to Sigma-Aldrich Co Ltd. 
 
HL-1 cells have been shown to harbour an array of cardiac myocyte currents (If, 
INa, ICaL, INa/Ca, IK, IKATP), gap junctions (Cx40, Cx43, Cx45), sarcomeric proteins 
(Alpha-myosin heavy chain (αMHC), Troponin, Titin, α-actin) and sarcoplasmic 
reticulum proteins (Ryanodine receptor (RyR2), FK506-binding protein (FKBP)) 
(White et al., 2004; Fox et al., 2005). Together with their ultrastructural features 
characteristic of atrial myocytes and their ability to beat both in isolation and in 
clusters setting up activating wavefronts, they represent a promising tool and 
model for cardiac myocyte electrophysiological study and investigation of 
arrhythmia mechanisms. 
 
Limitations of their use include cellular heterogeneity that has been 
demonstrated by differences in calcium current density, connexin expression 
and conduction velocity between selectively cultured clones, such that there is a 
non-uniformity in the above parameters in non-clone-selective syncytia (Dias et 
al., 2014). Conduction velocity across HL-1 syncytia has also been shown to be 
significantly slower than in mouse atrial myocytes (Dias et al., 2014). An 
alternative argument is that heterogeneities in properties such as conduction 
velocity and action potential duration, together with slow conduction, appear 
crucial for arrhythmogenesis, and so this as a starting point in experimental 
cultures could also be seen as an advantage. 
 
I wanted to first characterise, using whole-cell patch clamp, the KATP current in 
isolated HL-1 cells. I would then utilise the ability of clusters of HL-1 cells to 
beat spontaneously, to test the effects of KATP activation and inhibition on this 
spontaneous beating. For this I would use calcium fluorescence imaging of HL-
1 syncytia. 
 
The lab follows the instructions set out by Sigma Aldrich Co Ltd and Professor 
Claycomb's lab. 
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2.1.2.1 Materials 
 
All materials were obtained from Sigma Aldrich Co Ltd except the HL-1 cells, 
which were a kind gift from Professor Claycomb. The FBS was pre-ordered to 
obtain a batch that had been pretested by the Claycomb lab for use with HL-1 
cells to ensure a beating phenotype. 
 
100ml of supplemented Claycomb Medium consists of: Claycomb Medium 
87ml, FBS 10ml (10%), Penicillin/Streptomycin 1ml (100U/ml; 100µg/ml), 
Norepinephrine 1ml (from a 10mM stock; 0.1mM), L-Glutamine 1ml (from a 
200mM stock; 2mM). The Claycomb Medium bottle was wrapped in aluminium 
foil as it is light sensitive. After two weeks the L-Glutamine was replenished. 
 
Norepinephrine[(±)-arterenol] was first prepared by making ascorbic acid 30mM 
stock by adding 0.59g of ascorbic acid to 100ml of cell culture grade distilled 
water. 80mg of norepinephrine was then added to 25ml of the 30mM ascorbic 
acid. This was then filter-sterilised using a 0.2µM syringe-driven filter. 1ml 
volumes were aliquoted into sterile microtubes and stored at -20oC. 1ml of this 
10mM stock was then used per 100ml of medium for a 0.1mM final 
concentration. Norepinephrine was made up fresh monthly. 
 
L-Glutamine came as a 100X solution and was aliquoted into working volumes 
before addition to the medium. Otherwise it was frozen at -20oC ready for future 
use. 
 
Soybean Trypsin Inhibitor was prepared by dissolving 25mg of dessicate 
soybean trypsin inhibitor in 100ml of Dulbecco's phosphate buffered saline 
(PBS; Ca2+-free and Mg2+-free). This was then filter-sterilised using a 0.2µM 
syringe-driven filter and stored at 4oC. 
 
Gelatin/Fibronectin was prepared by adding 0.1g gelatin to 500ml of distilled 
water and autoclaved. The final concentration of dissolved gelatin was 0.02%. 
The fibronectin was received in a tube in liquid form at 1mg/ml and 1ml of this 
was added to 199ml of the 0.02% gelatin and mixed gently. Aliquots of 6ml 
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were then placed immediately into 15ml sterile plastic tubes and frozen to -20oC 
ready for future use. 
 
2.1.2.2 Culturing HL-1 Cells 
 
Cultures were fed 5ml for a T25 flask or 10ml for a T75 flask with supplemented 
Claycomb Medium every weekday. If necessary, 20ml of supplemented 
Claycomb Medium was added to each T75 flask on Friday afternoons and this 
medium was then changed again the following Monday morning. 
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2.1.2.3 Passaging HL-1 Cells 
 
T75 flasks were prepared by coating the base with 3ml of gelatin/fibronectin and 
incubating at 37oC for 1 hour. The T75 flask of confluent HL-1 cells to be 
passaged had its medium removed and the cells washed with 6ml of warmed 
PBS. 3ml of 0.05% trypsin/EDTA was then added and the flask incubated at 
37oC for 1 minute. The 0.05% trypsin/EDTA was removed and a fresh 3ml was 
added before further incubation at 37oC for 2 minutes. When cells had become 
non-adherent 3ml of wash medium (containing only Claycomb Medium + 5% 
FBS + Penicillin/Streptomycin 100µg/ml) was added directly to cells to 
inactivate the trypsin. The cells in this 6ml mixture were then transferred into a 
15ml tube for centrifugation along with an extra 8ml wash medium used to rinse 
the flask to obtain the last remaining cells, making a total of 14ml in the 15ml 
tube. This was then centrifuged at 500xg for 5 minutes. Meanwhile, the 
gelatin/fibronectin used to coat the new T75 flasks was removed from the flasks 
and 9ml supplemented Claycomb Medium was added and the flask set-aside at 
37oC. After centrifugation the supernatant was removed from the 15ml tube and 
the pellet of HL-1 cells was gently resuspended in 3ml of supplemented 
Claycomb Medium. 1ml of the cell suspension was then added to the 9ml of 
supplemented Claycomb Medium in the T75 flask for a 1:3 split. 
 
If cells were to be used for patch clamp experiments (see also section 2.7) 
10mm glass coverslips were pre-coated with 1µl gelatin/fibronectin in a 6 well 
plate and allowed to air dry in the culture hood for at least 1 hour. 3ml 
supplemented Claycomb Medium was used per well. Assuming the cells at the 
time of passage were ~80% confluent in a T75, and knowing that the area of 
each well of a 6-well plate is of the order of 9.62cm2, ~80µl of resuspended cells 
(post centrifugation) was added to each well of medium/coverslips in the 6-well 
plate and gentle swirling applied to spread the cells evenly in the medium. This 
volume of suspension would mean cells settled in the well at ~15% confluence. 
Patch clamp experiments were performed ~48 hours later when the cells were 
~40% confluent. The supplemented Claycomb Medium in the 9.62cm2 wells 
was changed every day. 
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If cells were to be used for fluorescence microscopy experiments (see also 
section 2.9) they were seeded into a perfusion chamber of a multielectrode 
array (MEA) (Multichannel Systems, Germany). The MEA was chosen as it 
could be used with a compatible temperature controller (TC02, Multichannel 
Systems, Germany), and potentially adapted for simultaneous electrogram 
and fluorescence measurement though this was not implemented in my work. 
MEAs were pre-coated with 300µl gelatin/fibronectin and incubated at 37oC for 
1 hour. The excess gelatin/fibronectin was then removed and the perfusion 
chamber washed twice with 1ml PBS. 1ml supplemented Claycomb Medium 
was then added per perfusion chamber. Assuming the cells at the time of 
passage were ~80% confluent in a T75, and knowing that the area of each 
perfusion chamber is of the order of 5.5cm2, then ~220µL of resuspended cells 
(post centrifugation) was added to each MEA perfusion chamber and gentle 
swirling applied to spread the cells evenly in the medium. This volume of 
suspension would mean cells settled in the perfusion chamber at ~80% 
confluence. The medium would be changed every day. Experiments would take 
place 48 hours after the cells were seeded. 
 
2.1.2.4 Freezing and Reviving Cells 
 
The contents of one confluent T75 flask were frozen down per cryovial. The T75 
flask of confluent HL-1 cells was briefly rinsed with 5ml of PBS warmed to 37oC 
and then removed by aspiration. 3ml 0.05% trypsin/EDTA was added to the 
flask, which was then incubated at 37oC for 2 minutes. After checking under 
microscopy that cells had become non-adherent, 3ml of soybean trypsin 
inhibitor was added to the flask and this 6ml mixture was then transferred to a 
15ml tube for centrifugation. The flask was also rinsed with 8ml of wash medium 
and this 8ml added to the 15ml tube making a total volume of 14ml in the 15ml 
tube. The tube was centrifuged for 5 minutes at 500xg. Thereafter the 
supernatant was aspirated and the pellet of HL-1 cells gently resuspended in 
1.5ml of freezing medium (95% FBS / 5% DMSO). The resuspended cells were 
then pipetted into a cryovial and this placed into a freezing jar containing room 
temperature isopropanol. This was then placed into a freezer at -80oC allowing 
the cells to freeze slowly at a rate of -1oC/minute. Cells would thereafter be 
stored at -80oC. 
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To revive cells, a T75 flask was first coated with gelatin/fibronectin for at least 
an hour at 37oC as previously described. The gelatin/fibronectin was removed 
and replaced with 10ml of supplemented Claycomb medium and the flask 
placed back into the incubator at 37oC to be used later. Then 10ml of wash 
medium was added into an empty 15ml tube and this incubated in a water bath 
at 37oC. A cryovial of frozen cells was fast thawed at 37oC in a water bath and 
transferred into the 15ml tube containing wash medium at 37oC. This was then 
centrifuged at 500xg for 5 minutes, the supernatant removed by aspiration and 
the pellet of cells gently resuspended in 5ml of supplemented Claycomb 
medium. This was then added to the 10ml of Medium at 37oC already in the T75 
flask. When the cells had become adherent (after ~4 hours), the medium was 
replaced with 15ml of fresh supplemented Claycomb medium. 
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2.2 Generation of Knockout Mice 
 
2.2.1 Kcnj8 
 
The initial aim was to produce a mouse with cardiomyocyte conditional 
knockout of Kir6.1 (Kir6.1-cKO) to investigate the importance of this pore-
forming subunit with respect to heart muscle electrophysiology and arrhythmia. 
A conditional knockout would potentially circumvent concerns that the 
hypertensive phenotype of a global knockout (see section 1.3.1) might lead to 
electrophysiological changes indirectly, through an increased afterload-induced 
tissue substrate of both fibrosis, and stretch-induced KATP opening, or from 
ischaemia (Miki et al., 2002; Chutkow et al., 2002; Lader et al., 2011). 
 
Mice with suggested cardiomyocyte conditional, and later another line with 
global deletion, of exon 2 of the Kcnj8 gene encoding the Kir6.1 subunit 
(rendering deletion of the ATG translation initiation codon) were produced with 
the help of genOway© (Lyon, France; project number genOway/EV/TIN1- Kcnj8 
070206) using Cre-lox, and Flp-recombinase technology. Briefly, Flp and Cre 
are recombinases that will excise DNA flanked by regions known as FRT or 
loxP sites respectively. Homologous recombination through homology arms 
either side of a construct containing exon 2 of the Kcnj8 gene and a neomycin 
resistance cassette, all flanked by loxP sites, enable its introduction into the 
specific site in the genome. FRT sites also flank the neomycin resistance 
cassette itself. Such a vector can be transfected into embryonic stem cells 
(ESCs) harvested from a developing blastocyst. ESCs exhibiting the transfected 
loxP flanking sequence can be selectively cultured in antibiotic-containing 
media since the neomycin resistance gene is expressed. The cultured ESCs 
are then injected back into a blastocyst before re-implantation into a 
pseudopregnant female (Bouabe & Okkenhaug, 2013). Chimeric pups are born 
and genetically modified ESCs can contribute to germ-cell formation. Flp and 
Cre are introduced into the genome by additive transgenesis. In additive 
transgenesis, the Flp or Cre carrying vector is injected directly into the 
pronucleus of the developing embryo and the sequence will find its way to a 
random site in the genome. If chimeric pups are crossed with mice expressing 
Flp-recombinase, pups are born where the neomycin resistance cassette is 
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excised. An example of one such possible group of constructs is shown in 
figure 2.1. Crossing animals harbouring Cre with animals harbouring the floxed 
allele will produce pups heterozygous for the knockout allele. Further crossing 
of these animals will produce pups homozygous for the knockout allele. 
 
 
 
If Cre expression is under the control of a tissue specific promoter ablation 
should occur solely in that tissue (see Figure 2.2).  
 
Figure 2.1. Schematic of constructs for the Kcnjx knockout allele 
(adapted from The International Mouse Phenotyping Consortium 
(Brown & Moore, 2012)). Numbers denote exons; FRT denotes excision 
sites for Flp recombinase; loxP denotes excision sites for Cre recombinase; 
lacZ denotes coding region for β-galactosidase; neo denotes coding region 
for the neomycin resistance protein. 
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2.2.2 Kcnj11 
 
I sought to compare, through identical experiments, the importance of each of 
the KATP pore-forming subunits in the murine atria. As such a mouse with global 
deletion of the Kcnj11 gene encoding the Kir6.2 subunit was produced with the 
help of The Medical Research Council Centre for Mouse Genetics, Harwell 
Campus, Oxfordshire, UK (MRC Harwell) in collaboration with the International 
Mouse Phenotyping Consortium (Brown & Moore, 2012). Gene trapping was 
performed using a construct containing a lacZ sequence followed by a 
neomycin-resistance cassette (for antibiotic selective culture) followed by the 
exon of Kcnj11. The lacZ sequence and neomycin-resistance cassette are 
flanked by FRT sites and the neomycin-resistance cassette and Kcnj11 exon 
are flanked by loxP sites. This construct is termed tm1a (see Figure 2.1). 
Homologous recombination through homology arms either side of the construct 
enable its integration into the specific site in the genome. A vector containing 
 
Figure 2.2. Schematic for Cre recombinase mediated knockout of the 
floxed allele (taken from The Mouse Genome Informatics Website, 
Jackson Laboratory, http://www.informatics.jax.org, September 2018). 
Demonstration of tissue-specific knockout, in this case in the heart, when Cre 
is under control of a cardiac specific promoter. If under control of no specific 
promoter the knockout will be global. 
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the construct was transfected into embryonic stem cells (ESCs) harvested from 
a developing blastocyst. ESCs exhibiting the transfected sequence were 
selectively cultured in antibiotic containing media. The cultured ESCs were then 
injected back into a blastocyst and implanted into a pseudo-pregnant female. 
Chimeric pups are born and crossed with wild-type mice to enable germ line 
transmission. Thereafter tm1a sperm can be isolated and in-vitro fertilisation 
(IVF) performed in the presence of soluble Cre thus mediating excision of the 
loxP flanked neomycin-resistance cassette and Kcnj11 exon, and generating 
pups heterozygous for the knockout tm1b allele (see Figure 2.1). When crossed 
these mice will give rise to litters containing pups homozygous for the knockout 
tm1b allele. The presence of the lacZ sequence under the control of the 
endogenous promoter means the allele can, if required, be used as a reporter 
for spatial Kcnj11 gene expression as the encoded enzyme β-galactosidase 
forms a blue precipitate in the presence of 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal). 
 
All mice were of a C57BL/6N background strain. 
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2.3 Animal Husbandry 
 
Animals and their offspring were maintained at Queen Mary University of 
London (QMUL) animal core facilities under UK Home Office guidelines relating 
to animal welfare. All mice were kept in a pathogen-free temperature controlled 
environment (21-23oC) with 12hr day/12hr night light cycles. Animals were 
allowed access to standard rodent chow and water. Mice were studied between 
12-24 weeks of age under standardised conditions. Use of animals in all the 
studies was in accordance with the United Kingdom Animal (Scientific 
Procedure) Act of 1986. Mice showing signs of poor health and barbarisation 
were excluded from use. Purely owing for the need to conserve housing space, 
the Kcnj11 knockout colony was bred and genotyped offsite at MRC Harwell. 
Experimental homozygous knockout animals and the wild-type littermate 
controls were transported over to QMUL animal core facilities at 6-8 weeks of 
age, and were acclimatised until experimental age of 12-24 weeks. 
 
All experiments were conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the British Home Office and the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996). The 
animal work was approved by the QMUL Animal Welfare and Ethical Review 
Body and covered by UK Home Office project licence PPL/7665. 
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2.4 Genotyping 
 
Mice were ear marked at 3-4 weeks of age for identification purposes and 
genomic DNA was isolated from the ear clips using 125µL of lysis buffer 402-E 
(proprietary of Viagen Biotech, Inc., Los Angeles, USA) containing 0.4mg/ml 
proteinase K (Sigma Aldrich Co Ltd). As per the manufacturer's instructions ear 
clips were incubated at 55oC for at least 3 hours and the proteinase K was 
deactivated by incubating at 85oC for 45 minutes before being cooled at room 
temperature for 10 minutes. The tubes were then placed in a centrifuge at 
14,000rpm for a minute to pellet any undigested material such as hair. The 
samples were then stored at -20oC or used immediately for polymerase chain 
reaction (PCR). 
 
PCR was performed using BioMix™ Red (Bioline Reagents Ltd, UK) the 
contents of which are proprietary but it is a ready-to-use 2x reaction mix 
containing a stable Taq DNA polymerase and an inert red dye that permits easy 
visualisation and direct loading onto a gel. Volumes were used as per the 
manufacturer's instructions: 
 
 
 
2.4.1 Kcnj8 Global Knockout 
 
The following primers were used: 
For the wild type allele - 
Forward primer 21841flp-TIN1 5' ACTAGCACCTCTATCCCCAGCTCCTACC 3' 
Reverse primer 21842flp-TIN1 5' CCGCCCCTCCCTCTGAACCTATATC 3'. 
  
Genomic DNA PCR mix 
BioMix™ Red 12.5µL 
DNase/RNase-free Water 6.5µL 
Forward Primer 2µL 
Reverse Primer 2µL 
DNA 2µL 
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For the knock out allele - 
Forward primer 21841flp-TIN1 5' ACTAGCACCTCTATCCCCAGCTCCTACC 3' 
Reverse primer 11349bct-TIN1 5' CTGACACCAAAGCTGCCTGACAACA 3'. 
Figure 2.3 demonstrates a simplified map of the Kcnj8 gene and where the 
primers bind. 
 
 
The following reaction conditions were followed: 
 
 
  
 
Genomic DNA PCR programme Kcnj8 Global KO 
94oC for 2 minutes 
94oC for 30 seconds 
65oC for 30 seconds                 for 35 cycles 
68oC for 40 seconds 
68oC for 8 minutes 
8oC for ∞ 
 
 
 
Figure 2.3. Simplified map of Kcnj8 and primer binding sites for 
genotyping. The presence of the floxed allele gives rise to a larger PCR 
product between 21841flp-TIN1 and 21842flp-TIN1 (due to the 1st LoxP site) 
that is distinguishable on gel electrophoresis. If the segment between the 
LoxP sites is not excised, ie. exon 2 is not knocked out, then the potential 
PCR product between 21841flp-TIN1 and 11349bct-TIN1 is too large to 
amplify and no band is seen on gel electrophoresis under the given 
conditions. 
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2.4.2 Kcnj8 Cardiac Conditional Knockout 
 
The following primers were used: 
To determine the presence of the floxed allele - 
Forward primer 21841flp-TIN1 5' ACTAGCACCTCTATCCCCAGCTCCTACC 3' 
Reverse primer 21842flp-TIN1 5' CCGCCCCTCCCTCTGAACCTATATC 3'. 
(See Figure 2.3). 
To determine the presence of alphaMHCCre - 
Forward primer CRE-ORF F [TM1408] 5' ATCCGAAAAGAAAACGTTGA 3' 
Reverse primer CRE-ORF R [TM1409] 5' ATCCAGGTTACGGATATAGT 3' 
 
The following reaction conditions were used: 
 
 
Products were then run on a 1% agarose gel with 5µL of Midori Green stain 
(Nippon Genetics Europe, Germany) per 100ml of gel. 
 
In the case of the Kcnj11 global knockout mice genotyping had kindly been 
performed at The Medical Research Council Centre for Mouse Genetics, 
 
Genomic DNA PCR programme alphaMHCCre 
94oC for 2 minutes 
94oC for 30 seconds 
60oC for 30 seconds               for 34 cycles 
72oC for 60 seconds 
72oC for 8 minutes 
8oC for ∞ 
 
 
Genomic DNA PCR programme floxed allele 
94oC for 2 minutes 
94oC for 30 seconds 
63oC for 30 seconds               for 35 cycles 
68oC for 60 seconds 
68oC for 8 minutes 
8oC for ∞ 
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Harwell Campus, Oxfordshire, UK (MRC Harwell). Further characterisation of 
the mice was carried out using a quantitative real-time reverse transcriptase 
polymerase chain reaction (qRT-PCR described below). 
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2.5 mRNA Quantification 
 
I sought to determine any differential expression of KATP subunits across the 
heart, and any differences between mouse and human using qRT-PCR. 
 
2.5.1 Murine RNA 
 
After undergoing schedule 1 cull via cervical dislocation, animals were 
harvested for cardiac atria and ventricles, the aorta and liver. Hearts were 
immersed in and flushed with PBS before the atrial appendages were removed 
and the ventricles from mid portion to apex. The aorta was also immersed in 
PBS and stripped and removed of para-aortic fat. Atrial appendages for each 
animal were combined together for RNA extraction, as were the ventricles. Not 
more than 30mg of each tissue type was collected. Tissue was placed in 1.5ml 
RNase-free tubes and placed in RNAlater® (Sigma Aldrich Co Ltd) to reduce 
RNA degradation. 
 
A pestle and mortar were treated with RNaseZap™ (Sigma Aldrich Co Ltd) to 
remove RNase and reduce RNA degradation. Tissue was then transferred to 
the mortar and flash frozen in liquid nitrogen before being crushed with a pestle. 
The crushed tissue was then transferred to a 2ml RNase-free tube. 
 
Thereafter, RNA was extracted using the Qiagen® RNeasy® Fibrous Tissue Mini 
Kit as per the manufacturer's instructions (Qiagen, 2010). Briefly, this involves 
first disrupting and homogenising the tissue in a lysis buffer (Qiagen® RLT 
buffer). The composition of this remains proprietary but it contains guanidine 
isothiocycanate that supports the binding of RNA to the silica membrane in the 
RNA collection columns. Before use 10µL of β-mercaptoethanol (Sigma Aldrich 
Co Ltd) is added per 1ml of RLT buffer, which helps to inactivate RNase. Tissue 
disruption and homogenisation was performed with a 21-gauge needle on the 
end of a 1ml sterile syringe with repeated aspiration and expelling of fluid and 
crushed tissue until a homogenous solution had developed. After dilution with 
RNase-free water, 10µL proteinase K is added, the solution mixed and then 
incubated at 55oC in a heat block for 10 minutes. The addition of proteinase K 
helps to digest contractile proteins, connective tissue, and collagen. These 
 114 
digested elements are then removed with centrifugation and the supernatant 
kept and mixed with an aliquot of 70% ethanol. It was then transferred to an 
"RNeasy column" which is a collecting column allowing flow of solution through 
a silica membrane under centrifugation. The silica membrane binds RNA of size 
> 200 nucleotides, thus allowing ribosomal and transfer RNA to pass through 
the membrane, and saving mRNA in the membrane. It also allows the passage 
of genomic DNA. A wash buffer (Qiagen® RW1 buffer) is then passed through 
the membrane under centrifugation. The composition of this remains proprietary 
but it too contains guanidine isothiocycanate, which supports the binding of 
RNA to the silica membrane. It also contains ethanol, and the buffer is said to 
remove biomolecules such as carbohydrates, proteins and fatty acids, that are 
non-specifically bound to the silica membrane. At the same time, RNA 
molecules larger than 200 bases remain bound to the membrane. Another 
milder wash buffer (Qiagen® RPE buffer) is then passed through the membrane 
under centrifugation. The composition of this remains proprietary but it contains 
ethanol and its main function is to remove traces of salts, which are still left on 
the membrane due to buffers used earlier in the protocol. Prolonged 
centrifugation helps to dry the membrane of residual RPE buffer or ethanol 
before mRNA bound to the membrane is eluted under centrifugation using 
RNase-free water. The concentration and purity was then checked with the use 
of spectrophotometry (NanoDrop® 1000) to ensure a 260/280 absorbance ratio 
of the order of 2 or above. 
 
2.5.2 Human RNA 
 
Isolated human total RNA from all four heart chambers (right atrium, left atrium, 
right ventricle and left ventricle) from three separate donors said to be "normal" 
with regards to no past medical history and normal cardiac structure and 
function, was purchased from AMS Biotechnology (Europe) Limited. Donors 
consisted of a 49 year old male, 69 year old male and 65 year old male. 
 
Fifty micrograms of RNA was available for each donor-chamber sample, all with 
RIN of 5 or above. All the samples were diluted to 100ng/µL and separated into 
10µL aliquots to be stored at -80oC before reverse transcriptase polymerase 
chain reaction to convert each 10µL aliquot to complementary DNA (cDNA). 
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Access was also obtained to fresh human atrial appendage tissue obtained 
from patients undergoing cardiac bypass. This was under the auspices of The 
Barts Cardiovascular Registry (BCVR). The BCVR is an umbrella project to 
collect and store biological samples and data from a multitude of patients at The 
Barts Heart Centre creating a bio-bank resource. The BCVR has ethical 
approval for a number of biosample collection processes with patients giving 
informed consent. Any investigator can apply to the BCVR to access these 
biosamples or data. I attended the operating theatre to receive fresh atrial 
appendage tissue from the cardiothoracic surgeon and flash freeze in 
RNAlater® (Sigma Aldrich Co Ltd). RNA was extracted on tissue thawed on ice 
using the same method as per the murine tissue (see above Qiagen® RNeasy® 
Fibrous Tissue Mini Kit) barring one difference. For human tissue an added 
optional DNase step was performed as per the manufacturer's instructions after 
the RW1 buffer wash step. A DNase stock is mixed with a buffer (Qiagen® RDD 
buffer). The composition of this remains proprietary but it is said to provide 
efficient on-column digestion of DNA and also ensures that the RNA remains 
bound to the column. After this DNase step there was a further RW1 buffer 
wash before proceeding with the same protocol as per murine tissue (see 
section 2.5.1). 
 
2.5.3 Quantitative real-time reverse transcriptase polymerase chain 
reaction (qRT-PCR) 
 
A two-step protocol was used to quantify the relative mRNA expression for the 
genes encoding the KATP subunits. 
 
Reverse transcription (see Figure 2.4) was first performed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems™). 
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Briefly, this involves making a reaction mix on ice and then processing in a 
thermal cycler as per the manufacturer's instructions: 
 
 
 
  
Reverse transcription reaction mix 
10X Reverse Transcription buffer 2µL 
Deoxynucleotide triphosphate mix 0.8µL 
Random primers 2µL 
Reverse Transcriptase 1µL 
RNase Inhibitor 1µL 
DNase/RNase-free Water 3.2µL 
RNA (2-200ng/µL) 10µL 
 
Reverse transcription programme 
25oC for 10 minutes 
37oC for 120 minutes 
85oC for 5 minutes 
4oC for ∞ 
 
 
 
Figure 2.4. Reverse Transcription step for qRT-PCR (taken from 
TaqMan® Gene Expression Mastermix Protocol, Applied Biosystems™, 
2010). In the first step mRNA strands are reverse transcribed to single cDNA 
strands. Such is the efficiency and capacity of the reaction mixture, assuming 
not more than 2µg of mRNA go in to the reaction mix, all mRNA is reverse 
transcribed. 
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Figure 2.5.  Quantitative Real-Time PCR (taken from TaqMan® Gene 
Expression Mastermix Protocol, Applied Biosystems™, 2010). In the 
second step of qRT-PCR TaqMan® probes bind specifically to sequences on 
the target of interest. Reporter dye is initially quenched due to Förster 
Resonance Energy Transfer (FRET) by the quencher end of the probe but 
during PCR the reporter is cleaved off allowing for fluorescence emission. 
This repeats itself during the PCR owing to the large amount of reaction mix 
available. The number of cycles required to reach a threshold fluorescence is 
recorded. The greater the amount of target, the lower the cycle number 
required to reach threshold. Fluorescence builds in an exponential fashion. 
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The concentration and purity of the single-stranded cDNA synthesised by this 
step was then quantified with spectrophotometry (NanoDrop® 1000) to ensure a 
260/280 absorbance ratio of 1.8 or above. 
 
Subsequently, quantitative real-time PCR was performed using inventoried 
TaqMan® gene expression assays (Applied Biosystems™) with FAM as the 
reporter dye and GAPDH as the housekeeping gene (see Figure 2.5). For each 
reaction cDNA was diluted in RNase-free water such that 90ng of murine cDNA 
and 50ng of human cDNA were used per 20µL reaction mix.  
 
In the case of murine cDNA, Kcnj8 was quantified using Assay ID: 
Mm00434620_m1 whose probe spans exon junction 2-3; Kcnj11 was quantified 
using Assay ID: Mm00440050_s1 whose probe was designed within the exon 
of the gene; Abcc8 was quantified using Assay ID: Mm00803450_m1 whose 
probe spans exon junction 28-29 and Abcc9 was quantified using Assay ID: 
Mm00441638_m1 whose probe spans exon junction 30-31. 
 
In the case of human cDNA, KCNJ8 was quantified using Assay ID: 
Hs00958961_m1 whose probe spans exon junction 2-3; KCNJ11 was 
quantified using Assay ID: Hs00265026_s1 whose probe was designed within 
the exon of the gene; ABCC8 was quantified using Assay ID: Hs01093770_m1 
whose probe spans exon junction 3-4; ABCC9 transcript variant SUR2A was 
quantified using Assay ID: Hs02514422_s1 whose probe was designed within 
exon 38A and ABCC9 transcript variant SUR2B was quantified using Assay ID: 
Hs02515384_s1 whose probe was designed within exon 38B. It should be 
noted that exon 38 at the 3' end of ABCC9 defines the two splice variants. 
Variant SUR2A is encoded with exon 38A and SUR2B encoded with exon 38B. 
 
The following mixture and PCR programme were used as per the 
manufacturer's instructions: 
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All genes were assayed in triplicate for all tissues and relative gene expression 
was then quantified using the 2-ΔΔCt method (Livak & Schmittgen, 2001). Using 
this method, the exact copy number of target molecules is not required to 
measure the relative quantification between two different sets of target. Instead 
the number of cycles of real-time PCR reaction required of a target to reach 
threshold fluorescence can be used. If XT is the number of target molecules 
when threshold fluorescence has been reached, then 
 
XT = X0.(1 + Ex)Ct,x = Kx  [1] 
 
where X0 is the initial number of target molecules, Ex is the efficiency of target 
amplification, Ct,x is the threshold cycle number for target amplification and Kx  
is a constant. Avoiding the use of absolute copy number requires normalising to 
an internal control reference gene that will have stability in expression through a 
range of experimental conditions. Standard housekeeping genes, such as 
GAPDH, make for good reference genes and GAPDH was chosen for this study 
based on its attributes in this context (Livak & Schmittgen, 2001; Vandesompele 
et al., 2002). Equation 1 can then be applied to the reference 
 
RT = R0.(1 + ER)Ct,R = KR  [2] 
 
where RT is the number of reference molecules when threshold fluorescence 
has been reached, R0 is the initial number of reference molecules (which should 
Quantitative Real-Time PCR programme 
95oC for 10 minutes 
95oC for 15 seconds x 40 cycles 
60oC for 1 minutes x 40 cycles 
Quantitative Real-Time PCR reaction mix 
TaqMan Gene Expression Master Mix (2X)  10µL 
TaqMan Gene Expression Assay (20X) 1µL 
cDNA Template + H2O 9µL 
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be stable between preparations and only depend on the quality of the 
preparation affecting both reference and target), ER is the efficiency of reference 
amplification, Ct,R is the threshold cycle number for reference amplification and 
KR is a constant. Therefore, if 
 
XN =  X0/R0 = amount of target X normalised to reference R  [3] 
 
and, 
 
XT/RT = K (a constant)  [4] 
 
and assuming the efficiencies of the target and reference are the same, then 
dividing equation 1 by equation 2 and rearranging gives, 
 
XN = K.(1 + E)-ΔCt  [5] 
 
where ΔCt is the difference in threshold cycles for target and reference        
(Ct,x - Ct,R). If the same process is performed for a separate experimental 
condition or different gene target, in order to make a relative comparison, then 
the amount of target 1 q normalised to a reference (in this case GAPDH) and 
relative to a calibrator target 2 cb is given by, 
 
XN,q / XN,cb = K.(1 + E)-ΔCt,q / K.(1 + E)-Δ,t,cb = (1 + E)-ΔΔCt  [6] 
 
where -ΔΔCt = -(ΔCt,q - ΔCt,cb). In this study utilising the commercially 
available probes and reaction mixtures, the efficiency is close to 1 and thus 
equation 6 can be re-written 
 
amount of target relative to calibrator = 2-ΔΔCt  [7] 
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2.6 Isolation of Murine Atrial Myocytes 
 
Apart from relative expression using qRT-PCR, I wanted to perform whole-cell 
patch clamp on isolated murine atrial myocytes. I would utilise the 
pharmacological tools developed using the HEK293 stable lines to delineate the 
KATP subunit composition in the murine atrial myocytes. I would also detect any 
changes in current in the knockout mice. 
 
Animals underwent schedule one killing via cervical dislocation. Hearts were 
then rapidly excised and placed in a warm Tyrode's solution at 37oC consisting 
of (in mM); NaCl 140, KCl 5.4, KH2PO4 1.2, CaCl2 1.8, MgCl2 1, HEPES-NaOH 
5, D-Glucose 5.5 (adjusted to pH 7.4 with NaOH). Using a small incision, the 
ventricles were flushed with Tyrode's to remove blood and then the left and right 
atrial appendages were removed and each cut into 4 pieces. Piece-meal atria 
were then placed in a low Mg2+/Ca2+ solution for 6 minutes at 37oC containing 
(in mM); NaCl 140, KCl 5.4, KH2PO4 1.2, CaCl2 0.2, MgCl2 0.5, HEPES-NaOH 
5, D-Glucose 5.5, Bovine serum albumin (BSA) 1mg/ml, Taurine 50 (adjusted to 
pH 6.9 with NaOH). This solution helps to disrupt intercellular connections at the 
intercalated discs. The tissue was then digested for 20 minutes in low 
Mg2+/Ca2+ solution at 37oC also containing 1mg/ml Collagenase Type 2 
(Worthington Biochemical Corporation), 1mg/ml Bacterial Protease Type 14 
(Sigma Aldrich Co Ltd) and CaCl2 400µM. Gentle agitation with a fire-polished 
Pasteur pipette was applied every 5 minutes. The tissue was then washed 4 
times (total of 12 minutes) in modified Kraft-Brühe solution (KB) at 37oC 
containing (in mM); KCl 20, KH2PO4 10, BSA 1mg/ml, Taurine 10, L-Glutamic 
acid 70, KOH 80, HEPES-KOH 10 (adjusted to pH 7.4 with KOH). The KB 
solution stops enzymatic dissociation. Atrial cells were further dissociated 
manually in the KB solution using a fire-polished Pasteur pipette and allowed to 
rest for 5 minutes prior to re-adaptation. Cells were allowed to re-adapt to 
physiological levels of Na+ and Ca2+ by incremental addition of a solution 
containing 10mM NaCl and 1.8mM CaCl2 and finally Tyrode's solution with 
1mg/ml BSA. 
 
Cells were centrifuged at 700rpm for 7 minutes after which some of the 
supernatant was removed before gentle resuspension to make a more 
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concentrated mixture of cells. Cells were then plated on laminin-coated 10mm 
coverslips and left for 30 minutes at 37oC before being bathed in Tyrode's 
solution with 1mg/ml BSA at 37oC for a further 30 minutes prior to patch clamp 
recordings. 
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2.7 Patch Clamp Recordings from Isolated Cells 
 
2.7.1 The Patch Clamp Technique 
 
2.7.1.1 The Equilibrium Potential 
 
If a selectively permeable membrane separates two ionic solutions of differing 
ionic concentrations, selective ions will tend to flow from one side of the 
membrane to the other from the side of highest concentration to that of the 
lower concentration, i.e. down the concentration gradient, until the potential 
difference set up by the net flow of charge opposes the concentration gradient. 
This potential difference is said to be the “Equilibrium Potential” and is 
dependent on the different concentrations of the selectively permeable ions on 
either side of the membrane (Molleman, 2003). In a simple example of two 
solutions, one containing sodium chloride (NaCl) and the other potassium 
chloride (KCl) each of the same concentration, and separated by a potassium 
(K+) selective permeable membrane, potassium ions will flow down their 
concentration gradient from the KCl solution to the NaCl solution (see Figure 
2.6). Initially the net charge on either side of the membrane is equal, but as now 
only K+ ions are flowing a net negative charge develops on the original KCl side 
of the membrane and a net positive charge on the original NaCl side of the 
membrane. As more K+ ions flow the potential difference across the membrane 
builds until the electrochemical gradient is neutral for K+. That is the 
concentration gradient is balanced by the electrical gradient driving K+ back 
across the membrane. 
  
 124 
  
 
 
Figure 2.6. Demonstration of Equilibrium Potential. If equal 
concentrations of NaCl and KCl solutions exist either side of a potassium 
selective permeable membrane, potassium ions flow down their chemical 
gradient until the chemical driving force is equal to the electrical driving force 
created by the ensuing electrical gradient. At this point no further potassium 
ion flow ensues and the current will be zero. The potential difference across 
the membrane at this point is equal to the equilibrium potential for potassium 
for this set of circumstances.  
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If the compartments either side of the membrane are thought of as the cytosolic 
and extracellular sides of a cell separated by the cell membrane, then at this 
point of equilibrium, depending on the concentrations of an ion on either side of 
the membrane, the Equilibrium Potential for the ion (E), is given by the equation 
founded by Walter Hermann Nernst (1864-1941) known as the Nernst Equation: 
 𝐸 = 𝑅𝑇𝑧𝐹 ln 𝑖𝑜𝑛 𝑜𝑖𝑜𝑛 𝑖  
 
where R is the universal gas constant (8.31 J mol-1 K-1), T is the temperature in 
Kelvin, z is the oxidation state (charge) of the ion under consideration, F is the 
Faraday constant (9.65 x 104 C mol-1), [ion]o is the concentration of the ion 
under consideration on the extracellular side and [ion]i is that on the intracellular 
side (Molleman, 2003). 
 
At rest in a standard physiological extracellular solution, the mammalian cell 
membrane is predominantly permeable to K+. The intracellular concentration of 
K+ tends to be of the order of 140mM and the extracellular concentration of the 
order of 5mM. These concentrations are maintained largely by the Na+/K+ 
ATPase pump transporting Na+ out of the cell and K+ inwardly. Thus the Na+ 
concentration is higher on the extracellular side. The equilibrium potential of K+ 
at these concentrations is of the order of -80mV. However, there is still some 
permeability to other ions and the net resting membrane potential, after 
contribution of all equilibrium potentials, is usually somewhere between -50mV 
to -90mV. In ventricular cardiac myocytes it is more of the order of -90mV 
(Nerbonne & Kass, 2005). The negative sign denotes that the intracellular side 
is of a more negative potential with respect to the extracellular side of the cell 
by the magnitude indicated. 
 
2.7.1.2 Patch Clamp Equipment set-up 
 
Glass microelectrode capillaries can be pulled in two stages using a vertical 
microelectrode puller (Narishige, Japan) to create micropipettes. The capillary 
glass is melted via a heating coil through which the capillary is placed and 
centred. Pulling occurs via gravity at two temperatures resulting in separation of 
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the capillary and two tapered pipettes each open at the tapered end through a 
very small aperture of the order of 0.5-1µm (Hamill et al., 1981). The pipettes 
can be backfilled with solution of desired ionic composition and then placed 
onto a chlorided silver wire that makes contact with a gold pin at the back of a 
commercially available pipette holder (Axon Instruments Inc., USA). This gold 
pin is then incorporated into circuitry incorporating a headstage (CV-203 BU, 
Axon Instruments Inc., USA), which then connects to an amplifier (Axopatch 
200B, Axon Instruments Inc., USA) that controls inputs and outputs out of a 
command module. Analog signals are then digitised through a low-noise data 
acquisition system (Digidata 1440A, Axon Instruments Inc., USA) and a 
computer with the relevant software (pClamp 10, Axon Instruments Inc., USA) 
enables the user to visualise and manipulate the data in real-time. As such 
voltage and current commands can be sent to the probe and transmitted 
through the electrode in the pipette solution. The circuitry is completed via 
another earth electrode that sits in the “bath” solution that incubates the 
experimental isolated cells (see Figure 2.10). If the pipette is merely dipped into 
the bath, a potential difference between the pipette electrode and bath 
electrode is set up and a current, carried by the ions in the bath and pipette 
solutions thus ensues. 
 
2.7.1.3 Single-Channel Recording 
 
1). Cell-attached (See Figure 2.7) 
  
 
Figure 2.7. Cell-attached patch clamp configuration. 
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If the tip of a pipette is lowered under microscopy very lightly onto the cell 
surface, a seal with the cell membrane can be formed via light suction (negative 
pressure) through tubing connected to a side-port of the pipette holder. This 
seal can have a high resistance >1GΩ (known as a Giga-seal) and thus 
electrically isolates the patch of membrane directly subtended by the pipette tip 
in a configuration known as “cell-attached” (Hamill et al., 1981). The resting 
membrane potential of the cell may not be known exactly, but it can be 
estimated as close to the equilibrium potential for K+ ions (Ek). If the bath is a 
physiological extracellular solution with [K+] ~ 5mM, Ek would be of the order of  
-80mV (Molleman, 2003). Given the patch of membrane subtended by the 
pipette tip is small relative to the surface area of the rest of the cell membrane, 
its resistance is very much higher than the rest of the cell membrane. Any 
command potential difference set up between the pipette electrode and the bath 
earth electrode will be dropped across the test patch of membrane due to the 
laws governing resistors in series (DeFelice, 1997). This added command 
voltage does not in essence affect the resting membrane potential of the cell as 
a whole, just the voltage clamped across the patch (discussed further below in 
section 2.7.1.5). The voltage clamped across the patch Epatch is then calculated 
as the difference between the resting membrane potential of the cell Em 
(relative to the bath electrode) calculated by the Nernst equation, and the 
potential of the pipette electrode Ep (relative to the bath electrode): 
 𝐸𝑝𝑎𝑡𝑐ℎ = 𝐸𝑚 − 𝐸𝑝 
 
Dependent on the ion channel composition of the cell membrane and the 
voltage clamped across the patch or the presence of activating or inhibiting 
molecules, certain ion channels may or may not be contributing to the 
membrane permeability at that voltage clamp. If they are open and the voltage 
clamp is either side of the equilibrium potential of the respective ions at the 
concentrations governed by the cytosolic solution and pipette solution, there will 
be an electromotive driving force (emf) on the ions, they will move through the 
respective open ion channels, and current will flow. In voltage clamp, the 
computer and software measure this current by injecting through the amplifiers 
the exact opposite current needed to maintain the voltage clamp across the 
patch. If the opposite current was not injected, the voltage across the patch 
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would change until the new overall equilibrium potential, dependent on the ionic 
permeability of the membrane and ionic concentrations either side of the 
membrane with respect to this permeability was reached. 
 
In membrane attached patch configurations such as cell-attached patch, the 
current through the number of ion channels in the patch subtended by the 
pipette tip is measured. This is a very small number compared to the total 
number of ion channels in the cell membrane as a whole and with pipette tips of 
resistance towards 5MΩ and above, conferring a pipette tip diameter of ~0.5µM 
or less, this can be limited in some cases to as little as 10 or fewer ion channels 
in the patch (Hamill et al., 1981; Molleman, 2003). Openings of channels can be 
seen as deflections from the baseline current. The baseline current is due 
merely to leak current through the membrane. Single channel currents can be 
delineated as the smallest current deflection or smallest “level” of deflection 
from this baseline. Larger current deflections can be produced by a multiple 
number of channels open at that moment and will thus be multiples of the single 
channel deflection. In the case of only one type of channel in the patch, 
designating baseline as a level itself then there will be n+1 current levels that 
can be seen where n is the number of channels in the patch. It is possible to 
measure a single ion channel current (I) for a particular driving force (emf, 
electromotive force supplied by the voltage clamp of the amplifier) and then the 
single channel unitary conductance (g) via the equation: 
 𝑔 = 𝑒𝑚𝑓. 𝐼 
 
Similarly single channel current-voltage (I-V) relationship plots can also be 
produced. 
 
It is also possible to measure the open probability of the channel under the 
experimental conditions (driving force, ionic concentrations, and presence of 
opening or blocking molecules). The time that is spent at each current level can 
be plotted in a histogram. Due to thermal noise the current trace tends to 
“quiver” at each current level. The distribution of the current trace around the 
level due to this noise is Gaussian and this is represented in the current level 
amplitude histogram (Molleman, 2003). The peak of the Gaussian distribution 
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will represent the actual value of the current level and events due to noise lie 
around this mean. Using automated software packages it is possible to 
manually set thresholds for each current level that take into account the 
distribution of events around the level due to noise. This then creates an 
idealised trace of the dwell time at each current level and can cut down 
dramatically the amount of data to be stored and analysed compared with 
looking at the pure amplitude histogram. Open probability P(o) is then the open 
dwell time as a proportion of the total dwell time of the recording: 
 𝑃 𝑜 = 𝑡 𝑜𝑝𝑒𝑛𝑡 𝑜𝑝𝑒𝑛 + 𝑡 𝑐𝑙𝑜𝑠𝑒𝑑 
 
The dwell times take into account the number of channels involved in the open 
or closed time. i.e. time spent at a current level of 3 involves 3 channels open 
and a multiplication factor of 3 will be applied to the open dwell time 
apportioned to this level. If the total number of channels in the patch is 4, then 1 
channel must be closed at a current level of 3, and therefore this contributes to 
the closed dwell time of the recording with a multiplication factor of 1. 
 
2). Inside-Out Patch (See Figure 2.8) 
  
 
 
Figure 2.8. Inside-out patch clamp configuration. 
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The main disadvantage of the cell-attached configuration is the requirement to 
estimate the resting membrane potential of the cell and thus not knowing 
exactly the voltage clamp and driving force across the patch subtended by the 
pipette tip (Molleman, 2003). Given that the seal generated between the pipette 
and the cell membrane can be very tight, it is possible to lift the pipette off the 
cell pulling with it the piece of membrane subtended by the pipette tip together 
with excess membrane that then forms a vesicle at the tip of the pipette. If the 
pipette is then lifted momentarily out of the bath the vesicle disperses leaving 
just the piece of membrane subtended by the pipette. This piece of membrane 
is such that if the pipette is lowered back into the bath, what was the 
intracellular side of the membrane is facing outwards and is in contact with the 
bath solution (“inside-out”), and what was the extracellular side of the 
membrane subtended by the pipette tip and in contact with the pipette solution 
remains so. As such, any voltage clamp command between the pipette 
electrode and the bath electrode is directly dropped across the patch (Epatch) 
without the need to factor in the resting membrane potential of the cell 
(Molleman, 2003). An added advantage of this configuration is that with 
superfusion systems connected to the bath supply, dynamic changes to the 
virtual “intracellular” environment can be maintained and thus experimented 
with. 
 
3. Outside-Out Patch 
 
This as it suggests is similar to Inside-Out Patch but for the fact that what was 
the extracellular side of the membrane is now facing outwards and is in contact 
with the bath solution and what was the intracellular side of the membrane now 
becomes subtended by the pipette tip and in contact with the pipette solution. 
This configuration is achieved by lifting the pipette off the cell whilst in the 
whole-cell configuration which will be discussed below. 
 
2.7.1.4 Whole-Cell Recording (See Figure 2.9) 
 
After formation of a giga-seal, it is possible to rupture the patch of membrane 
subtended by the pipette tip by applying further negative pressure through the 
tubing connected to the side port of the pipette holder. 
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After rupture, the cell membrane still creates a seal on either side of the pipette 
tip, but the pipette solution is now in direct contact with the intracellular 
compartment through the opening of the pipette. This allows control of the 
voltage and current clamp of the whole of the cell membrane, hence, the name 
“whole-cell” recording. A process of dialysis also occurs where the pipette 
solution will mix through diffusion with the intracellular fluid of the cell. Given the 
amount of solution in the pipette is vastly greater than that of the intracellular 
fluid, the pipette solution will, after a period of 3-5 minutes, effectively engulf 
and become the intracellular fluid composition (Molleman, 2003). 
 
2.7.1.5 Pipette and Cell Capacitance, and Series Resistance 
 
Figure 2.10 demonstrates measuring equipment (a) and equivalent electronic 
schematic (b) diagrams of RC circuits moving from placing a pipette in the bath 
solution to getting a giga-seal in cell-attached patch and going to the whole-cell 
configuration. Epc, Rpc and Cpc represent the driving force of the patch clamp 
amplifier, the resistance in the patch clamp amplifier and any stray capacitance 
in the amplifier circuit when the pipette is in the air. The switch Scpip/Srpip is a 
double switch that closes on entering the pipette into the bath thus exposing the 
amplifier to the pipette capacitance Cpip and pipette resistance Rpip. The 
switch Sseal is closed short-circuiting away from the circuit that will be provided 
by the cell that is not yet present. When a seal is made with the cell, Sseal 
opens exposing this circuit provided by the cell (DeFelice, 1997). Rcap is the 
resistance afforded by the cell-attached patch of membrane subtended by the 
 
Figure 2.9. Whole-cell patch clamp configuration. 
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pipette tip and Rseal the resistance afforded by the sides of the seal itself that 
may have a tiny degree of leak. The hope is Rseal will be very large signifying a 
tight and not leaky seal. In cell-attached configuration it can be noted that the 
driving force of the amplifier is now exposed to the effects of the driving force of 
the membrane potential of the cell Em, the membrane resistance of the cell Rm 
and the capacitance effect of the cell membrane Cm. However, what with Rcap 
being relatively large, the voltage applied by the amplifier is dropped over the 
patch of membrane subtended by the pipette and does little to influence the 
membrane potential of the cell as a whole (DeFelice, 1997). In fact therefore, 
the membrane potential of the cell contributes to that across the pipette-
subtended patch as previously explained in the section on cell-attached patch 
(2.7.1.3). When the patch is ruptured going to whole-cell configuration, and 
simulated by closing of switch Sacc, this short circuits Rcap given the access 
resistance Racc is much lower than Rcap. Racc is ideally very low such that the 
capacitance of the membrane can be charged easily and quickly by the 
controlling voltage of the amplifier as a large current then flows across the 
pipette tip to affect the cell membrane (DeFelice, 1997). Thus the membrane 
potential Em is itself then controlled by that of the amplifier by charging the 
membrane. 
  
 133 
  
 
 
Figure 2.10. Electronic equivalent circuits demonstrating cell-attached 
and whole-cell patch clamp configurations (taken from DeFelice, 1997). 
Epc, Rpc and Cpc represent the driving force of the patch clamp amplifier, 
the resistance in the patch clamp amplifier and any stray capacitance in the 
amplifier circuit when the pipette is in the air. The switch Scpip/Srpip is a 
double switch that closes on entering the pipette into the bath thus exposing 
the amplifier to the pipette capacitance Cpip and pipette resistance Rpip. 
Sseal is a switch that when opens on contact with the cell exposing to the 
cell circuit. Rcap is the resistance afforded by the cell-attached patch of 
membrane subtended by the pipette tip and Rseal the resistance afforded by 
the sides of the seal itself that may have a tiny degree of leak. In cell-
attached configuration (CAP) Epc is now exposed to the effects of the 
driving force of the membrane potential of the cell Em, the membrane 
resistance of the cell Rm and the capacitance effect of the cell membrane 
Cm. Rcap is relatively large and Epc is dropped near solely over the patch of 
membrane subtended by the pipette. When the patch is ruptured going to 
whole-cell configuration, and simulated by closing of switch Sacc, this short 
circuits Rcap given the access resistance Racc is much lower than Rcap. 
When Racc is low, the capacitance of the membrane can be charged easily 
and quickly by Epc as a large current then flows across the pipette tip to 
affect the cell membrane. The membrane potential Em is itself then 
controlled by that of the amplifier by charging the membrane. 
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The pipette glass and, after membrane rupture in the whole-cell configuration, 
the cell membrane, both have a capacitance to store charge. As such in 
applying a potential difference through the circuitry there is a delay in the 
attainment of that potential difference across the cell membrane and as such a 
delay in the attainment of the driving force. The glass of the pipette and the cell 
membrane have capacitance (C) governed by the equation: 
 𝐶 =   𝜀 𝜀𝑜 𝐴𝑑   
 
where εo is the polarisability of free space (8.85 x 10-12 CV-1m-1),  ε is the 
dielectric constant of the insulator between two plates of a capacitor each of 
area A and separated by distance d (Axon Instruments Inc, 1993). In this case 
the plates are the two sides of the glass pipette or the individual layers of the 
lipid bilayer of the cell membrane and the insulators are the material between 
these layers. Ions in solution move towards the two sides of the pipette glass 
and cell membrane until the charge stored provides an equal and opposite 
potential difference across the capacitor that opposes the driving voltage of the 
amplifier (DeFelice, 1997). Only then is this intended voltage applied across the 
cell membrane. 
 
The amount of charge Q moving towards the plates of a capacitor is related to 
the driving voltage E and capacitance C by the equation: 
 𝐶 = 𝑄𝐸 
 
As the charge moves it carries a current that is manifest in the recording as an 
excess current peak or transient that decays as the potential difference across 
the capacitor rises towards the driving voltage. This decay of current transient I 
and rise of potential difference E are described by the exponential functions: 
 𝐼 = 𝐼! 𝑒! !!" 
 𝐸 = 𝐸!(1− 𝑒! !!") 
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where I0 and E0 are the starting current and final potential difference 
respectively, t is the time since the driving voltage was applied by the amplifier, 
R is the total resistance in series of the circuit and C is the capacitance. These 
relationships constitute the principles governing capacitors and resistors in 
series known as RC circuits (DeFelice, 1997). 
 
These capacitance current transients are not current carried across the cell 
membrane but will be represented in the recording unless they are accounted 
for. A parallel circuit that contains a variable RC circuit enables this cancellation. 
The parallel capacitor and resistor can be adjusted such that they provide an 
equal and opposite capacitance to the cell and pipette thus effectively 
cancelling them (Axon Instruments Inc, 1993). 
 
The aim of voltage clamp experiments is to measure the current across the cell 
membrane being clamped at the driving voltage. Unfortunately, the resistances 
of the pipette and pipette electrode reduce the voltage that is finally dropped 
over the membrane, and thus the current measured, because they are in series 
with it and are known as the “series resistance” (Molleman, 2003). The series 
resistance can be estimated in the capacitance transient cancellation process 
because it contributes to the RC circuit as a whole. A compensatory mechanism 
can then be enforced where the amplifier is instructed to inject slightly more 
current than would be necessary to clamp at a particular voltage to compensate 
for the proportion of the voltage that will be dropped across the series 
resistance. For most cells, the amount of compensation that can be practically 
enforced is about 70%, with any more than this usually being detrimental to the 
cell because of current oscillations set up in the RC circuit (Axon Instruments 
Inc, 1993). 
 
With voltage clamp the cell membrane is clamped at the controlling voltage. In 
order for this the resistance in the amplifier/pipette aspect of the circuit needs to 
be significantly lower than that of the membrane to allow fast charging (via a 
large current) of the pipette capacitance. This in turn enables a large potential 
difference to be dropped across the membrane fully charging its capacitance 
(DeFelice, 1997). If the resistance of the amplifier is significantly large, the 
various capacitances of the circuit never become fully charged as the current 
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passing is too small and this too includes that of the cell membrane. Whilst then 
the voltage of the membrane cannot be clamped this albeit small current 
passing through can, and if there are any endogenous variations in the 
membrane potential affecting this current, they can be calculated and 
represented by the software. This then is current clamp. If a cell activates and 
produces an action potential, the voltage waveform can be produced on screen 
by the software. 
 
2.7.1.6 Pros and Cons of the different configurations 
 
Whole-cell recording allows for experimenting with different environments on 
the intracellular side of the cell membrane as well as the extracellular 
environment without the added technical difficulty of achieving inside-out or 
outside-out patch.  That said, for obtaining dose-response relationships for 
changes in environment on the intracellular side of the membrane, inside-out 
patch is superior given the ability to superfuse the bath solution with the 
required concentrations of investigatory ligand and gain data for these different 
concentrations from the same cell. 
 
Whilst cell-attached patch would appear the most direct configuration, tight 
seals reaching at least 5GΩ are required to limit noise on the baseline of the 
recording, a factor very important to delineate single channel openings (Hamill 
et al., 1981). However, whole-cell recordings also give a whole-cell current, and 
thus, real-time assessment of current responses to drugs, for example, can be 
easier in the whole-cell configuration (Molleman, 2003). Whole-cell 
conductance can also be measured and whilst it is not known exactly how many 
ion channels exist in the whole of the cell membrane, the whole-cell current can 
be normalised to the cell capacitance estimated during the capacitance 
transient cancellation process explained above. Cell capacitance is a surrogate 
for the area of the cell membrane, and whilst assumptions are made that the 
membrane ion channel density between cells is similar, nonetheless the 
capacitance thus provides an estimate of the number of ion channels in the cell 
(Molleman, 2003). Whole-cell current can then be normalised to the cell 
capacitance and expressed as the current density. 
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A possible problem with whole-cell recording, particularly during long recording 
experiments, is that dialysis of the cell contents is met by the loss of molecules 
potentially critical to ion channel function and thus the phenomenon of “run-
down” of current can ensue. The phenomenon can be overcome by Perforated 
Patch Whole-Cell recording. 
 
2.7.1.7 Perforated-Patch Whole-Cell Recording (See Figure 2.11) 
 
This involves adding an antibiotic such as amphotericin to the pipette solution. 
Before back filling the pipette with this antibiotic-containing solution, the pipette 
tip is dipped in standard pipette solution without antibiotic in order to draw up a 
very small amount into the pipette tip by capillary action. Thus the antibiotic 
containing solution will rest on top of the standard solution in the pipette and the 
antibiotic will slowly diffuse towards the pipette tip down its concentration 
gradient (Molleman, 2003). This gives just enough time to achieve a tight seal 
onto a cell before the antibiotic starts to make contact with the cell membrane. 
Antibiotics such as amphotericin, then act by slowly forming pores in the cell 
membrane that happen to be permeable to ions, but impermeable to the 
majority of intracellular and membrane bound protein species such that they are 
maintained in the intracellular environment. In due course, there are enough 
pores in the membrane to simulate a ruptured membrane in whole-cell 
configuration and whole-cell current can be measured by clamping voltage 
 
 
Figure 2.11. Perforated patch clamp configuration.  
 138 
across the whole-cell membrane by the access to the cell conferred by the 
antibiotic pores. The problem of “run-down” is also largely eliminated. The 
downside to perforated-patch whole-cell recording is the length of time it can 
take to achieve a perforated patch and the yield of good quality perforated 
patches achieved. Indeed it can take up to 45 minutes to achieve a cell ready 
for recording. In that time the cell’s health in general may have deteriorated 
(Molleman, 2003). 
 
2.7.2 Experimental Conditions 
 
Whole-cell patch clamp recordings were performed. Capacitance transients and 
series resistance were compensated electronically by using amplifier circuitry 
(Axopatch 200B). Data were filtered at 2kHz (four-pole Bessel) and sampled at 
10kHz using a Digidata 1550 (Axon Instruments). Currents were acquired and 
analysed using pClamp10 (Axon Instruments). Whole-cell currents were 
recorded using a voltage-ramp protocol (-150 to +50mV over 1s at 0.1Hz). 
Baseline current density was taken after 3 minutes of dialysis if there was no 
change in current from developing the whole-cell configuration, or at plateau of 
current if there was any change in current after developing the whole-cell 
configuration. Similarly, maximum drug action was measured at plateau of any 
change in current. Mean current-density values at +40mV were taken from the 5 
sweeps of the voltage ramp protocol after plateau was reached. 
 
Whole-cell action potentials were recorded using the current-clamp 
configuration. Action potentials were triggered by 600pA/5ms square pulses at 
1Hz. Data were analysed using pClamp10 (Axon Instruments) and Clampfit10 
(Axon Instruments). After 3 minutes dialysis action potentials were recorded for 
2 minutes with each drug condition. The last 10 action potentials of each 
recording period were averaged. Measurements were taken as per the 
schematic example in figure 2.12. Vmax (dV/dt) was taken as the mean gradient 
of the upstroke of the action potential given by the change from resting to peak 
membrane potential (Δ) over the time for this change. 
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Figure 2.12. Action potential measurements. RMP, resting membrane 
potential; APD90, action potential duration at 90% repolarisation; MDP, 
maximum diastolic potential. 
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Glass micropipettes were pulled from capillary tubes made of borosilicate with 
filament, 1.5mm outer diameter, 1.17mm inner diameter, 100mm length 
(Harvard Apparatus, USA). Pipette resistance varied between 2-3MΩ. 
 
The pipette solution for voltage-clamp contained (mM): KCl 110, MgCl2 1, 
HEPES 10, EGTA 10, MgATP 3, Na2ADP 1, pH 7.2 with KOH and final [K+]      
~ 150. The bath solution contained (mM): NaCl 130, KCl 4, CaCl2 1.8, MgCl2 1, 
HEPES 10, D-Glucose 10, pH 7.35 with NaOH and final [Na+] ~ 135. 
 
The pipette solution for current-clamp recordings contained (mM); K-Gluconate 
110, KCl 20, HEPES 10, EGTA 0.05, MgCl2 0.5, MgATP 5, Na2-GTP 0.3, Na2-
phosphocreatine 5, pH 7.4 using KOH. 
 
Pipettes were backfilled with intracellular solution and the pipette tip then 
dipped in Sigmacote® (Sigma Aldrich Co Ltd) which is a liquid siliconising 
reagent that will coat glass and render it electrically inert. It is hydrophobic and 
thus will not coat the aperture of the pipette that is filled with pipette solution. 
The Sigmacote® thus helps to reduce the pipette capacitance by shielding from 
the bath solution when immersed. 
 
KATP channel opening drugs diazoxide (DZX) and pinacidil (PIN) (Sigma Aldrich 
Co Ltd) and inhibitors glibenclamide (GLIB) and tolbutamide (TOLB) (Sigma 
Aldrich Co Ltd), and the inhibitor HMR1098 (HMR) (Axon Medchem BV, 
Netherlands), were dissolved in ≥99.5% dimethylsulfoxide (DMSO, Sigma 
Aldrich Co Ltd) to make stock solutions. Stock was further diluted in 
extracellular solution for use in experiments. Stock solutions of diazoxide and 
tolbutamide were made to 100mM and those of pinacidil, glibenclamide and 
HMR1098 to 10mM. The suggested pore blocker PNU37883A (PNU) (Axon 
Medchem BV, Netherlands) was dissolved in double distilled water to make a 
stock solution at 10mM before further dilution in extracellular solution for use in 
experiments. Final concentrations for experiments were chosen based on 
selectivity for subunits defined by the literature (see section 1.3.2) and were as 
follows: diazoxide and tolbutamide 100µM; pinacidil, glibenclamide and 
HMR1098 10µM and PNU37883A 50µM. A maximum of DMSO 0.2% was used 
in drug-containing extracellular solutions and an extracellular solution 
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containing the addition of DMSO 0.2% alone was prepared as a control. 
Extracellular perfusate was then introduced to the bath via a gravity driven 
superfusion system running at ~1.5ml/minute. All experiments were conducted 
at room temperature. 
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2.8 Electrophysiology from Cardiac Tissue 
 
Apart from looking for any significance of KATP current modulation in isolated 
atrial myocytes, I wanted to look for any further differences at the tissue level. 
Specifically, I wanted to test for differences in ERP and CV, electrophysiological 
parameters that contribute to arrhythmogenicity. 
 
2.8.1 Signal analysis via the surface electrogram 
 
When measuring electrical activity by means of electrodes placed on the 
surface of tissue, it is the charge build-up in the extracellular space directly 
beneath the electrode that leads to the potential difference measured via the 
electrode. Two configurations may be utilised as described below and depicted 
in Figure 2.13. 
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Figure 2.13. Generation of unipolar and bipolar electrograms (taken 
from Stevenson & Soejima, 2005). In the case of unipolar electrograms (A), 
the developing wavefront of activation passes underneath the exploring 
electrode and the potential difference in the extracellular space is measured 
with respect to a remote indifferent electrode (not shown). As the wavefront 
moves towards and then passes the exploring electrode the extracellular 
space develops a more negative potential difference with respect to the 
indifferent electrode giving different morphologies of electrogram as shown 
dependent on the position of the exploring electrode. In the case of bipolar 
electrograms (B), the instantaneous sum of the potential differences in the 
extracellular space between two local unipolar electrodes is measured. One 
unipolar signal is inverted given it is attached to the negative input of the 
amplifier. 
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1). Unipolar electrograms (UEGM) 
 
In panel A of Figure 2.13 an exploring electrode resting on the surface of, for 
example, cardiac tissue, would be connected to the positive terminal of a 
recording amplifier and a second electrode, referred to as the indifferent 
electrode, would be placed at a distance, ideally infinite, away from the tissue 
and connected to the negative terminal. As a depolarisation wave spreads 
across the tissue towards the exploring electrode, the extracellular space 
surrounding depolarised cells becomes negatively charged and the exploring 
electrode transiently sits above extracellular space that is relatively more 
positively charged. A current thus flows across the extracellular space down the 
voltage gradient. The amplifier detects the potential that is set up. It becomes 
gradually more positive as the wave of depolarisation approaches the exploring 
electrode. At the point of depolarisation, or activation, of the tissue directly 
beneath the exploring electrode, the extracellular space directly beneath the 
electrode rapidly becomes negatively charged and this is reflected in the 
voltage waveform which develops a sharp transition and downward deflection to 
negative values before resetting to zero as the wave of depolarisation passes. 
The bottom 3 inset waveforms show how recording at either extreme end of the 
wavefront demonstrates directionality. If the wavefront moves completely away 
from an electrode the UEGM is solely negative, and it is solely positive if the 
wavefront moves only towards an electrode. It has been shown that at the point 
where the first derivative (dV/dt) of the unipolar electrogram is most negative, 
corresponds to the activation time of the tissue directly beneath the exploring 
electrode, as given by the point where the first derivative of a simultaneous 
monophasic action potential (MAP) is at its most positive (during the upstroke) 
(Wyatt et al., 1981; Millar et al., 1985; Coronel et al., 2006). This also 
corresponds well with the greatest flux of sodium during the upstroke. 
 
A wave of repolarisation then follows and also produces gradients of charge 
and, therefore, voltage, in the extracellular space. In a unipolar electrogram the 
T wave inscribes this gradient of repolarisation. In human, the T wave is distinct 
and can usually be clearly demarcated. It either has positive or negative 
polarity. Some groups argue that the point of the greatest modular value of the 
first derivative of the second limb of a T wave, descending for a positive T wave 
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and ascending for a negative T wave, marks the moment of local repolarisation, 
and that this correlates with the MAP90, the point at which the MAP is 
repolarised by 90% of its absolute amplitude (Yue et al., 2004; Yue, 2007). 
However, this notion does not fit with the first principles that govern the 
mechanics for the morphology of the unipolar electrogram for activation as 
described above. More in keeping with these first principles is the finding that 
the point where the first derivative of the T wave is most positive, on the 
ascending limb of either a positive or negative T wave, correlates with local 
repolarisation (Coronel et al., 2006; Potse et al., 2007; 2009). 
 
It is attractive to measure the activation-recovery interval (ARI), as there is good 
correlation with the duration of the MAP and therefore the APD. However, whilst 
visualisation and assessment of the UEGM activation waveform in murine 
cardiac tissue can be performed with relative ease, it is notoriously difficult to 
discern and assess the T wave. What's more, controversies exist as to exactly 
where local repolarisation time is inscribed on the murine UEGM (Knollmann et 
al., 2001; Boukens et al., 2014). This makes it difficult to measure an ARI in the 
mouse as a surrogate for APD. One might make an attempt to measure a MAP 
and whilst this is possible, it too is technically challenging given the size and 
friability of the mouse heart and tissue. Changes in ERP correlate well with 
changes in APD, and under albeit normal conditions, ERP has been shown to 
be on average 85% of APD90 (Knollmann et al., 2001). Thus, it is reasonable to 
monitor changes in ERP as a surrogate for APD and ERP itself has important 
implications for arrhythmogenicity, certainly with regards re-entrant 
mechanisms. 
 
Whilst the UEGM can demonstrate directionality of a wavefront and has 
properties that allow for measurement of activation time and in some cases 
repolarisation time, it is open to far-field contamination from surrounding areas 
not local to the area directly beneath the electrode and also to noise. 
 
2). Bipolar electrograms (BEGM) 
 
In panel B of Figure 2.13 the sum of the potential differences at any moment 
between two closely spaced unipolar electrodes records the BEGM. Since 
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electrode 2 is connected to the negative terminal of the amplifier, its output is 
also inverted. Noise and far-field contamination are, thus, subtracted from the 
signal. 
 
Whilst the BEGM is useful to help eliminate noise and far-field contamination, it 
is virtually impossible to delineate exactly where between the electrodes the 
local activation of the tissue occurs and controversies exist as to whether to 
take the onset of the BEGM or the peak of the BEGM as the activation time. It is 
also virtually impossible to assess the directionality of a wavefront and if the 
wavefront moves near perpendicular to the axis of the electrodes, a very low 
amplitude signal will be seen as there will be near no potential difference 
between the electrodes (Cantwell et al., 2015). 
 
2.8.2 Langendorff Heart Preparations 
 
After schedule one killing via cervical dislocation, hearts were excised 
following thoracotomy and placed briefly in ice-cold oxygenated (95% O2/5% 
CO2) Krebs solution containing (mM) NaCl 118, KCl 4.75, MgSO4.7H2O 1.19, 
NaHCO3 25, KH2PO4 1.19, D-glucose 5, CaCl2 1.4 and C3H3NaO3 2. Hearts 
were then quickly cannulated on ice via the aorta with a 14G aortic cannula 
(ADInstruments, Oxford), held in place with a clip, and mounted onto a modified 
Langendorff setup. Hearts were retrogradely perfused via the ascending aorta 
with warmed Krebs solution (contents as above) at constant flow of 2 ml 
min－1 via a peristaltic pump. The temperature of the perfusate was maintained 
at 37.0±0.5 °C using an automated temperature controller and heatable 
perfusion cannula with temperature sensor (TC02, Multichannel Systems, 
Germany). Hypoxic conditions were produced by pre-bubbling Krebs with 95% 
N2/5% CO2. Drug containing Krebs solutions were made in the same manner 
and to the same concentrations as described in section 2.7.2. Solutions could 
be switched seamlessly using a custom-made manifold perfusion system. 
Experimental protocols were commenced after a 10 minute stabilisation period. 
A custom-made plastic cup was pressed lightly against the anterior surface of 
the heart and helped support and stabilise it during beating.  
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A commercially available flexible microelectrode array was used, known as 
FlexMEA for short (Multichannel systems, Germany). This is made of flexible 
polyimide 2611 foil with 32 circular titanium nitride electrodes of diameter 30µm 
and interelectrode distance of 300µm (see Figure 2.14). Two further electrodes 
act as reference electrodes and another 2 electrodes ground the array to help 
eliminate noise. The polyimide foil is perforated with holes of 30µm diameter to 
help ensure optimal tissue contact that make the FlexMEA ideal for recording 
from whole heart preparations. Each electrode records a local UEGM, or, 
extracellular field potential. 
 
The FlexMEA is mounted on to a 32 channel miniature pre-amplifier (MPA32I, 
Multichannel Systems, Germany) using an adapter (ADPT-FM-32, Multichannel 
Systems, Germany), and then connected to a portable filter amplifier (USB-
ME32-FAI-System, Multichannel Systems, Germany) for data acquisition via PC 
with accompanying software (MC Rack v4.6.2, Multichannel Systems, 
Germany). 
 
The FlexMEA was held in place with a clamp stand on the surface of the right 
atrial appendage for experiments of spontaneous sinus rate, and that of the left 
atrial appendage for experiments with pacing protocols. The set-up for position 
 
Figure 2.14. The FlexMEA (Courtesy of Multichannel Systems, 
Germany). 
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and orientation of the FlexMEA did not differ between preparations of the same 
experiments. Positioning the FlexMEA in this way could ensure large and sharp 
atrial electrograms for analysis and only small far-field ventricular electrograms 
(see Figure 2.16 bottom panel). Similarly, for protocols involving pacing of the 
heart, a custom-made unipolar platinum electrode was then always positioned 
on the posterior aspect of the heart in-between the two atria and directly 
adjacent to the left atrium. Figure 2.15 demonstrates a schematic of the set-up. 
 
Pacing was performed via 1ms biphasic 2V stimuli using a stimulus generator 
(STG4002, Multichannel Systems) as programmed using its dedicated software 
interface (MC_Stimulus II, Multichannel Systems, Germany). Such stimuli were 
adopted as standard for all preparations through experience of having produced 
consistent and reliable tissue capture whilst also not saturating the electrogram 
signal. The programmed electrical stimulation (PES) protocol consisted of a 
drive train of eight paced beats (S1) at cycle length (CL) 120ms each followed 
by an extra stimulus (S2) every ninth beat. After the first drive train the S1-S2 
interval was set at 120ms and after each subsequent drive train the S1-S2 
interval reduced by 2ms until refractoriness was reached. 
  
 
 
Figure 2.15. Langendorff set-up. Schematic, left and real life photo, right, 
showing the FlexMEA in yellow placed on the surface of the left atrium of the 
heart in red. Note also the stimulating electrode (in blue on the schematic) 
placed posteriorly. 
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2.8.3 FlexMEA Signal Analysis 
 
Signals recorded through the MC Rack software are stored as .mcd files and 
then were converted to .h5 files before analysis using a modified Matlab script 
known as "EcgSplitter" (see Figure 2.16). Dr Malcolm Finlay, University College 
London and Queen Mary University of London, developed the EcgSplitter from 
a signal analysis graphical user interface (GUI, wave_inspector.m) created by 
David Western, University College London. EcgSplitter is a simple GUI allowing 
import, analysis and export of signals imported from a commercial 
electrophysiology system such as the FlexMEA system. 
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Figure 2.16. The EcgSplitter GUI. Upper Panel: The EcgSplitter allows 
automatic import of electrogram data from various file types. The bottom left 
window of the ECG Splitter shows automatically detected timing intervals, in 
this case the S2 coupling interval. The signal window demonstrates the 
penultimate and final S1 beats, and S2 beat, of a drive train whereby the S2 
interval is 78ms as depicted by the selection in the bottom left window. The 
bottom middle window demonstrates all the electrodes across the FlexMEA 
for individual selection. The control panel on the right allows filtering and 
functionality including activation time and conduction velocity calculation 
across the array for that data selected in the bottom left window (see main 
text for explanation of conduction velocity calculation). Bottom Panel: 
Enlarged signal window showing final S1, and S2 beats of the drive train. 
The pink lines show positions of automatically detected pacing spikes. Note 
the large sharp local atrial signal and small far-field ventricular electrogram.  
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Dr Finlay's adaptations allow recognition of pacing spikes (by time differential of 
signal and signal magnitude), QRS complexes, as well as functionality involving 
selection of electrogram channels for analysis. A key adaptation was automatic 
recognition of the final 3 complexes in an S1-S2 pacing protocol drive train. 
After inputting the drive train constant, the script was able to recognise the final 
beats of a drive train, and select these for export. These "snippets" of the large 
electrogram data could then be checked for accuracy. Given the PES protocol 
brought the S2 down in 2ms intervals, ERP was taken as 1ms longer than the 
shortest coupled S2 that did not activate the tissue. 32 signals were obtained 
for each beat. In wild-type mice the atrial ERP can be of the order of 20ms 
(Kaese & Verheule, 2012). In the case of steady state conduction velocity 
measurement, the signals of the final two S1 activations (at CL 120ms) are 
taken to ensure an adequate number of beats of the drive train to overdrive the 
tissue. If, for example, the ERP is 20ms, this would constitute 11 time points 
and a total ~35,000 electrograms to assess over the course of a 20 minute 
experiment. In order to maintain fidelity via manual checking of every 
electrogram, for steady state conduction velocity, this was rationalised by 
including only the first 3 drive trains of the PES protocol for each time point of 
the experiment. Activation was defined as the point of most negative dV/dt of 
the electrogram. Having rationalised the number of electrograms to be included 
in the analysis, manual checking of every electrogram took place. Grossly 
fragmented electrograms, where no clear dominant negative intrinsicoid 
deflection of the field potential could be visualised and thus ambiguity existed 
as to the point of most negative dV/dt, were excluded from the analysis. 
EcgSplitter can present signal-averaged data from a manually selected drive 
train and manually selected electrodes. It presents the averaged data for that 
drive train across all the selected electrodes depicting the mean±2SD of the 
final two S1 beats in red, and that of the S2 beats in blue (see Figure 2.17). The 
data is presented with respect to time from the pacing spike such that S2 data 
is later than S1 data due to activation delay at shorter coupling intervals. The 
user then selects a window from this data to exclude, for example, any remnant 
artefact from the pacing spike, and EcgSplitter then measures the activation 
time for all manually included drive trains and electrode data as the time from 
the pacing spike detection to the point of the most negative dV/dt within the time 
window manually selected. If, in selecting the window, the drive train with the 
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shortest coupled S2 is used, and the window is placed at the end of the S2 
triggered electrogram, the window should incorporate all electrogram data timed 
from a pacing spike for all the manually included drive trains. 
 
Classical measurement of conduction velocity via measurement of the time for 
impulse propagation between two points relies on knowledge of the path of 
activation and in a 2D planar surface this can be complex to determine. For 
example, the path may not be linear which would confound the final 
measurement. Alternatively, the overall activation gradient as measured across 
the entire tissue can be calculated. For each manually included beat, and also 
as per the windowing function, the activation time for each included electrode is 
plotted to its corresponding point on the array. A topographical function fits a 2D 
least-squares regression surface to activation time data across the entire 
electrode array grid. The distance between each electrode is known (300µm) 
and given the "grid" nature of the FlexMEA, is equal in both the 𝑥 and 𝑦 planes. 
Activation gradients (time/distance) can be measured at each point of the fitted 
surface corresponding to each included electrode data point. The gradient (G) 
has vector directionality and at each point is calculated in a Cartesian fashion 
whereby G = √(G𝑥! + G𝑦!) (see figure 2.18). This circumvents the potential 
confounding of non-linear activation. The inverse of the activation gradient 1/G 
 
Figure 2.17. The EcgSplitter manual window selection tool. Mean (bold 
lines) and 2 standard deviations either side of the mean are presented for all 
manually selected electrodes for data pertaining to a particular drive train. 
Red represents the final 2 S1 beats of the drive train and blue the S2 beats. 
Note the small far field ventricular data to the right of the window in red 
corresponding to that from the S1 beats. That from the S2 beats is not shown 
as it falls too late due to activation delay. See also main text for details. 
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is the conduction velocity at that point. The mean of these was then taken as 
the overall conduction velocity across the FlexMEA. The mean is then taken of 
data from all beats pertaining to a particular coupling interval. Hence, in the 
case of steady state conduction velocity at CL 120ms, seeing as the final 2 S1 
beats of the drive train were used and the first 3 drive trains of the PES 
protocol, the final CV measurement will be the average from 6 beats. In the 
case of CV restitution, in order to take a mean of a number of beats, data was 
averaged from 5 beats, that of the S2 interval in question, and the 2 intervals 
either side of that S2 interval. A potential limitation of this method using the 
present materials in the whole heart, is that the FlexMEA rests solely on the 
epicardial surface of the heart and conduction could also proceed perpendicular 
to the FlexMEA or, at least, not truly parallel to it. Care was taken to ensure 
activation maps supported propagation parallel to the FlexMEA and where this 
was not the case data were excluded from analysis. Figure 2.18 demonstrates 
a typical activation map from the experiments where propagation appeared 
parallel to the FlexMEA. It is colour coded for activation time where like colours 
are isochrones (red = early, blue = late). The method for CV calculation has 
been validated previously (Finlay et al., 2014). 
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Figure 2.18. Calculation of conduction velocity from a regression 
surface. A typical regression surface for calculation of conduction velocity is 
shown. The 𝑥 and 𝑦 axes represent 2D positions. The height of the blue dots 
gives the activation time measured at that location. This 𝑧 axis is inverted 
(early activation = high, late activation = low). A regression surface is fitted to 
these co-ordinates, which here is colour-scaled to represent activation time 
(red = early, blue = late, note also the square pulse indicating point of 
stimulus). At any point on this surface, the slope (G) can be calculated in a 
Cartesian fashion G = √(G𝑥! + G𝑦!), where G𝑥 is the gradient in the x plane 
and G𝑦 that in the y plane. The inverse 1/G is the conduction velocity at that 
point. The mean is then taken of all conduction velocity points across the 
array to give the overall conduction velocity for that beat. 
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In the absence of pacing spikes EcgSplitter recognises the QRS complex and 
also has the functionality to set a manual threshold level for detection. This is 
useful since when the FlexMEA is placed on the surface of the atrial 
appendage, atrial electrograms are sharper and have greater amplitude (see 
Figure 2.16). Thus, for measurement of spontaneous sinus rate, the mean of 
the last 10 R-R intervals (for atrial electrograms) for a particular time point was 
taken. 
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2.9 Calcium Transient Measurement from HL-1 Syncytia 
 
Given the tendency of HL-1 cells to beat spontaneously in clusters, I utilised this 
property to investigate the effects of KATP activation or inhibition on this 
spontaneous beating. 
 
Referring to section 2.1.2, HL-1 cells were seeded such that they would be 
confluent as syncytia in a 5.5cm2 MEA perfusion chamber on the day of 
experiments. 10µL of DMSO was added to 50µg of fluo-4 acetoxymethyl ester 
(Fluo-4,AM) (Thermofisher Scientific) making a 5mM stock. Fluo-4 is a labelled 
calcium indicator molecule that exhibits an increase in fluorescence upon 
binding Ca2+. It has high fluorescence excitation at 488nm. Cells may be loaded 
with the AM ester form of Fluo-4 that allows cell permeation, by adding 
dissolved indicator directly to dishes containing cultured cells. 
 
5µL of the Fluo-4,AM/DMSO 5mM stock was added to HL-1 syncytia in 1ml of 
Claycomb medium such that the concentration of Fluo-4,AM was ~20µM. 
Syncytia were allowed to incubate with the Fluo-4-AM for 20 minutes before the 
medium was changed to 1ml of oxygenated Krebs with the same contents as 
described in section 2.8.2. The temperature of the Krebs solution was 
maintained at 37oC by use of a temperature controller (TC02, Multichannel 
Systems, Germany). The syncytia were imaged with a Nikon Eclipse TE200 
inverted microscope with an integrated digital CMOS camera (ORCA Flash4.0 
V2 C11440-22CU; Hamamatsu Photonics UK Limited, Hertfordshire, UK). A 
light emitting diode illumination system was synchronised with the camera for 
epifluorescence. Recordings were taken at 100fps. 
 
Syncytia would tend to display spontaneous calcium transients in the form of 
organised wavefronts across the MEA and in a rotational fashion. After a 5 
minute period of stabilisation, recordings (1min) of spontaneous calcium 
transients were made under baseline conditions, after 3 minutes incubation with 
diazoxide 100µM, after 3 minutes incubation with diazoxide 200µM and finally 
after 3 minutes incubation with diazoxide 200µM / tolbutamide 100µM. Drugs 
were added sequentially directly to the bath. 
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Recordings were processed as stacks using the public domain software Image 
J (http://imagej.nih.gov/ij) to measure the frequency of activating wavefronts by 
selecting a small area of the array encroached by the wavefront. The absolute 
size of this area was kept uniform between arrays. Where representation of 
calcium transients is depicted, the median fluorescence over the whole 
recording has been subtracted in an attempt to reduce the confounding of the 
background signal likely to be due largely to non-esterified Fluo-4 bound to 
extracellular calcium. 
 
Various limitations apply to the use of the calcium transient solely as an 
indicator of wave front propagation. Firstly, activation time is not accurately 
delineated by any parameter of the calcium transient given changes in 
membrane potential defining the action potential do not coincide directly or 
ubiquitously with changes in cytosolic calcium. Isolated calcium sparks or 
release events from the SR may not trigger activation or be related to a 
propagating wave front. Voltage sensitive dyes demonstrate changes in 
membrane potential and action potential morphology and a measurement of the 
maximum rate of change of the upstroke of the action potential can be defined 
as the true activation time (duBell et al., 1991; Herron et al., 2012; Jaimes et al., 
2016). Similarly calcium transient duration does not mirror action potential 
duration and the calcium transient usually outlasts the action potential, partly 
due to a calcium-buffering effect of many calcium sensitive dyes, though there 
tends to be correlation between the two (Jaimes et al., 2016). Thus, it is not 
reliable to use calcium transients to measure conduction velocity or activation-
recovery intervals and propagation maps have to be interpreted with an element 
of caution. That said, macroscopic wave front propagation can be clearly 
visualised through the above calcium imaging in HL-1 syncytia, and 
demonstration of this propagation with time through peak measurement of the 
transient is possible, recognising it as a surrogate of any true activation time. 
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2.10 Statistical Analyses 
 
Statistical analyses were carried out using GraphPad Prism V6.0h (GraphPad 
Software, Inc., California) with, where appropriate: the independent samples 
Student's t test for comparison of two independent parametric means, the 
paired samples Student's t test for comparison of two paired parametric data 
sets, ordinary one-way ANOVA for comparison of 3 or more independent 
parametric means, or repeated measures one-way or two-way ANOVA for 
comparison of 3 or more dependent parametric means and the effects of more 
than one independent variable. Tukey's post-hoc test was utilised when 
comparing every mean with every other mean, Dunnett's post-hoc test in the 
instance of comparing means to the mean at baseline, and Bonferroni post-hoc 
test when comparing a specific selection of means. Fisher's exact test or Chi-
square test were used to compare categorical data. Data are presented as 
mean±SEM. A p value of <0.05 was regarded as statistically significant. Where 
markers of statistical significance are shown, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. 
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Section 3: Results 
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3.1 Confirmation of Selective Pharmacology of KATP Openers 
and Inhibitors using HEK293 Stable Cell Lines 
 
Further to the current knowledge and some of the contentions regarding KATP 
modulator specificity as delineated in section 1.3.2, the first task was to 
demonstrate in my own hands the ability of various openers and inhibitors to be 
selective with regards particular KATP subunit composition. I therefore set about 
performing a comprehensive and systematic approach utilising HEK293 cell 
lines stably overexpressing KATP channels of every homomultimeric Kir6x/SURx 
composition. I subjected isolated cells to whole-cell patch clamp and chose 
drug concentrations empirically guided by previous literature. The aim was to 
develop a repertoire of drugs at specific concentrations that, in my hands and 
under the intracellular/extracellular conditions set by the experimental solutions, 
would be able to delineate the underlying subunits contributing to a KATP 
current. 
 
3.1.1 SURx subunit pharmacology 
 
Openers 
 
SUR1-containing channels were strongly activated by diazoxide 100µM (DZX) 
but in the same cells pinacidil 10µM (PIN) failed to activate current 
(Kir6.1/SUR1: baseline, 187 ± 56; PIN, 125 ± 24; DZX, 427 ± 84 pA/pF; n=5; 
PIN vs baseline, p > 0.05; DZX vs baseline, p < 0.0001; Kir6.2/SUR1: baseline, 
127 ± 28; PIN, 100 ± 27; DZX, 407 ± 75 pA/pF; n=5; PIN vs baseline, p > 0.05; 
DZX vs baseline, p < 0.0001). (See Figure 3.1). 
 
The opposite was true for channels containing SUR2A subunits in that pinacidil 
10µM strongly activated current but in the same cells diazoxide 100µM failed to 
activate current (Kir6.1/SUR2A: baseline, 19 ± 5; DZX, 22 ± 5; PIN, 269 ± 53 
pA/pF; n=6; DZX vs baseline, p > 0.05; PIN vs baseline, p < 0.01; 
Kir6.2/SUR2A: baseline, 30 ± 3; DZX, 28 ± 3; PIN, 549 ± 195 pA/pF; n=5; DZX 
vs baseline, p > 0.05; PIN vs baseline, p < 0.0001). (See Figure 3.1). 
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Figure 3.1. Selective pharmacology for the SUR subunit. Mean whole-
cell current density at +40mV of a ramp (+50 to -150mV over 1s) protocol in 
HEK293 cells stably overexpressing KATP channels with sulphonylurea 
subunits as indicated in the presence of KATP openers and inhibitors. Cells 
were separated based on the pore-forming subunit that was in composition, 
Kir6.1 or Kir6.2. SUR1 containing channels are activated by DZX 100µM not 
PIN 10µM and inhibited by TOLB 100µM. SUR2A containing channels are 
activated by PIN 10µM not DZX 100µM and inhibited by GLIB 10µM. SUR2B 
containing channels are activated by DZX 100µM and more strongly by PIN 
10µM and are inhibited by GLIB 10µM (Data shown are mean±SEM, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs baseline unless depicted). 
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In the case of KATP channels with SUR2B subunits, both diazoxide 100µM and 
pinacidil 10µM activated current, though pinacidil more so (Kir6.1/SUR2B: 
baseline, 38 ± 4; DZX, 111 ± 19; PIN, 160 ± 28 pA/pF; n=5; DZX vs baseline, p 
< 0.05; PIN vs baseline, p < 0.001; PIN vs DZX, p < 0.01; Kir6.2/SUR2B: 
baseline, 19 ± 2; DZX, 148 ± 50; PIN, 300 ± 32 pA/pF; n=5; DZX vs baseline, p 
< 0.001; PIN vs baseline, p < 0.0001; PIN vs DZX, p < 0.01). (See Figure 3.1). 
 
Inhibitors 
 
For SUR1-containing channels, and in repeated measures from the 
experiments with openers, tolbutamide 100µM abolished the diazoxide 100µM 
activated current and inhibited a basally active current when added sequentially 
to the bath solution (Kir6.1/SUR1: baseline, 187 ± 56; DZX/TOLB, 15 ± 3 pA/pF; 
n=5; p < 0.01; Kir6.2/SUR1: baseline, 127 ± 28; DZX/TOLB, 27 ± 3 pA/pF; n=5; 
p > 0.05). (See Figure 3.1). 
 
In the case of SUR2A and SUR2B containing channels, and in repeated 
measures from the experiments with openers, glibenclamide 10µM completely 
inhibited the pinacidil 10µM activated current when added sequentially to the 
bath solution (Kir6.1/SUR2A: baseline, 19 ± 5; PIN/GLIB, 10 ± 1 pA/pF; n=6; p > 
0.05; Kir6.2/SUR2A: baseline, 30 ± 3; PIN/GLIB, 24 ± 5 pA/pF; n=5; p > 0.05; 
Kir6.1/SUR2B: baseline, 38 ± 4; PIN/GLIB, 22 ± 5 pA/pF; n=5; p > 0.05; 
Kir6.2/SUR2B: baseline, 19 ± 2; PIN/GLIB, 12 ± 2 pA/pF; n=5; p > 0.05). (See 
Figure 3.1). 
 
To investigate the effects of HMR1098, I inferred from the results encountered 
above. As such I investigated the fractional inhibition of inhibitor-sensitive peak-
activated current (using diazoxide 100µM/tolbutamide 100µM in the case of 
SUR1 containing channels, and pinacidil 10µM/glibenclamide 10µM in the case 
of SUR2A containing channels) for HMR1098. No difference was found 
between the inhibitory effects of HMR1098 10µM after peak activation for 
Kir6.2/SUR1 or Kir6.2/SUR2A channels. (Kir6.2/SUR1: 0.99 ± 0.03, n=5; 
Kir6.2/SUR2A: 0.95 ± 0.01, n=6; p > 0.05). (See Figure 3.2). 
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Figure 3.2. Effects of HMR1098 and Tolbutamide. HMR1098 10µM inhibits 
both SUR1 and SUR2A containing channels whilst TOLB 100µM only inhibits 
those containing SUR1. Representative whole-cell current density trace for 
HEK293 cells overexpressing Kir6.2/SUR1 (A) and Kir6.2/SUR2A (B) 
channels in the presence of KATP activators and inhibitors. (C) Mean 
fractional inhibition by HMR1098 10µM of the inhibitor-sensitive peak-
activated KATP current in HEK293 cells overexpressing KATP channels (DZX 
100µM activation / TOLB 100µM inhibition for Kir6.2/SUR1 channels, n=5; 
PIN 10µM activation / GLIB 10µM inhibition for Kir6.2/SUR2A channels, 
n=6). (D) Mean fractional inhibition by HMR1098 10µM and TOLB 100µM of 
the inhibitor-sensitive peak-activated KATP current (PIN 10µM activation / 
GLIB 10µM inhibition) in HEK293 cells overexpressing Kir6.2/SUR2A 
channels, n=6 (Data shown are mean±SEM; ***p<0.001). 
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Fractional inhibition of the inhibitor-sensitive peak-activated current (pinacidil 
10µM / glibenclamide 10µM) was then compared between HMR1098 10µM and 
tolbutamide 100µM in repeated measures for cells overexpressing 
Kir6.2/SUR2A channels. Tolbutamide was found to be a weak inhibitor of these 
channels indicative of its more SUR1-specific effects. (HMR: 0.95 ± 0.01; TOLB: 
0.27 ± 0.06; n=6; p < 0.001). (See Figure 3.2). 
 
3.1.2 Kir6x subunit pharmacology 
 
Fractional inhibition of the inhibitor-sensitive peak-activated current (diazoxide 
100µM/tolbutamide 100µM in the case of SUR1 containing channels and 
pinacidil 10µM/glibenclamide 10µM in the case of SUR2A containing channels) 
was then investigated for the suggested pore blocker PNU37883A at 50µM. 
This concentration was chosen based on its representation in existing literature 
depicting ~70% inhibition of Kir6.1-containing channels and ~10% inhibition of 
Kir6.2-containing channels (Surah-Narwal et al., 1999; Kovalev et al., 2004). I 
sought to reproduce similar results under the given experimental conditions as 
this would serve as a pharmacological tool to distinguish between the two pore-
forming subunits. A stark and reproducible difference was found between 
channels containing the two different pore types with a selectivity of inhibition 
for channels containing Kir6.1 pore-forming subunits as shown in figure 3.3. 
(SUR1-containing channels: Kir6.1, 0.93 ± 0.004, n=5; Kir6.2, 0.19 ± 0.02, n=5; 
p < 0.0001; SUR2A-containing channels: Kir6.1, 0.94 ± 0.02, n=5; Kir6.2, -0.06 
± 0.06, n=5; p < 0.0001; SUR2B-containing channels: Kir6.1, 0.95 ± 0.01, n=5; 
Kir6.2, 0.13 ± 0.05, n=5; p < 0.0001). Given the reproducibility of this pore 
selective inhibition regardless of the SUR subunit, summative data are also 
presented combining recordings from all channels with the same pore-forming 
subunit as shown in figure 3.3. (Kir6.1, 0.94 ± 0.01, n=15; Kir 6.2, 0.09 ± 0.04, 
n=15; p < 0.0001). 
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3.1.3 Representative recordings 
 
Figures 3.4, 3.5 and 3.6 demonstrate representative traces of whole-cell current 
density with time, and corresponding I-V plots, for HEK293 cells stably 
overexpressing KATP channels as indicated and in the presence of the KATP 
openers and inhibitors. In the case of cells with Kir6.2/SUR1 and Kir6.2/SUR2A 
channels, PNU37883A was investigated on a separate cell set, hence, the 
traces are presented on separate graphs. 
  
 
Figure 3.3. PNU37883A KATP pore selectivity. PNU 50µM selectively 
inhibits Kir6.1 containing channels not Kir6.2. (A) Mean fractional inhibition 
by PNU37883A 50µM of the inhibitor-sensitive peak-activated KATP current in 
HEK293 cells overexpressing KATP channels (DZX 100µM activation / TOLB 
100µM inhibition for SUR1 containing channels; PIN 10µM activation / GLIB 
10µM inhibition for SUR2A and SUR2B containing channels; n=5 for all 
channel compositions). (B) Mean summative data of that in (A) combining 
that from all channels with the same pore-forming subunit, n=15 for each 
pore type. (Data shown are mean±SEM; ****p<0.0001). 
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Figure 3.4. Representative recordings for SUR1 containing channels. 
Whole-cell current density (left panels) and corresponding I-V plots at plateau 
of activation / inhibition (right panels) of HEK293 cells stably overexpressing 
SUR1 containing KATP channels (pore as indicated) in the presence of KATP 
openers and inhibitors. 
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Figure 3.5. Representative recordings for SUR2A containing channels. 
Whole-cell current density (left panels) and corresponding I-V plots at plateau 
of activation / inhibition (right panels) of HEK293 cells stably overexpressing 
SUR2A containing KATP channels (pore as indicated) in the presence of KATP 
openers and inhibitors. 
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3.1.4 Untransfected HEK293 cells 
 
To demonstrate the above effects were not due to other endogenous currents, 
the same experiments were repeated on HEK293 cells not transfected with KATP 
subunits. The openers diazoxide 100µM and pinacidil 10µM had no effect on 
the baseline current. Glibenclamide 10µM inhibited a basal current and 
PNU37883A 50µM provided further inhibition of this basal current. (Baseline, 22 
Figure 3.6. Representative recordings for SUR2B containing channels. 
Whole-cell current density (left panels) and corresponding I-V plots at plateau 
of activation / inhibition (right panels) of HEK293 cells stably overexpressing 
SUR2B containing KATP channels (pore as indicated) in the presence of KATP 
openers and inhibitors. 
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± 5; DZX, 20 ± 5; PIN, 19 ± 5; PIN/GLIB, 17 ± 4; PIN/PNU, 7 ± 2 pA/pF; n=5; 
GLIB vs baseline, p < 0.05; PNU vs baseline, p < 0.05). (See Figure 3.7). 
  
 
Figure 3.7. Effects of KATP openers and inhibitors in untransfected 
HEK293 cells. There exists an endogenous KATP current in HEK293 cells 
whilst PNU 50µM has a small off-target inhibitory effect. (A) Representative 
whole-cell current density trace and (B) corresponding I-V plot in the 
presence of KATP openers and inhibitors. (C) Mean whole-cell current density 
in the presence of KATP openers and inhibitors. (Data shown are mean±SEM; 
n=5; *p<0.05 vs baseline). 
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3.1.5 Summary 
 
The above provides a very useful pharmacological tool to distinguish the 
subunits present of any KATP channel population as a whole expressed at the 
cell membrane. This may well contain a mixture of channels of varying subunit 
composition, and indeed some channels may even be heteromultimers. 
Nevertheless the pharmacological tools can confirm or refute the presence of a 
particular KATP subunit. There appears to be a small endogenous basally active 
KATP current in HEK293 cells. The results suggest PNU37883A weakly inhibits 
currents other than KATP, but this only strengthens the data showing its 
specificity for blocking Kir6.1, as compared to Kir6.2 where it produced ~90% 
inhibition. Even off-target effects are not likely to cloud its inhibitory effects on 
Kir6.1-containing channels. The weak inhibition (~10%) seen in HEK293 cells 
overexpressing KATP channels with Kir6.2 pore forming subunits, however, 
could be explained in part, by its action on a non-KATP current, and not much 
inhibition of Kir6.2 at all. Table 2 summarises the findings. 
 
 
SUBUNIT OPENERS INHIBITORS 
Kir6.1  PNU37883A 50µM - strong 
Kir6.2  PNU37883A 50µM - weak/nil 
SUR1 diazoxide 100µM - strong 
pinacidil 10µM - nil 
tolbutamide 100µM - strong 
HMR1098 10µM - strong 
SUR2A pinacidil 10µM - strong 
diazoxide 100µM - nil 
glibenclamide 10µM - strong 
HMR1098 10µM - strong 
tolbutamide 100µM - weak 
SUR2B pinacidil 10µM - strong 
diazoxide 100µM - moderate 
glibenclamide 10µM - strong 
 
 
Table 2. Summary of the investigated effects of KATP openers and 
inhibitors. 
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3.2 Generation of knockout mice 
 
3.2.1 Attempt to generate a cardiomyocyte conditional Kcnj8 knockout 
mouse 
 
The initial aim was to produce a mouse with cardiomyocyte conditional 
knockout of Kir6.1 (Kir6.1-cKO) to investigate the importance of this pore-
forming subunit with particular respect to heart muscle electrophysiology and 
arrhythmia. A conditional knockout would potentially circumvent concerns that 
the hypertensive phenotype of a global knockout (see section 1.3.1) might lead 
to electrophysiological changes indirectly, through an increased afterload-
induced tissue substrate of both fibrosis, and stretch-induced KATP opening, or 
from ischaemia (Miki et al., 2002; Chutkow et al., 2002; Lader et al., 2011). 
 
Figure 3.8 demonstrates the PCR products from genomic DNA in the Kir6.1-
cKO knockout line. The "floxed" allele gives rise to a 600bp product that is 
larger than the wild-type 474bp product due to additional FRT and loxP 
elements. The presence of Cre recombinase (under control of the alphaMHC 
promoter) is detected by a 650bp product. 
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Figure 3.8. Genomic DNA PCR for the cardiomyocyte conditional Kir6.1 
knockout mice. Top half shows the Cre band and bottom half the "floxed" 
and wild-type bands. The alphaMHCCre gives rise to a 650bp product, 
"floxed" allele a 600bp product and WT band a 474bp product. The "floxed" 
allele is longer given it contains FRT and loxP elements. 
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Using qRT-PCR, I demonstrated that there was no difference between the ΔCt 
values for all KATP subunits, and with respect to tissue type, when comparing 
the "non-knockout" genotypes (wt/wt alphaMHCCre-; wt/wt alphaMHCCre+, 
flx/flx alphaMHCCre-). This is presented in figure 3.9. 
 
 
Figure 3.9. Tissue specific ΔCt values for Kir6.1-cKO mice "non-
knockout" genotypes. No difference exists in expression of KATP subunits 
between "non-knockout" genotypes in different tissue types. Mean mRNA 
expression by ΔCt values (normalised to GAPDH) for genes encoding the 
KATP channel proteins and separated for each genotype. Note SUR1 is not 
expressed in aorta and liver as evidenced by ΔCt values over the limits of 
the assay (Data shown are mean±SEM; n=3 mice for each genotype with 
expression measured for all genes in each mouse; +, wild-type allele; flx, 
floxed allele; C+, Cre present; C-, Cre absent; p>0.05 for comparisons by 
one-way ANOVA with Tukey's multiple comparisons for each family of 
gene/tissue). 
 
 174 
Based on these findings "non-knockout" genotypes were pooled as wild-type 
(WT) mice going forward. Of note, indications were SUR1 was not expressed at 
all in wild-type aorta and liver. 
 
Figure 3.10 shows the results of qRT-PCR relative quantification using the 2-ΔΔCt 
method for Kir6.1-cKO mice as compared to littermate WT animals between 
tissue types. There was a high degree of knockout in all tissue types not just the 
heart (relative expression in cKO compared to WT: atria 0.29 ± 0.08, p < 0.05; 
ventricle 0.51 ± 0.09, p = 0.12; aorta 0.20 ± 0.07, p < 0.01; liver 0.30 ± 0.07, 
p<0.05; WT n=9, KO n=4). 
 
Given the heterogeneous mix of cell type in whole heart tissue, cardiomyocyte 
conditional knockout would be expected to produce a relative knockdown of 
~50% (Pinto et al., 2016). However, this degree of knockdown was also seen in 
the aorta and liver suggesting that the alphaMHCCre could have been "leaky" 
so as not to be cardiomyocyte conditional.  
 
Figure 3.10. Relative expression as compared to WT of Kir6.1 between 
tissue types in Kir6.1-cKO mice. There is a significant degree of knockout 
even in non-cardiac tissue types in the supposed cardiac conditional 
knockout mouse (Mean±SEM; WT n=9, cKO n=4; *p<0.05, **p<0.01 relative 
to wild-type). 
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3.2.2 Kcnj8 global knockout 
 
With the uncertainty of cardiomyocyte conditional knockout of Kir6.1 in the cKO 
mouse line, I decided to focus my attention on a global knockout where I could 
be sure of genetic deletion. Whilst the concerns about indirect afterload effects 
on electrophysiological substrate could be argued, the degree of knockdown in 
the aorta in the cKO mouse line was also significant. In terms of a model for the 
effects of Kir6.1 modulation on single cell and tissue electrophysiology, a global 
knockout has its advantages given naturally occurring germ line loss of function 
mutations, or indeed pharmacological manipulation, are not likely to be 
cardiomyocyte specific. 
 
Figure 3.11 demonstrates the PCR products from genomic DNA in the Kir6.1 
global knockout mouse (Kir6.1-gKO). The wild-type allele PCR gives rise to a 
474bp product, just as it did in the cKO mouse given the same primers were 
used and the wild-type allele contains no loxP or FRT site (see also Figure 2.3). 
The knockout allele PCR gives rise to a 724bp product only if the critical region 
has been removed. If this does not take place, then the product would be too 
large to amplify with the given PCR conditions, and no band would be seen on 
gel electrophoresis. 
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Figure 3.11. Genomic DNA PCR for the Kir6.1 global knockout mouse. 
Top half shows WT band (474bp product) and bottom half KO band (724bp) 
product, which is only amplified under the given conditions if the critical 
region of the gene is knocked out allowing for a shorter product. 
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Figure 3.12 shows the results of qRT-PCR relative quantification of the Kir6.1-
gKO mice when compared to littermate WT animals between tissue types. 
There was essentially complete knockout in all tissue types (relative expression 
in gKO compared to WT: atria 0.01 ± 0.01, p < 0.0001; ventricle 0.00 ± 0.00, p < 
0.0001; aorta 0.00 ± 0.00, p < 0.0001; liver 0.01 ± 0.00, p < 0.0001; WT n=3, 
KO n=3). 
 
 
I then compared the relative expression of the different KATP subunits in the 
Kir6.1-gKO heart. This is presented in figure 3.13. Statistical significance was 
found for a down-regulation of Abcc8 (coding for SUR1) in the atria. The 
functional significance of what this finding might mean was not completely clear. 
Whilst this was whole heart RNA the finding could be examined further when 
measuring the KATP current density in atrial cardiomyocytes by patch clamp 
(expression relative to WT: Kir6.2, atria 1.1 ± 0.2, ventricle 0.5 ± 0.2; SUR1, 
atria 0.3 ± 0.1 p < 0.05, ventricle 0.5 ± 0.2; SUR2, atria 0.8 ± 0.2, ventricle 0.7 ± 
0.2; WT n=3, KO n=3). 
  
 
Figure 3.12. Relative expression as compared to WT of Kir6.1 between 
tissue types in Kir6.1-gKO mice. Knockout throughout tissue types was 
highly efficient with essentially complete deletion (Mean±SEM; WT n=3, gKO 
n=3; ****p<0.0001 relative to wild-type). 
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3.2.3 Kcnj11 global knockout 
 
As discussed in section 2.2 the Kir6.2 global knockout mouse (Kir6.2-gKO) was 
engineered at The Medical Research Council Centre for Mouse Genetics, 
Harwell Campus, Oxfordshire, UK (MRC Harwell) in collaboration with the 
International Mouse Phenotyping Consortium. Mice were genotyped and 
delivered to order. Further characterisation by qRT-PCR was then carried out. 
 
Figure 3.14 shows the results of qRT-PCR relative quantification of the Kir6.2-
gKO mice when compared to littermate WT animals between tissue types. 
There was essentially complete knockout in all tissue types (expression in gKO 
relative to WT: atria 0.00 ± 0.00, p < 0.001; ventricle 0.00 ± 0.00, p < 0.001; 
aorta 0.03 ± 0.01, p < 0.01; liver 0.03 ± 0.01, p < 0.0001; WT n=4, KO n=4). 
  
 
 
Figure 3.13. Relative expression compared to WT of KATP subunits in 
the Kir6.1-gKO heart. There appeared to be a down-regulation of SUR1 in 
the atria of knockout mice but no change in the other subunits (Mean±SEM; 
A - atria, V - ventricles; WT n=3, KO n=3; *p<0.05, ****p<0.0001 relative to 
wild-type). 
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I then compared the relative expression of the different KATP subunits in the 
Kir6.2-gKO heart. This is presented in figure 3.15. Statistical significance was 
found for an up-regulation of Kcnj8 in the ventricle. The functional significance 
of this was not clear. I did not plan to perform patch clamp on ventricular 
myocytes and expanding on the meaning of this finding would fall out of the 
scope of the project (relative expression compared to WT: Kir6.1, atria 1.2 ± 
0.1, ventricle 1.4 ± 0.1 p < 0.05; SUR1, atria 1.5 ± 0.4, ventricle 1.6 ± 0.1; 
SUR2, atria 1.3 ± 0.1, ventricle 1.1 ± 0.04; WT n=4, KO n=4). 
  
 
Figure 3.14. Relative expression compared to WT of Kir6.2 between 
tissue types in Kir6.2-gKO mice. Knockout throughout tissue types was 
highly efficient with essentially complete deletion (Mean±SEM; WT n=4, gKO 
n=4; **p<0.01, ***p<0.001, ****p<0.0001 relative to wild-type). 
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3.2.4 Summary 
 
Whilst knockdown in off-target tissues in the Kir6.1-cKO mouse might be related 
to cardiomyocyte knockdown, I could not be sure that the alphaMHCCre was 
functioning as intended. The Kir6.1-gKO mouse appeared robust with 
essentially complete knockdown of Kir6.1 in all tissues as expected and so too 
was the case with Kir6.2 in the Kir6.2-gKO mouse. Together with being able to 
make comparisons between both global knockouts, potential advantages exist 
of a global knockout as a model for effects that might be produced by naturally 
occurring germ line loss of function mutations, and indeed pharmacological 
manipulation, which are not likely to be cardiomyocyte specific. Thus I used the 
global knockouts for further experiments. 
  
 
 
Figure 3.15. Relative expression compared to WT of KATP subunits in 
the Kir6.2-gKO heart. There appeared to be an up-regulation of Kir6.2 in 
the ventricles of knockout mice but no change in the other subunits 
(Mean±SEM; A - atria, V - ventricles; WT n=4, KO n=4; *p<0.05, ***p<0.001 
relative to wild-type). 
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3.3 Isolated murine atrial cardiomyocytes demonstrate a 
functional expression and predominance for sarcolemmal KATP 
channels comprising Kir6.2/SUR1 subunits 
 
A body of evidence has already delineated that Kir6.2/SUR1 appears as the 
prominent KATP subunit composition at the sarcolemma of murine atrial 
cardiomyocytes (Saegusa et al., 2005; Flagg et al., 2008; Glukhov et al., 2010). 
This drove initial excitement for a translatable therapeutic target for atrial 
arrhythmias as the classic ventricular KATP subunit composition was defined as 
Kir6.2/SUR2A (Inagaki et al., 1996; Babenko et al., 1998; Suzuki et al., 2001; 
Chutkow et al., 2001). Thus, SUR1 might be an atrial specific drug target that 
would not have any off-target detrimental effects in the ventricle. This 
excitement was blunted by further human studies suggesting that SUR1 was 
not an important KATP subunit in the human heart, at least not in non-failing 
heart (Zünkler et al., 1997; Fedorov et al., 2011). 
 
Mouse models with knockout of either pore-forming subunit and sulphonylurea 
receptor subunits have been extensively investigated for the ventricle, and to 
some degree, the sulphonylurea receptor in the atria, but there has been a 
paucity of studies looking at the effects of knockout of the pore-forming subunits 
in murine atria. I therefore sought to directly compare, with identical 
experiments, the effects of global knockout of either pore-forming subunit on the 
atria of these mice. I wanted to further delineate any contribution of Kir6.1 to the 
sarcolemmal current in murine atrial cardiomyocytes as has been previously 
suggested in other rodent models (Baron et al., 1999; Poitry et al., 2003; van 
Bever et al., 2004). 
 
3.3.1 Differential cardiac KATP subunit mRNA expression 
 
I first investigated the relative expression of mRNA encoding for the various 
KATP subunits in wild-type whole heart mRNA. The results are displayed in 
figure 3.16. Kir6.2 and SUR1 were more abundantly expressed than their 
alternative subunits in the atria, and Kir6.2 and SUR2 in the ventricles. There 
was still evidence for Kir6.1 expression in both chambers. There was 
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significantly more expression of SUR1 in the atria relative to the ventricles and 
for SUR2 in the ventricles relative to the atria. (Expression normalised to 
GAPDH and relative to the mean of atrial Kir6.1: Atria - Kir6.1 1.1 ± 0.1, Kir6.2 
9.5 ± 1.0, p < 0.0001; SUR1 10.3 ± 0.8, SUR2 3.4 ± 0.3, p < 0.0001. Ventricles - 
Kir6.1 1.8 ± 0.2, Kir6.2 5.9 ± 0.7, p < 0.0001; SUR1 1.5 ± 0.1, SUR2 14.6 ± 0.7, 
p < 0.0001; SUR1 atria vs ventricle, p < 0.0001; SUR2 atria vs ventricle, p < 
0.0001. n=16 mice). 
 
 
3.3.2 Kir6.2 deletion, but not Kir6.1 deletion, abolishes the KATP current in 
isolated murine atrial cardiomyocytes 
 
To investigate the functional consequences of deletion of each pore-forming 
subunit on atrial cardiomyocytes, isolated cells from Kir6.1-gKO, Kir6.2-gKO 
and WT mice were subjected to whole-cell patch clamp. In both WT and Kir6.1-
gKO, diazoxide 100µM but not pinacidil 10µM activated current, and addition of 
tolbutamide 100µM but not PNU37883A inhibited the current activated by 
diazoxide 100µM. No difference was seen in the peak activated current 
between right and left atria in these genotypes (WT n=8-15 cells from 13 mice 
 
Figure 3.16. Relative expression of mRNA encoding for the various 
KATP subunits in wild-type murine whole heart. The predominant 
expression pattern for KATP subunits differs between cardiac chambers in the 
mouse. The predominant atrial composition is Kir6.2/SUR1, and in the 
ventricle Kir6.2/SUR2 (Mean±SEM; n=16 mice; ****p<0.0001). 
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(see figure 3.17): RA; baseline 22 ± 6, PIN 18 ± 3, DZX 137 ± 29, DZX/PNU 
142 ± 30, DZX/TOLB 19 ± 6 pA/pF; DZX and DZX/PNU vs baseline, p < 0.0001. 
LA; baseline 18 ± 2, PIN 19 ± 3, DZX 141 ± 28, DZX/PNU 137 ± 34, DZX/TOLB 
11 ± 2 pA/pF; DZX and DZX/PNU vs baseline, p < 0.0001. Kir6.1-gKO n=4-8 
cells from 4 mice (see figure 3.18): RA; baseline 46 ± 14, PIN 48 ± 14, DZX 244 
± 58, DZX/PNU 301 ± 46, DZX/TOLB 22 ± 4 pA/pF; DZX and DZX/PNU vs 
baseline, p < 0.0001. LA; baseline 22 ± 5, PIN 25 ± 6, DZX 185 ± 39, DZX/PNU 
163 ± 39, DZX/TOLB 13 ± 4 pA/pF; DZX vs baseline, p < 0.001; DZX/PNU vs 
baseline, p < 0.01). 
 
In the case of Kir6.2-gKO atrial cardiomyocytes, neither diazoxide 100µM or 
pinacidil 10µM activated current. Both tolbutamide 100µM and glibenclamide 
10µM failed to significantly inhibit any baseline endogenous current. However, 
PNU37883A 50µM did inhibit a baseline endogenous current (Kir6.2-gKO n=4-8 
cells from 5 mice (see figure 3.19): RA; baseline 17 ± 3, PIN 16 ± 4, DZX 15 ± 
2, DZX/TOLB 14 ± 2, DZX/GLIB 13 ± 2, DZX/PNU 5 ± 1 pA/pF; DZX/PNU vs 
baseline, p < 0.01. LA; baseline 20 ± 3, PIN 18 ± 2, DZX 16 ± 2, DZX/TOLB 16 
± 2, DZX/GLIB 12 ± 2, DZX/PNU 5 ± 1 pA/pF; DZX/PNU vs baseline, p < 
0.001). 
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Figure 3.17. Demonstration of a KATP current in wild-type murine atrial 
cardiomyocytes with the pharmacological signature of Kir6.2/SUR1 
subunits. In wild-type murine atrial cardiomyocytes PIN 10µM fails to 
activate but DZX 100µM strongly activates current. TOLB 100µM but not 
PNU 50µM inhibits this current which is indicative of Kir6.2/SUR1 KATP 
channels. (A) Representative trace. (B) Representative I-V plots. (C) 
Summary data (mean±SEM). n = 8-15 cells from 13 mice. ****p<0.0001 vs 
baseline. 
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Figure 3.18. Kir6.1 deletion does not reduce KATP current activation in 
isolated murine atrial cardiomyocytes. The same pharmacological 
signature remains after deletion of Kir6.1. PIN 10µM fails to activate but DZX 
100µM strongly activates current. TOLB 100µM but not PNU 50µM inhibits 
this current. (A) Representative trace. (B) Representative I-V plots. (C) 
Summary data (mean±SEM). n = 4-8 cells from 4 mice. ****p<0.0001, 
***p<0.001, **p<0.01 vs baseline. 
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Figure 3.19. Kir6.2 deletion leads to an absence of activated KATP 
current in isolated murine atrial cardiomyocytes. After Kir6.2 deletion 
KATP current can no longer be activated by DZX 100µM. There is no inhibition 
of any basal current by TOLB 100µM. GLIB 10µM shows a trend to inhibiting 
a small basal current but did not reach statistical significance. PNU 50µM 
appears to inhibit a basal current though this is probably an off-target effect 
as seen in HEK293 cells. (A) Representative trace. (B) Representative I-V 
plots. (C) Summary data (mean±SEM). n = 4-8 cells from 5 mice. ***p<0.001, 
**p<0.01 vs baseline. 
 187 
Further, the tolbutamide-sensitive diazoxide-activated current was abolished in 
the Kir6.2-gKO murine atrial cardiomyocytes but it was increased in the Kir6.1-
gKO mouse (WT n=22 cells from 13 mice: 120 ± 20 pA/pF; Kir6.1-gKO n=12 
cells from 4 mice: 199 ± 36 pA/pF, p<0.05 vs WT; Kir6.2-gKO n=12 cells from 5 
mice: 0.7 ± 0.3 pA/pF, p<0.001 vs WT see figure 3.20). 
 
 
 
3.3.3 Kir6.2 but not Kir6.1 contributes to the resting membrane potential in 
isolated murine atrial cardiomyocytes 
 
The equilibrium potential, taken as the clamped voltage on the ramp protocol 
where no current flowed, was taken as the resting membrane potential (RMP). 
Resting membrane potential did not differ between WT and Kir6.1g-KO atrial 
cardiomyocytes but those in the Kir6.2-gKO were more depolarised (WT n=28 
cells from 13 mice: -41 ± 3 mV; Kir6.1-gKO n=14 cells from 4 mice: -49 ± 5 mV; 
Kir6.2-gKO n=14 cells from 5 mice: -27 ± 2 mV, p < 0.01 vs WT) see figure 
3.21). 
 
 
Figure 3.20. Kir6.2 deletion abolishes, but Kir6.1 deletion increases, the 
tolbutamide-sensitive diazoxide-activated current in isolated murine 
atrial cardiomyocytes. Mean±SEM, WT n= 22 cells from 13 mice, Kir6.1-
gKO n=12 cells from 4 mice, Kir6.2-gKO n=12 cells from 5 mice; ***p<0.001 
*p<0.05 vs WT). 
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Further, on activation of KATP current by diazoxide, resting membrane potential 
was hyperpolarised in WT and Kir6.1-gKO atrial cardiomyocytes, an effect that 
was reversed by addition of tolbutamide. No such effect was seen in atrial 
cardiomyocytes from Kir6.2-gKO mice. (WT n=21 cells from 13 mice: baseline   
-42 ± 3, DZX -73 ± 2, DZX/TOLB -28 ± 5 mV; DZX vs baseline, p < 0.0001; 
DZX/TOLB vs baseline, p < 0.01; Kir6.1-gKO n=10 cells from 4 mice: baseline -
53 ± 6 mV, DZX -75 ± 2, DZX/TOLB -38 ± 7 mV; DZX vs baseline, p < 0.01; 
DZX/TOLB vs baseline p < 0.05; Kir6.2-gKO n=11 cells from 5 mice: baseline -
26 ± 2, DZX -25 ± 2, DZX/TOLB -26 ± 2 mV, see figure 3.21). 
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Figure 3.21. Kir6.2 deletion but not Kir6.1 deletion leads to a more 
depolarised resting membrane potential in isolated murine atrial 
cardiomyocytes. (A) Mean resting membrane potential at baseline. Kir6.1 
deletion does not affect the RMP but Kir6.2 deletion leads to more 
depolarised cells (Data shown are mean±SEM; WT n=28 cells from 13 mice; 
Kir6.1g-KO n=14 cells from 4 mice; Kir6.2-gKO n=14 cells from 5 mice; 
**p<0.01 vs WT). (B) Like WT atrial cardiomyocytes, Kir6.1-gKO cells also 
hyperpolarise on application of diazoxide, an effect reversed with 
tolbutamide, but none of these effects are seen after Kir6.2 deletion 
(repeated measures WT n=21 cells from 13 mice; Kir6.1g-KO n=10 cells 
from 4 mice; Kir6.2-gKO n=11 cells from 5 mice; ***p<0.001, **p<0.01, 
*p<0.05 vs baseline).  
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3.3.4 Knockout of either KATP pore-forming subunit does not lead to 
hypertrophy in isolated atrial cardiomyocytes 
 
Cell capacitance can be measured via capacitance transient cancellation after 
going into the whole-cell configuration during patch clamp. The capacitance of 
the cell is a surrogate for cell size as it is proportional to the membrane surface 
area, which, assuming the cell as a sphere, is itself proportional to the volume 
of the cell. No difference was seen in the capacitance of isolated atrial 
cardiomyocytes from WT, Kir6.1-gKO or Kir6.2-gKO mice (WT n=28 cells from 
13 mice, 32 ± 2; Kir6.1-gKO n= 14 cells from 4 mice; 33 ± 4, Kir6.2-gKO n=14 
cells from 5 mice; 36 ± 3 pF see figure 3.22). 
 
 
 
3.3.5 Kir6.2 contributes to the resting membrane potential in isolated atrial 
cardiomyocytes - reproducible with whole-cell action potential analysis 
 
To confirm the effects of Kir6.2 deletion seen on the resting membrane potential 
of isolated atrial cardiomyocytes, my colleague Dr Aziz measured whole-cell 
action potentials triggered at 1Hz by 600pA/5ms square pulses in wild type and 
Kir6.2-gKO mice. Again, we found that the resting membrane potential, but also 
 
Figure 3.22. KATP pore deletion does not affect the size of isolated atrial 
cardiomyocytes. No difference was seen in the cell capacitance of isolated 
atrial cardiomyocytes for deletion of each KATP pore forming subunit. (Mean 
±SEM; WT n=28 cells from 13 mice, Kir6.1-gKO n=14 cells from 4 mice, 
Kir6.2-gKO n=14 cells from 5 mice). 
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the maximum diastolic potential (MDP), were both more depolarised in the 
Kir6.2-gKO mouse. Trends were also seen for a reduction in Vmax and a lesser 
degree of change of membrane potential during the action potential (delta, Δ)  
(RMP: WT -30 ± 3, Kir6.2-gKO, -21 ± 1 mV, p < 0.05; MDP: WT -34 ± 4, Kir6.2-
gKO -24 ± 2 mV, p < 0.05; Vmax: WT 17 ± 2, Kir6.2-gKO 11 ± 2 mV/ms, p = 
0.06; Delta: WT 78 ± 10, Kir6.2-gKO 51 ± 10 mV, p =0.06; WT n=10 cells from 6 
mice, Kir6.2-gKO n=11 cells from 5 mice; see figures 3.23 and 3.24). 
 
Furthermore, in the absence of Kir6.2, again we found that the application of 
diazoxide was unable to hyperpolarise the RMP like it did in wild type isolated 
atrial cardiomyocytes (Paired data for RMP: WT n=5 cells from 3 mice, baseline 
-37 ± 4, DZX -57 ± 7 mV, p < 0.05; Kir6.2-gKO n=10 cells from 5 mice, baseline 
-22 ± 1, DZX -20 ± 2 mV; see figures 3.23 and 3.24). 
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Figure 3.23. Representative action potentials from isolated atrial 
cardiomyocytes. Cells of Kir6.2-gKO mice had a more depolarised RMP 
and diazoxide failed to shorten the action potentials of these cells unlike in 
wild type mice. (A) Overlay of wild type and Kir6.2-gKO action potentials at 
baseline. (B) Overlay of wild type action potentials at baseline and with 
application of diazoxide 100µM. (C) As in (B) but for Kir6.2-gKO. 
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Figure 3.24. Kir6.2 deletion leads to changes in the parameters of the 
action potential in isolated atrial cardiomyocytes. Both RMP (A) and 
MDP (B) are more depolarised, and a trend is also seen for a reduction in 
Vmax (C) and a lesser degree of change of membrane potential during the 
action potential (D), in isolated atrial cardiomyocytes of the Kir6.2-gKO 
mouse. (WT n=10 cells from 6 mice, Kir6.2-gKO n=11 cells from 5 mice, 
*p<0.05). (E) Diazoxide fails to hyperpolarise the RMP of isolated atrial 
cardiomyocytes of the Kir6.2-gKO mouse like it does in the wild type 
(*p<0.05). 
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3.3.6 Kir6.2 deletion leads to a failure of action potential shortening on 
KATP activation 
 
Whilst cells were more depolarised at rest, action potentials of Kir6.2-gKO atrial 
cardiomyocytes did not differ in duration at any point of repolarisation compared 
to wild type as can be seen by figure 3.25. Models of best fit were applied to the 
data. This was performed for two reasons. Firstly, to aid in comprehensive 
statistical comparisons, and secondly, to later extrapolate data on ERP from a 
whole heart tissue model back into the single cell model (see section 4.3). Data 
were best represented by an exponential growth model given by 𝑌 =  𝑌!. 𝑒!" 
where Y is the action potential duration at the percentage repolarisation of 
interest and x is that percentage repolarisation. This was also visible by 
morphology of the action potentials such as in figure 3.23. Best fits were applied 
using the least squares method and the preferred model was a unifying fit for  
both wild type and Kir6.2-gKO (WT: n=10 cells from 6 mice, Y0 6.0 ± 2.1, k 
0.031 ± 0.004, R2 0.58; Kir6.2-gKO: n=11 cells from 5 mice, Y0 5.0 ± 1.9, k 
0.032 ± 0.005, R2 0.55; p = 0.7115 for a difference between models; unifying 
model Y0 5.5 ± 1.4, k 0.032 ± 0.003, R2 0.56). 
 
Paired data were then analysed before and after application of diazoxide 
demonstrating shortening of action potentials in wild type mice but not in the 
Kir6.2-gKO. Again an exponential growth model could be best fitted to the data 
whereby separate fits were the preferred models for baseline and after 
diazoxide for wild type (n=5 cells from 3 mice; baseline Y0 7.9 ± 2.8, k 0.031 ± 
0.004, R2 0.73; DZX Y0 3.3 ± 1.7, k 0.029 ± 0.006, R2 0.50; p < 0.0001) but a 
unifying model for Kir6.2-gKO (n=10 cells from 5 mice; baseline Y0 5.1 ± 2.0, k 
0.033 ± 0.005, R2 0.56; DZX Y0 4.0 ± 1.5, k 0.036 ± 0.005, R2 0.65; p = 0.9, 
unifying model Y0 4.5 ± 1.2, k 0.034 ± 0.003, R2 0.60). When wild type data 
were subjected to repeated measures two-way ANOVA with Tukey's correction 
for multiple comparisons, an overall effect was seen for diazoxide in line with 
the difference between models with non-linear regression (repeated measures 
two-way ANOVA p < 0.01 by interaction) and significance specifically also for 
APD90 (baseline 125 ± 19, DZX 46 ± 13 ms, p < 0.0001), APD80 (baseline 94 ± 
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17, DZX 31 ± 8 ms, p < 0.001) and APD70 (baseline 71 ± 16, DZX 23 ± 6 ms, p 
< 0.01). 
 
  
 
Figure 3.25. Kir6.2 deletion does not alter the APD of isolated atrial 
cardiomyocytes at baseline but does lead to failure to shorten the APD 
on KATP activation. (A) No difference in APD at baseline between WT (n=10 
cells from 6 mice) and Kir6.2-gKO (n=11 cells from 5 mice). (B) 
Demonstration that diazoxide shortens APD in WT mice (paired data n=5 
cells from 3 mice). (C) Failure to shorten APD in the Kir6.2-gKO mouse 
(paired data n=10 cells from 5 mice). (Mean±SEM; ****p<0.0001, 
***p<0.001, **p<0.01). 
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Given the APD did not differ between WT and Kir6.2-gKO at baseline but RMP 
and MDP both did, an expected difference was found for the membrane 
potential at each time point of repolarisation, a factor defining the difference in 
AP morphology between the genotypes. Data were best represented by a linear 
function 𝑌 =  𝑚𝑥 + 𝑐 
where Y is the membrane potential at the percentage repolarisation of interest 
and x is that percentage repolarisation. Best fits were applied using the least 
squares method and the preferred model was one of two separate fits for WT 
and Kir6.2-gKO (WT n=10 cells from 6 mice, m -0.78 ± 0.09, c 48 ± 6, R2 0.47; 
KO n=11 cells from 5 mice, m -0.51 ± 0.07, c 29 ± 4, R2 0.35; p < 0.05; see 
figure 3.26). 
  
  
 
Figure 3.26. Kir6.2 deletion leads to altered action potential morphology 
in isolated atrial cardiomyocytes and differential momentary membrane 
potential. What with a more depolarised RMP in Kir6.2-gKO mice, a trend 
towards a lesser degree of change of membrane potential during the action 
potential, but no difference in APD, the rate of change of membrane potential 
throughout the action potential is slower in the Kir6.2-gKO as compared to 
wild type. This defines the difference in action potential morphology and 
leads to differential momentary membrane potential throughout the action 
potential. (Data shown are mean±SEM; WT n=10 cells from 6 mice, Kir6.2-
gKO n=11 cells from 5 mice).  
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3.3.7 Summary 
 
The message from these data are that Kir6.2 and SUR1 are, in line with 
previous literature, the predominant subunits that make up the sarcolemmal 
KATP current in isolated murine atrial cardiomyocytes. The relative expression of 
mRNA and pharmacological signature through whole-cell patch clamp both 
support this. A current was present that was activated by diazoxide and not 
pinacidil, and was inhibited by tolbutamide but not PNU37883A. However, 
Kir6.1 may make up a small contributing proportion to the KATP current. Whilst 
there was no reduction in current with Kir6.1 deletion, there was an increase in 
current, and this could be manifested by a compensatory increase in Kir6.2 
expression at the sarcolemma in place of deleted Kir6.1. Kir6.2 pore-forming 
subunits have an approximately double unitary conductance compared to Kir6.1 
and, thus, if Kir6.2 compensates for loss of Kir6.1, one could expect the whole-
cell current to be larger. With these data the apparent down-regulation of SUR1 
in the Kir6.1-gKO did not appear to manifest any functional significance given 
the KATP current was increased in the Kir6.1-gKO. 
 
A deletion of either pore, but particularly Kir6.2, might be expected to lead to 
cell hypertrophy if action potential duration is prolonged and there are greater 
influxes of calcium leading to secondary messenger switch on of hypertrophy 
genes by the calcineurin/NFAT pathway. Cell capacitance was not different 
between the genotypes suggesting this was not the case. The mice were, 
however, not stressed in the lead up to experiments. Data exist that deletion of 
Kir6.2 leads to a maladaptive response to stress and ischaemia in the murine 
heart, particularly with respect to the ventricle. This compromises contractile 
function and increases the incidence of arrhythmias, and that this is in large part 
due to an inability to shorten the action potential and leads to calcium handling 
abnormalities (Suzuki et al., 2001; 2002; Zingman et al., 2002; Suzuki et al., 
2003). I did not see a difference in action potential duration at baseline but 
deletion of Kir6.2 did lead to a failure of action potential shortening on 
application of the KATP opener diazoxide, a finding not reported in isolated atrial 
cardiomyocytes before. Another finding not previously reported in the literature 
is that Kir6.2 appears to contribute to the resting membrane potential given by 
the more depolarised state in the Kir6.2-gKO. The action potential morphology 
 198 
in this knockout is also different with a shallower change of membrane potential 
through repolarisation back to the more depolarised resting state. This might 
well contribute to differences in refractoriness of cells and tissue, and the more 
depolarised resting state could induce periods of post-repolarisation 
refractoriness due to failure of recovery from inactivation of a significant 
population of sodium channels. 
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3.4 KATP activation slows automaticity in a murine atrial tissue 
model utilising HL-1 cells 
 
HL-1 cells are immortalised cells derived from murine atrial cardiomyocytes that 
retain their differentiated adult phenotype and continue to beat spontaneously 
despite repeated culture. When cultured as syncytia they set up cell-to-cell 
communication via gap junctions and are a useful model of a 2D tissue sheet. 
They share electrophysiological properties of both murine atrial and SAN 
cardiomyocytes which also lends them as a good model for an ectopic atrial 
automatic focus (White et al., 2004; Yang & Murray, 2011). A proposed 
mechanism for the drivers of atrial fibrillation are automatic or triggered activity 
emanating from the inter-digitating cardiomyocyte sleeves of the pulmonary 
veins (Haïssaguerre et al., 1998; Chen et al., 1999; 2001). HL-1 cells are a 
reasonable model for such cells. 
 
3.4.1 HL-1 cells exhibit a KATP current and the functional expression is one 
of Kir6.2/SUR1 subunit composition 
 
I first sought to look for a KATP current in HL-1 cells and characterise it using 
whole-cell patch clamp. Isolated HL-1 cells were kindly cultured by Dr Muriel 
Nobles. 
 
In isolated HL-1 cells pinacidil 10µM failed to activate current but diazoxide 
100µM strongly activated current. This current was completely inhibited by the 
subsequent application of tolbutamide 100µM. (Baseline 6.7 ± 0.6, PIN 7.2 ± 
1.0, DZX 13 ± 2, DZX/TOLB 5.5 ± 0.6 pA/pF; n=18 cells; DZX vs baseline p < 
0.01; see figure 3.27). 
 
In a separate set of cells the effect of PNU37883A was investigated. After 
activation with diazoxide, PNU37883A did not significantly inhibit the current. 
(Baseline 10.8 ± 3.5, DZX 27.2 ± 7.5, DZX/PNU 22.2 ± 6.3, DZX/TOLB 3.8 ± 
2.7 pA/pF; n=6 cells; DZX and DZX/PNU vs baseline p < 0.05; see figure 3.28). 
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Figure 3.27. HL-1 cells exhibit a KATP current activated by diazoxide but 
not pinacidil. (A) Representative trace. (B) Representative I-V plot. (C) 
Summary data. (Mean±SEM; n=18 cells, **p<0.01 vs baseline). 
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Figure 3.28. The KATP current in HL-1 cells is inhibited by tolbutamide 
but not PNU37883A. (A) Representative trace. (B) Representative I-V plot. 
(C) Summary data. (Mean±SEM; n=6 cells, *p<0.05 vs baseline). 
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Furthermore, the resting membrane potential, taken as the clamped voltage on 
the ramp protocol where no current flowed, was hyperpolarised by the 
application of diazoxide but not pinacidil, an effect reversed by the subsequent 
application of tolbutamide. (RMP: baseline -58 ± 3, PIN -58 ± 3, DZX -66 ± 2, 
DZX/TOLB -56 ± 3 mV; n=18 cells; DZX vs baseline p < 0.0001; see figure 
3.29). 
 
 
3.4.2 HL-1 cell syncytia exhibit spontaneous rotational activity that can be 
abolished by application of the KATP opener diazoxide 
 
Syncytia of HL-1 cells were cultured in an MEA (Multichannel Systems, 
Germany). They have a circular dish 1600µm in diameter with 60 flat electrodes 
30µm in diameter spaced 200µm apart in an 8x8 grid fashion for measuring 
field potentials as necessary. I did not utilise the function to measure field 
potentials and focussed on recording calcium transients as described in section 
2.9. The MEA was used as it provided a convenient vessel for culture that could 
also be temperature-controlled at 37oC for experiments, as it was compatible 
with the TC02 temperature controller (Multichannel Systems, Germany). 
 
Syncytia would typically set up spontaneous rotational wavefronts of activation. 
Examples are shown in figure 3.30.  
 
Figure 3.29. Diazoxide but not pinacidil hyperpolarises the resting 
membrane potential of HL-1 cells. Mean±SEM; n=18 cells; ****p<0.0001 
vs baseline. 
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Figure 3.30. Example HL-1 syncytia demonstrating rotational wavefront 
propagation. Left panels, Time-lapse isochronal colour coded images of 
calcium transient propagation through one rotation with blue early and red 
late activation and 'early-meets-late' completing rotation where blue and red 
meet. White crosses mark estimated hinge points and white arrows direction 
of propagation. Right panels, still images at regular intervals of calcium 
transient propagation through the rotation depicted in the left panels.          
(A) Appearances of 'figure-of-eight' re-entry with 2 re-entrant loops.            
(B) Appearances of spiral wavefront propagation. 
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The frequency of spontaneous wavefront activation was recorded after 
application of diazoxide and tolbutamide as described in section 2.9. Diazoxide 
100µM slowed the frequency of activation in all syncytia, and re-organised the 
activation wavefront from that of rotational activity to a straight and flat wave 
front spreading uniformly across the array in 5 out of 6 syncytia (p < 0.05 by 
Fisher's exact test). Adding a further diazoxide 100µM (200µM total) would 
abolish activation and silence the syncytia in all but 1 out of the 6. In the 
syncytium where diazoxide 200µM did not abolish activation, the frequency of 
activation was still slowed considerably further to that in the presence of 
diazoxide 100µM. Adding tolbutamide 100µM would recover activity in the 5 
synycita that were silenced by diazoxide 200µM, and increased the frequency 
of activation in the syncytium that was not silenced. (Frequency of activation 
n=6: Baseline 1.2 ± 0.24, DZX 100µM 0.58 ± 0.19, DZX 200µM 0.03 ± 0.03, 
DZX 200µM/TOLB 100µM 0.73 ± 0.15 Hz; DZX 100µM vs baseline p < 0.05, 
DZX 200µM vs baseline p < 0.05; see figure 3.31). 
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Figure 3.31. HL-1 syncytia - diazoxide slows the frequency of 
spontaneous rotational / automatic activity. (A) Representative trace of 
normalised calcium fluorescence when adding DZX 100µM to the bath 
solution. Frequency of transients (activation) slows on the right of the trace. 
(B) As in (A) except adding a further DZX 100µM (200µM total) to the bath 
solution demonstrating silencing of activity. (C) As in (A) and (B) but after 
sequentially adding TOLB 100µM to the bath solution. Activity recovers with 
KATP inhibition. (D) Summary data showing Mean±SEM of frequency of 
activation (n=6; *p<0.05 vs baseline). 
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3.4.3 Summary 
 
HL-1 cells exhibit a KATP current that has the pharmacological signature of a 
subunit composition given by Kir6.2/SUR1, the same predominant composition 
as that in murine atrial cardiomyocytes. This finding is somewhat unsurprising, 
but nonetheless reassuring, given HL-1 cells are derived from murine atrial 
cardiomyocytes. KATP activation hyperpolarises HL-1 cells in isolation. 
 
HL-1 cells have been shown to express gap junction proteins and evidence on 
the arrays through calcium fluorescence shows they exhibit cell-to-cell 
conduction and set up spontaneous activation wavefronts in a rotational 
fashion. KATP activation slows the frequency of this activation in a dose 
dependent manner. At a high dose KATP activation can silence activation 
completely. KATP activation also re-organises rotational activation wavefronts to 
straight and uniform wavefronts. Such findings are interesting from a 
translational perspective in terms of arrhythmia mechanisms and potential 
therapies. If automatic or micro-re-entrant circuits in, for example, the extending 
myocardial sleeves of left atrium into pulmonary vein are at play in driving atrial 
arrhythmias, then KATP channel activation might be a pharmacological 
therapeutic target. 
  
 
Figure 3.32. HL-1 syncytia - diazoxide can re-organise activation 
wavefronts from rotational to straight and uniform. *p<0.05 by Fisher's 
exact test. 
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3.5 KATP activation during hypoxia contributes to sinus node 
depression, but pharmacological activation alone does not 
 
Further to the findings from the experiments with the HL-1 syncytia where 
spontaneous activation was slowed by KATP activation, I sought to investigate 
whether KATP activation could slow spontaneous sinus node activation. 
Evidence from our lab has uncovered that Kir6.1 contributes to a KATP current in 
the murine sinus node. Whilst a proportion of isolated cells displayed current 
activation with pinacidil 10µM, the vast majority of cells displayed a current with 
the pharmacological signature of the SUR1 sulphonylurea receptor subunit and 
activation by diazoxide 100µM (Aziz et al., 2018). The KATP openers pinacidil 
and cromakalim have been shown to hyperpolarise and slow spontaneous 
activation in isolated rabbit SAN cells and another group has demonstrated that 
Kir6.2 deletion reverses hypoxia driven slowing of sinus node spontaneous 
activation in a whole heart Langendorff model (Han et al., 1996; Fukuzaki et al., 
2008). 
 
3.5.1 Pharmacological KATP activation does not slow sinus node rate in a 
whole heart model 
 
I first tested whether KATP activation in a whole heart Langendorff model would 
slow spontaneous sinus node activation. The Langendorff set up and signal 
recording via the FlexMEA (Multichannel Systems, Germany) has been 
described in sections 2.8.2 and 2.8.3. After a period of stabilisation the 
spontaneous cycle length of Langendorff beating wild type hearts was recorded 
at baseline, after 3 minutes perfusion of diazoxide 100µM, and then followed by 
3 minutes perfusion with diazoxide 200µM. No change in spontaneous cycle 
length was seen. (Cycle length: baseline 145 ± 11, DZX 100µM 143 ± 8, DZX 
200µM 142 ± 6 ms; n=8 hearts; see figure 3.33). 
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3.5.2 Inhibition of KATP during hypoxia prevents sinus node rate slowing 
 
Langendorff wild type mouse hearts were then subjected to hypoxic conditions. 
As described in section 2.8.2 this was achieved by pre-bubbling Krebs solution 
with 95% N2 / 5% CO2. After a period of stabilisation hearts were perfused with 
the hypoxic solution continuously for 9 minutes followed by 4 minutes washout 
with oxygenated Krebs solution. A separate set of hearts were perfused with 
hypoxic solution containing tolbutamide 100µM for 5 minutes, and then 
switched to hypoxic solution containing glibenclamide 10µM for 4 minutes, 
before washout with oxygenated Krebs for 4 minutes.  
 
Hypoxia caused marked sinus node rate slowing, see figure 3.34 (selected time 
points, cycle length: baseline, 182 ± 16 ms; 5mins hypoxia, 560 ± 72 ms, p < 
0.01 vs baseline; 9mins hypoxia, 969 ± 184 ms, p < 0.0001 vs baseline; 4mins 
washout, 206 ± 12 ms; n=5-12 hearts). With the addition of KATP inhibitors there 
was no significant difference to baseline of sinus node rate (selected time 
points, cycle length: baseline, 182 ± 16 ms; 5mins hypoxia with TOLB 100µM, 
309 ± 67 ms; 9mins hypoxia with 4mins GLIB 10µM, 315 ± 36 ms; 4mins 
washout, 231 ± 20 ms; n=5-12 hearts). 
 
 
Figure 3.33. Pharmacological KATP activation does not slow 
spontaneous sinus node rate in the whole heart. Perfusate containing up 
to diazoxide 200µM did not slow sinus node rate in the Langendorff mouse 
heart (n=8). 
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On comparisons between the condition of having KATP inhibitors added to the 
perfusate and hypoxia alone at each time point, the blunting effect of KATP 
inhibitors on sinus node slowing during hypoxia was seen further (cycle length: 
7 minutes of hypoxia alone, 744 ± 117 ms, n=7 hearts vs 7 minutes hypoxia 
with KATP inhibitors (5 minutes tolbutamide 100µM / 2 minutes glibenclamide 
10µM), 321 ± 55 ms, n=5 hearts; p < 0.05 for comparison; 8 minutes of hypoxia 
alone, 1015 ± 225 ms, n=7 hearts vs 8 minutes hypoxia with KATP inhibitors (5 
minutes tolbutamide 100µM / 3 minutes glibenclamide 10µM), 334 ± 60 ms, n=5 
hearts; p < 0.0001 for comparison; 9 minutes of hypoxia alone, 969 ± 184 ms, 
n=7 hearts vs 9 minutes hypoxia with KATP inhibitors (5 minutes tolbutamide 
100µM / 4 minutes glibenclamide 10µM), 315 ± 36 ms, n=5 hearts; p < 0.001 for 
comparison, see figure 3.34.  
 
Figure 3.34. Inhibition of KATP during hypoxia prevents sinus node rate 
slowing. KATP inhibitors, when added to hypoxic perfusion solution, blunt and 
prevent sinus node rate slowing. Tolbutamide 100µM initiates the effect 
which is continued despite switching to glibenclamide 10µM. (n=5-12 hearts; 
+p<0.05, ++p<0.01, +++p<0.001, ++++p<0.0001 for hypoxia only vs baseline; 
*p<0.05, ***p<0.001, ****p<0.0001 for comparison between drug on or off). 
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3.5.3 Summary 
 
Pharmacological activation alone is unable to slow the spontaneous sinus node 
rate in wild type Langendorff mouse hearts. Hypoxia appears to produce a 
much more profound effect on sinus node rate causing considerable 
depression. This is, in at least part, due to KATP activation during hypoxia as 
other investigators have shown that Kir6.2 deletion causes an absence of this 
effect (Fukuzaki et al., 2008), and I have shown that pharmacological KATP 
inhibition produces the same effect. In line with our lab's previous work 
suggesting that the pharmacological signature of the sinus node KATP current is 
one of SUR1 as the sulphonylurea subunit, tolbutamide 100µM is able to 
reverse sinus node rate slowing during hypoxia. 
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3.6 Both KATP pore-forming subunits contribute to tissue-level 
electrophysiology of the atria in murine whole heart 
 
Given that the HL-1 syncytia atrial model demonstrated that KATP activation had 
an important impact on cardiac myocyte activity and arrhythmia generation, I 
wanted to next investigate the effects of KATP inhibition on parameters thought 
widely to affect arrhythmogenicity, ERP and conduction velocity. The data had 
suggested there was an, albeit small, Kir6.1 contribution to the sarcolemmal 
KATP current in isolated atrial cardiomyocytes, delineated by an increase in 
current in the Kir6.1-gKO atrial cells which may well be due to compensation by 
Kir6.2 with its larger unitary conductance. I was keen to investigate any 
differences in electrophysiology of tissue in the Kir6.1-gKO that would support 
this. On top of this, a complete dissection of these electrophysiological 
parameters directly comparing both pore-forming knockout mice had not been 
reported in the literature. As such, hearts from both pore-forming knockout mice 
were subjected to programmed electrical stimulation in a Langendorff set-up, 
and ERP and CV measured using the FlexMEA (Multichannel Systems, 
Germany) as described in sections 2.8.2 and 2.8.3. Experiments were repeated 
at various time points during perfusion of hypoxic solution to activate a KATP 
current. After a period of stabilisation and baseline recordings, hypoxia was 
induced by switching to a Krebs solution pre-bubbled with 95% N2 / 5% CO2. 
Hypoxia was maintained for 12 minutes. For a cohort of wild type and Kir6.1-
gKO hearts, between minutes 8 to 12 the perfusing solution was changed to a 
hypoxic one also containing tolbutamide 100µM. The final 6 minutes of the 
protocol were washout back to an oxygenated perfusing solution with no drugs. 
Programmed electrical stimulation was performed every 2 minutes. 
 
3.6.1 Both KATP pore-forming subunits affect the atrial effective refractory 
period, and Kir6.2 is crucial to preventing its prolongation during hypoxia 
 
Baseline heart rate was recorded. No significant difference was seen between 
the genotypes (WT, 391 ± 21 bpm, n=20; Kir6.1-gKO, 329 ± 20 bpm, n=15; 
Kir6.2-gKO, 429 ± 41 bpm, n=8; see figure 3.35). 
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Baseline ERP was prolonged in both Kir6.1-gKO and Kir6.2-gKO atria (WT, 26 
± 2 ms, n=20; Kir6.1-gKO, 47 ± 5 ms, n=15, p < 0.0001 vs WT; Kir6.2-gKO, 42 
± 4 ms, n=8, p < 0.05 vs WT). ERP after 8 minutes of hypoxia was also 
prolonged in both knockout mice, and Kir6.2-gKO more prolonged than Kir6.1-
gKO (WT, 21 ± 2 ms, n=16; Kir6.1-gKO, 46 ± 9 ms, n=12, p < 0.05 vs WT; 
Kir6.2-gKO, 74 ± 11 ms, n=8, p < 0.0001 vs WT, p < 0.05 vs Kir6.1-gKO). In the 
cohort of wild type hearts that were also given tolbutamide 100µM in the 
hypoxic perfusate, after hypoxia for 12 minutes, ERP was prolonged in the 
tolbutamide group (No TOLB, 22 ± 3 ms, n=11; +TOLB, 44 ± 10 ms, n=6; p < 
0.05; see figure 3.36). 
 
Whilst atrial ERP was prolonged compared to wild type in terms of absolute 
values for both knockouts, when normalised to baseline, like the WT, Kir6.1-
gKO atria maintained their ERP through hypoxia. In the Kir6.2-gKO mouse, 
however, ERP prolonged out even further (selected time points % change in 
ERP compared to baseline: 6 minutes hypoxia - WT, -7 ± 8%, n=17; Kir6.1-
gKO, -17 ± 11%, n=11; Kir6.2-gKO, +60 ± 17%, n=8, p < 0.001 vs WT; 12 
minutes hypoxia - WT, -9 ± 9%, n=11; Kir6.1-gKO, -41 ± 11%, n=4; Kir6.2-gKO, 
+114 ± 47%, n=7, p < 0.0001 vs WT; after 8 minutes washout - WT, +17 ± 9%, 
n=12; Kir6.1-gKO, +13 ± 20% n=5; Kir6.2-gKO, +66 ± 22%, n=7, p < 0.05 vs 
WT). In the cohort of WT and Kir6.1-gKO hearts that were also given 
tolbutamide in the hypoxic perfusate, ERP prolonged out in a similar fashion to 
 
Figure 3.35. Baseline heart rate was unaffected by either KATP pore 
knockout. (n). 
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Kir6.2-gKO hearts in the absence of tolbutamide (ERP % change compared to 
baseline at 12 minutes hypoxia: WT no TOLB, -9 ± 9%, n=11; WT+TOLB, +74 ± 
33%, n=6, p < 0.0001; Kir6.1-gKO no TOLB, -41 ± 11%, n=4 Kir6.1-gKO+TOLB, 
+56 ± 20%, n=7, p < 0.01; see figure 3.36). 
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Figure 3.36. Atrial ERP is prolonged in both KATP pore knockout mice 
and Kir6.2 is crucial to maintain it during hypoxia. (A) Baseline ERP 
(significance shown vs WT) (B) ERP after 8 mins hypoxia (C) WT ERP after 
12 mins hypoxia with/without TOLB (D) ERP % change compared to baseline 
in all genotypes (significance shown vs WT) (E) as for (D) but WT with and 
without TOLB (significance shown vs no TOLB) (F) as for (E) but Kir6.1-gKO 
(significance shown vs no TOLB). (n); */+p<0.05, **/++p<0.01, +++p<0.001, 
****/++++p<0.0001. 
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3.6.2 Both KATP pore-forming subunits affect the atrial conduction velocity 
 
A trend was observed in a lower baseline steady state CV in both knockout 
mice (WT, 0.66 ± 0.04 m/s, n=19; Kir6.1-gKO, 0.52 ± 0.06 m/s, n=13, p = 0.05 
vs WT; Kir6.2-gKO, 0.55 ± 0.03 m/s, n=8, p = 0.26 vs WT). This finding was 
reinforced when examining CV restitution at progressively shorter coupling 
intervals down to ERP, whereby the knockout atria developed consistently 
lower CV compared to WT (CV at selected coupling intervals: S2-100ms - WT, 
0.63 ± 0.04 m/s, n=19; Kir6.1-gKO, 0.44 ± 0.06 m/s, n=13, p < 0.01 vs WT; 
Kir6.2-gKO, 0.44 ± 0.07 m/s, n=8, p < 0.05 vs WT; S2-60ms - WT, 0.52 ± 0.04 
m/s, n=19; Kir6.1-gKO, 0.32 ± 0.06, n=8, p < 0.05 vs WT; Kir6.2-gKO, 0.31 ± 
0.06 m/s, n=7, p < 0.05 vs WT). Steady state CV after 8 minutes of hypoxia was 
also lower in both knockout mice (WT, 0.46 ± 0.04 m/s, n=15; Kir6.1-gKO, 0.32 
± 0.05 m/s, n=10, p < 0.05 vs WT; Kir6.2-gKO, 0.30 ± 0.04 m/s, n=8, p < 0.05 
vs WT). This finding was reinforced when examining CV restitution after 8 
minutes hypoxia. At progressively shorter coupling intervals down to ERP, the 
knockout atria had consistently lower CV compared to WT (CV at 8 minutes 
hypoxia, selected coupling intervals: S2-100ms - WT, 0.47 ± 0.05 m/s, n=15; 
Kir6.1-gKO, 0.31 ± 0.05 m/s, n=9, p < 0.05 vs WT; Kir6.2-gKO, 0.25 ± 0.03, 
n=6, p < 0.01 vs WT; S2-60ms - WT, 0.41 ± 0.04 m/s, n=15; Kir6.1-gKO, 0.19 ± 
0.03, n=7, p < 0.01 vs WT; Kir6.2-gKO, 0.17 ± 0.06 m/s, n=3, p < 0.05 vs WT). 
In the cohort of wild type hearts that were also given tolbutamide 100µM in the 
hypoxic perfusate, after hypoxia for 12 minutes steady state CV was no 
different in the tolbutamide group (No TOLB, 0.37 ± 0.04 m/s, n=10; +TOLB, 
0.39 ± 0.04 m/s, n=6). No difference was seen either in CV restitution between 
the hypoxia only group and that with tolbutamide (see figure 3.37). Example 
isochronal activation maps are presented in figure 3.38. 
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Figure 3.37. Atrial CV is lower in both KATP pore knockout mice.           
(A) Baseline steady state CV (B) Baseline CV restitution (significance shown 
vs WT) (C) Steady state CV at 8mins hypoxia (D) CV restitution at 8mins 
hypoxia (significance shown vs WT) (E) Steady state CV at 12mins hypoxia 
with or without tolbutamide in the WT (F) CV restitution at 12mins hypoxia 
with or without tolbutamide in the WT. CV=conduction velocity. (n);            
*/#/+ p<0.05, ##/++ p<0.01, ###p<0.001. 
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When normalised to baseline, like the WT, both KATP pore knockout atria had 
further reductions in CV through hypoxia (selected time points % change in CV 
compared to baseline: 12 minutes hypoxia - WT, -47 ± 6%, n=10, p < 0.0001 vs 
baseline; Kir6.1-gKO, -40 ± 15%, n=4, p <0.05 vs baseline; Kir6.2-gKO, -53 ± 
7%, n=7, p < 0.0001 vs baseline; after 8 minutes washout - WT, -28 ± 7%, 
n=10, p < 0.01 vs baseline; Kir6.1-gKO, -44 ± 14% n=5 p < 0.01 vs baseline; 
Kir6.2-gKO, -35 ± 10%, n=6, p < 0.05 vs baseline). In the cohort of WT and 
Kir6.1-gKO hearts that were also given tolbutamide in the hypoxic perfusate, 
there was no difference in the percentage change in steady state CV in the 
tolbutamide groups, as compared to no tolbutamide, through hypoxia (CV % 
change compared to baseline at 12 minutes hypoxia: WT no TOLB, -47 ± 6%, 
n=10; WT+TOLB, -39 ± 4%, n=6; Kir6.1-gKO no TOLB, -40 ± 15%, n=4; Kir6.1-
gKO+TOLB, -33 ± 11%, n=5; see figure 3.39). 
  
 
Figure 3.38. Example isochronal activation maps from Langendorff 
hearts. Maps demonstrate typical activation from a single stimulus across 
the atrial tissue. Black dots signify electrode positions where data was 
collected on the FlexMEA and contours and colour fill signify isochrones of 
activation. Activation times are given by the colour bar legend. (A) Baseline 
(B) Hypoxia demonstrating conduction slowing. 
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3.6.3 Kir6.2 deletion, and pharmacological KATP inhibition, cause 
prolongation of atrial minimum wavefront path length during hypoxia 
 
Measurements of ERP and steady state CV were then used to calculate the 
minimum wavefront path length (WFPL) of the tissue through hypoxia given by 
their product. Despite a prolonged ERP in both KATP pore knockouts at baseline, 
a reduction in CV compensated in that there was no difference in WFPL (WT, 
1.7 ± 0.2 cm, n=19; Kir6.1-gKO, 2.5 ± 0.4cm, n=13; Kir6.2-gKO, 2.3 ± 0.3cm, 
n=8). At 8 minutes of hypoxia, due to the prolongation in ERP with fall in CV, 
the WFPL was maintained in the Kir6.2-gKO and, as such, became longer than 
 
Figure 3.39. Atrial steady state CV falls through hypoxia at the same 
rate in both KATP pore knockout mice as WT. (A) Steady state CV % 
change to baseline through hypoxia in all genotypes (significance shown vs 
baseline) (B) Steady state CV % change to baseline through hypoxia with or 
without tolbutamide in WT hearts (C) As for (B) but Kir6.1-gKO hearts. 
CV=conduction velocity. (n); */#/+ p<0.05, **/##/++p<0.01, ***/###/+++p<0.001, 
****/####/++++p<0.0001. 
 219 
the WT. This was not the case in the Kir6.1-gKO where the ERP was 
maintained during hypoxia with a fall in CV leading to a shorter WFPL, akin to 
the WT (WFPL at 8mins hypoxia: WT, 0.9 ± 0.1 cm, n=15; Kir6.1-gKO, 1.6 ± 0.5 
cm, n=10; Kir6.2-gKO, 2.3 ± 0.5 cm, n=8, p < 0.05 vs WT). At 12 minutes 
hypoxia, KATP inhibition with tolbutamide produced a prolongation in ERP that 
was not accompanied by a fall in CV, leading to a longer WFPL (WT no TOLB, 
0.7 ± 0.1cm, n=10; WT+TOLB, 1.7 ± 0.3 cm, n=6, p < 0.01 for comparison, see 
figure 3.40). 
 
The change in absolute values of WFPL is well summarised by the percentage 
change compared to baseline through hypoxia. In both WT and Kir6.1-gKO 
atria, the maintenance of ERP together with a fall of CV led to a fall in WFPL, 
whereas in the Kir6.2-gKO, the prolongation of ERP compensated the fall in CV 
and WFPL was maintained through hypoxia. (Selected time points % change in 
WFPL compared to baseline: 6 minutes hypoxia - WT, -32 ± 7%, n=16, p < 0.05 
vs baseline; Kir6.1-gKO, -30 ± 15%, n=9; Kir6.2-gKO, -3 ± 9%, n=8; 12 minutes 
hypoxia - WT, -49 ± 8%, n=10, p < 0.001 vs baseline; Kir6.1-gKO, -66 ± 11%, 
n=4, p < 0.01 vs baseline; Kir6.2-gKO, -4 ± 27%, n=7, p < 0.01 vs WT; after 8 
minutes washout - WT, -16 ± 10%, n=10; Kir6.1-gKO, -43 ± 11% n=5; Kir6.2-
gKO, +2 ± 14%, n=6). Similarly, KATP inhibition with tolbutamide led to a 
prolongation in ERP which compensated the fall in CV, and the ensuing fall in 
WFPL was reversed (WFPL % change compared to baseline at 12 minutes 
hypoxia: WT no TOLB, -49 ± 8%, n=10; WT+TOLB, +1 ± 13%, n=6, p < 0.05; 
Kir6.1-gKO no TOLB, -66 ± 11%, n=4; Kir6.1-gKO+TOLB, +8 ± 22%, n=5, p < 
0.05, see figure 3.40). 
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Figure 3.40. Kir6.2 deletion, and pharmacological KATP inhibition, cause 
prolongation of atrial minimum wavefront path length during hypoxia. 
(A) Baseline WFPL (B) WFPL after 8 mins hypoxia (C) WT WFPL after 12 
mins hypoxia with/without TOLB (D) WFPL % change compared to baseline 
in all genotypes (+p<0.05, ++p<0.01 vs WT; */#p<0.05, **/##p<0.01, ***p<0.001 
vs baseline) (E) as for (D) but WT with and without TOLB (*p<0.05 vs no 
TOLB) (F) as for (E) but Kir6.1-gKO (*p<0.05 vs no TOLB). (n). 
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3.6.4 Kir6.2 deleted mice display reduced arrhythmia inducibility to 
programmed electrical stimulation during hypoxia / reperfusion 
 
Arrhythmias induced by programmed electrical stimulation (PES) were 
observed. A run of 500ms or longer was considered a sustained atrial 
arrhythmia. At baseline sustained atrial arrhythmia was observed in WT 1/20 
hearts, Kir6.1-gKO 1/15 hearts, Kir6.2-gKO 0/8 hearts. Where hearts with data 
existed for the duration of the hypoxia/washout 20-minute protocol, sustained 
atrial arrhythmia was observed in WT 6/11 hearts, Kir6.1-gKO 5/7 hearts, 
Kir6.2-gKO 0/7 hearts (p < 0.05 Kir6.2-gKO vs WT by Fisher's exact test). It can 
be noticed, and it is important to point out, that in only one heart in the Kir6.2-
gKO group could data not be extracted for the duration of the protocol and as 
such this heart was omitted from this part of the analysis. However, even up to 
8 minutes of the protocol where data could be extracted in this heart, still no 
sustained atrial arrhythmia was observed. During the period of 4 minutes 
hypoxia with or without tolbutamide (8-12min of protocol), sustained atrial 
arrhythmia was observed in WT with no tolbutamide 3/11 hearts and WT with 
tolbutamide 0/6 hearts. Sustained atrial arrhythmia was observed similarly in 
Kir6.1-gKO with no tolbutamide 1/4 hearts and Kir6.1-gKO with tolbutamide 0/6 
hearts. See figures 3.41 and 3.42. 
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Figure 3.41. Kir6.2 deleted mice display reduced arrhythmia inducibility 
to programmed electrical stimulation (PES) during hypoxia/reperfusion. 
Proportions of hearts with PES-induced sustained atrial arrhythmia (500ms 
or longer): (A) At baseline (B) during the hypoxia/washout 20-minute protocol 
(C) 8-12mins of hypoxia with and without tolbutamide in the WT (D) as (C) 
but for Kir6.1-gKO. (Significance shown vs WT, *p<0.05 by Fisher's exact 
test). 
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3.6.5 Summary 
 
I have shown in section 3.3 that in line with previous literature, Kir6.2 is a crucial 
subunit of a sarcolemmal KATP current in murine atria and this further work 
demonstrating its contribution to atrial tissue electrophysiology supports this. In 
section 3.3 I also demonstrated that Kir6.1 deletion leads to an increase in KATP 
current in isolated atrial cardiomyocytes. I postulated that this might be due to a 
small population of Kir6.1-containing KATP channels whereby Kir6.1 deletion 
could lead to substitution by Kir6.2, which has a larger unitary conductance. 
This would be expected to enhance effects of hypoxia on KATP activation and 
the prolongation of ERP and reduction in CV seen in the Kir6.1 deleted mouse 
is counter-intuitive to this argument. It may be, however, that Kir6.1 deletion has 
different effects in tissue to that of isolated cells and it could be, for example, a 
factor of its subcellular localisation that is more important in tissue than in the 
isolated cell. This or there is an indirect effect of Kir6.1 deletion, either via the 
vascular smooth muscle or endothelium, that leads to the changes seen on 
atrial tissue electrophysiology. Whether or not Kir6.1 is present in an atrial 
sarcolemmal KATP current, the data demonstrate that global modulation of the 
 
 
Figure 3.42. Example trace of arrhythmia induced by programmed 
electrical stimulation. Trace showing the final 3 beats of a drive train with 
preceding pacing artefact (purple), followed by the S2 with shorter coupling 
interval with preceding pacing artefact (blue), followed by what appears to be 
atrial fibrillation (further pacing artefact is also present from the next drive 
train in the automated sequence), which on this occasion went on to last for 
25 beats and ~700ms. 
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current will have effects on parameters known to affect arrhythmia inducibility, 
just as with Kir6.2 modulation. The presence of Kir6.2 in the Kir6.1 knockout 
continues to compensate for the electrophysiological changes seen during 
hypoxia and maintains the ERP just as in the wild type. Pharmacological 
blockade of KATP, via inhibition at the SUR1 subunit using tolbutamide, 
recapitulates the effects of Kir6.2 deletion in wild type and Kir6.1 knockout mice.  
 
Kir6.2-deleted mice display reduced arrhythmia inducibility to programmed 
electrical stimulation during hypoxia. This is likely to reflect the absence of 
wavefront path length shortening displayed by the Kir6.2-gKO that was 
observed in WT and Kir6.1-gKO mice. 
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3.7 Whole heart RNA quantification suggests the presence of 
all KATP subunits except SUR1 in the human heart 
 
I began to examine the contribution of the various KATP subunits to a 
sarcolemmal KATP current in the human heart by performing relative 
quantification of mRNA transcripts encoding the subunits. 
 
3.7.1 Commercially available human whole heart RNA 
 
Isolated human total RNA from all four heart chambers (right atrium, left atrium, 
right ventricle and left ventricle) from three separate donors said to be "normal" 
with regards to no past medical history and normal cardiac structure and 
function, was purchased from AMS Biotechnology (Europe) Limited. Donors 
consisted of a 49 year old male, 69 year old male and 65 year old male. 
 
Two runs of qRT-PCR were performed for all samples. Samples were analysed 
in triplicate and the mean Ct values were taken. Quantification was normalised 
to GAPDH. Data were grouped from all 3 donors in terms of subunit and 
chamber, and after normalising to GAPDH, quantification was made relative to 
the mean of the right atrial GAPDH normalised Kir6.1 value. 
 
There was no significant difference in relative quantity of Kir6.1 and Kir6.2 
transcripts within each cardiac chamber, but the left ventricle had consistently 
greater relative quantity of both pore-forming transcripts than all the other 
chambers. This was also the case for SUR2B transcripts, which were 
significantly more abundant in the left ventricle than all the other chambers. 
SUR2B transcripts were also significantly more abundant than SUR2A within 
the left ventricle and left atrium. There was a consistent signal suggesting that 
no SUR1 transcripts were present in human whole, "normal heart", RNA. See 
figure 3.43. 
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CHAMBER SUBUNIT RELATIVE 
QUANTIFICATION 
RA Kir6.1 1.06 ± 0.14 
 Kir6.2 1.10 ± 0.27 
 SUR1 0.03 ± 0.01 
 SUR2A 1.78 ± 0.57 
 SUR2B 6.42 ± 1.19 
LA Kir6.1 2.38 ± 0.87 
 Kir6.2 0.78 ± 0.20 
 SUR1 0.02 ± 0.01 
 SUR2A 0.71 ± 0.10 
 SUR2B 11.43 ± 3.38 
RV Kir6.1 2.31 ± 0.60 
 Kir6.2 1.45 ± 0.25 
 SUR1 0.01 ± 0.01 
 SUR2A 3.93 ± 1.47 
 SUR2B 10.02 ± 2.32 
LV Kir6.1 5.11 ± 1.59 
 Kir6.2 4.04 ± 1.20 
 SUR1 0.04 ± 0.02 
 SUR2A 6.85 ± 3.42 
 SUR2B 22.92 ± 6.88 
 
Figure 3.43. Relative quantification of KATP subunit transcripts in 
human whole "normal heart" RNA. Data from 2 runs of triplicates, 3 
donors.. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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3.7.2 Human whole heart RNA from The Barts Cardiovascular Registry 
 
To confirm the findings from the commercially available human whole heart 
RNA, I performed identical experiments on the RNA extracted from the samples 
of atria I collected from 5 patients in the cardiothoracic theatre. Patients were all 
male, ages 56, 62, 59, 74, 61, non-diabetic with normal valvular and preserved 
LV systolic function undergoing coronary artery bypass grafting. Samples were 
obtained from right and left atrium from all 5 patients. The data from these 
samples complemented the atrial data from the commercially available samples 
in an almost identical pattern. See figure 3.44. 
 
 
 
 
CHAMBER SUBUNIT RELATIVE 
QUANTIFICATION 
RA Kir6.1 1.01 ± 0.07 
 Kir6.2 1.12 ± 0.13 
 SUR1 0.09 ± 0.00 
 SUR2A 2.57 ± 0.65 
 SUR2B 4.49 ± 0.58 
LA Kir6.1 1.29 ± 0.74 
 Kir6.2 0.73 ± 0.07 
 SUR1 0.02 ± 0.02 
 SUR2A 2.38 ± 0.70 
 SUR2B 13.69 ± 7.04 
 
Figure 3.44. Relative quantification of KATP subunit mRNA transcripts 
from human atrial samples through the Barts Cardiovascular Registry. 
Data from 5 patients, samples run in triplicate. 
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3.7.3 Summary 
 
These data are in keeping with reports in the literature that SUR1 is not an 
important subunit in the composition of KATP in the normal human heart 
(Fedorov et al., 2011). It does, however, suggest that there may be an equal 
contribution of both pore-forming subunits throughout the heart. SUR2B is 
expressed in abundance throughout the heart. With the data being from whole 
heart RNA, it is impossible to make inferences about what cellular populations 
the transcripts are emanating from, and it may be the large proportion of 
SUR2B is in large part provided by vascular smooth muscle or endothelium. 
Similarly, the equal proportions of the pore-forming subunit transcripts might 
look very different if RNA could be isolated solely from cardiomyocytes. 
Nonetheless, the findings make pursuing further investigations in this vein 
worthwhile, and the stark difference to the proportionality found in mouse whole 
heart RNA is clear. 
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Section 4: Discussion 
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4.1 Unique findings and addressment of the hypotheses and 
aims  
 
Aims of this project were to further define the KATP subunit expression and 
current characteristics in murine atria with a view to comparing with human 
atria, and to explore any effect on cardiac rhythm generation of KATP 
modulation. 
 
These were based on hypotheses that, in addition to literature demonstrating an 
importance for Kir6.2 as the major atrial sarcolemmal pore-forming KATP subunit 
in the mouse, Kir6.1 is also present, and that both pore-forming subunits 
contribute to murine atrial electrophysiology. Further, a differential subunit 
expression existed between the atria and ventricles that could be exploited 
pharmacologically in the event of anti-arrhythmic mechanisms of KATP 
modulation. With this in mind I postulated that KATP activation would be anti-
arrhythmic in the case of reducing automaticity through membrane 
hyperpolarisation, whilst KATP inhibition would also be anti-arrhythmic by 
increasing minimum wavefront path length and reducing the chances of 
perseveration of re-entry. 
 
Mice with global deletion of Kir6.1 and Kir6.2 were bred. Whole cell patch clamp 
of isolated wild-type murine atrial cardiomyocytes demonstrated an activation of 
current with diazoxide 100µM that was strongly inhibited by tolbutamide 100µM 
but not PNU37883A 50µM. Pinacidil 10µM failed to activate current in these 
cells. This was in keeping with a pharmacological signature of Kir6.2/SUR1 as 
that making up the predominant sarcolemmal KATP current in these cells. In 
keeping with this, genetic deletion of Kir6.2 abolished a KATP current in these 
cells. However, Kir6.1 deletion caused an increase in KATP current and KATP 
inhibitors still produced an effect, albeit subtle, after Kir6.2 deletion. When atrial 
tissue electrophysiology was investigated in a whole heart model, both pore-
forming knockout mice showed pronounced changes with ERP prolongation 
and CV reduction as compared to wild-type littermate control mice. Kir6.2 
appeared more important, particularly with regards to adaptation to hypoxic 
conditions. Thus, both pore-forming subunits contribute to atrial 
electrophysiology in the mouse. In keeping with this whole heart mRNA 
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quantification demonstrated greater expression of Kir6.2 and SUR1 subunits 
compared to Kir6.1 and SUR2 in the atria, though the latter were still present. 
The data pertaining to the direct comparison of the KATP pore-forming knockouts 
in isolated murine atrial myocytes is novel, and the suggestion that Kir6.1 
contributes to a murine sarcolemmal atrial KATP current has not been reported 
before. A direct assessment and comparison of atrial tissue electrophysiology 
between KATP pore-forming knockouts has also not been performed before and 
these findings are also novel. 
 
Kir6.2 deletion, or KATP pharmacological inhibition, led to increases in minimum 
wavefront path length and this was accompanied by trends towards reduced 
arrhythmia inducibility to programmed electrical stimulation, suggesting a 
reduction in re-entrant activity. Conversely, KATP activation first organised 
rotational wavefronts to straight and uniform wavefronts in spontaneously 
beating syncytia of HL-1 cells, and then silenced these syncytia completely in a 
dose-dependent fashion. Both the characterisation of the KATP current in HL-1 
cells, and the effects on rotational wavefronts of KATP activation are novel 
findings. Both KATP activation and inhibition appear to have anti-arrhythmic 
effects by different means. 
 
In the mouse heart, mRNA quantification supported existing literature that the 
ventricles have a different KATP subunit expression profile to the atria whereby 
Kir6.2/SUR2A predominates in the ventricle (Suzuki et al., 2001; Chutkow et al., 
2001; Flagg et al., 2008). Human whole heart mRNA quantification did not show 
the same results. The pore-forming subunits were equally expressed 
throughout the four heart chambers, SUR1 appeared to not be expressed, and 
SUR2B was consistently expressed more than SUR2A. Whilst this was whole 
heart RNA and does not explore expression in different cellular populations, it 
infers that human cardiac KATP expression is different to the mouse as 
suggested by existing literature (Fedorov et al., 2011). Thus, it may well be 
possible to create an atrial specific anti-arrhythmic therapy using KATP 
modulation in the mouse, but whether this can be translated to humans requires 
further dissection. 
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4.2 KATP subunit pharmacology 
 
I utilised HEK293 cells overexpressing KATP channels of varying subunit 
composition. With 3mM ATP and 1mM ADP in the intracellular solution I was 
able to delineate through whole cell patch clamp of these cells, that diazoxide 
100µM is a relatively specific activator of SUR1-containing channels though 
also activates weakly SUR2B-containing channels. Pinacidil 10µM is an 
activator of SUR2A- and SUR2B-containing channels. Tolbutamide 100µM is a 
relatively specific inhibitor for SUR1-containing channels. This is all in keeping 
with current literature (Ashfield et al., 1999; Uhde et al., 1999; Babenko et al., 
2000; Moreau et al., 2000; Dabrowski et al., 2002; Moreau et al., 2005a; 
2005b). 
 
Of perhaps more interest, is that I found PNU37883A 50µM to be a relatively 
specific inhibitor for all Kir6.1-containing channels relative to those containing 
Kir6.2. Some groups have demonstrated a specificity for Kir6.1- over Kir6.2-
containing KATP channels when expressed with SUR1 or SUR2B in Xenopus 
laevis oocytes, and activated pharmacologically by diazoxide (Surah-Narwal et 
al., 1999; Kovalev et al., 2004). The IC50 for Kir6.1/SUR1 was ~30µM and for 
Kir6.1/SUR2B ~5µM. This is in contrast to the results seen by another group, 
whereby SUR2B-containing channels in general were inhibited selectively 
regardless of the pore-forming subunit, with an IC50 of 15.2µM for Kir6.2-
containing channels, and 6µM for Kir6.1-containing channels (Cui et al., 2003). 
In the same series of experiments 100µM of PNU37883A was required to inhibit 
to only less than 40% of the BaCl2 sensitive current in Kir6.2/SUR1 and 
Kir6.2/SUR2A channels, thus demonstrating a SUR2B-containing channel 
selectivity of the drug. The results of Cui and colleagues do not dispute the pore 
as the site of block. The current from a truncated form of Kir6.2 (Kir6.2Δ26), 
which can be expressed at the cell surface in the absence of SUR, was also 
inhibited by PNU37883A (Cui et al., 2003). Kovalev and colleagues also 
demonstrated that the C-terminus of the pore was important for drug effect 
(Kovalev et al., 2004). However, the experiments of Cui and colleagues 
delineated an interaction of the SUR subtype in composition with the pore, 
which then conferred selective inhibition to the drug. There were differences in 
the experimental conditions between the studies. Cui and colleagues, for 
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example, expressed channels in HEK293 cells and used metabolic inhibition to 
activate current. The authors stipulate that differences in nucleotide 
concentrations can affect the action of both KCOs and inhibitors as evidenced 
by various studies (Jahangir et al., 1994; Gribble et al., 1997b; D'hahan et al., 
1999; Reimann et al., 2003). In my experiments HEK293 cells were used ruling 
out this as the cause for the differences, and activating pharmacologically with 
3mM ATP/ 1mM ADP in the pipette solution, PNU37883A 50µM appears to 
selectively inhibit Kir6.1-containing channels over those containing Kir6.2. 
 
PNU37883A 50µM also had off-target effects as indicated by its inhibition of 
basal current beyond that induced with the non-specific KATP inhibitor 
glibenclamide. A caveat to this is that the inhibitory effects of both PNU37883A 
and glibenclamide are potentiated in each others' presence (Ohrnberger et al., 
1993). Though in my experiments the drugs were applied separately and 
PNU37883A has been seen to have effects on other non-KATP targets in other 
studies (Teramoto, 2006a). Despite this, given the clarity of PNU37883A 
inhibition for Kir6.1-containing channels after pharmacological KATP activation in 
my experiments, under certain experimental conditions the drug appears to be 
a reasonable tool to distinguish between each pore-forming subunit. 
 
Also of note, discrepancies exist between the results of selective inhibition by 
HMR1098 (Gögelein et al., 1998; Russ et al., 2001; Manning Fox et al., 2002; 
Zhang et al., 2011). Under the experimental conditions in this study, no 
apparent selectivity was seen, and HMR1098 10µM inhibited both SUR1- and 
SUR2A-containing channels equally, thus limiting its utility at distinguishing 
between them. 
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4.3 Kir6.2 is the predominant pore-forming subunit, but is there 
a role for Kir6.1 in murine atrial cardiomyocytes? 
 
An overwhelming message from these experiments is that Kir6.2 is the 
predominant sarcolemmal KATP pore-forming subunit in murine atrial 
cardiomyocytes. Whilst not thought to be active under baseline physiological 
conditions due to inhibiting concentrations of ATP, the data from this study 
suggest that Kir6.2 does contribute to the resting membrane potential in 
isolated cells. Kir6.2 deletion produced more depolarised cells at baseline. 
Kir6.1-containing channels have an inherent greater open probability at rest due 
to differing sensitivity to the co-expressed SUR in combination, and differing 
sensitivity to ADP (Satoh et al., 1998; Babenko & Bryan, 2001). Vascular 
smooth muscle cells contain Kir6.1-containing KATP channels (Cui et al., 2002) 
and in vascular smooth muscle, KATP channels have been shown to contribute 
to the resting membrane potential even under resting conditions (Teramoto, 
2006b). Whilst Kir6.2 is strongly inhibited by Mg2+-independent ATP, co-
expression with SUR sensitises the KATP pore to release from ATP inhibition by 
Mg2+-dependent ATP hydrolysis to MgADP, with ensuing conformational 
change of the channel and pore opening. SUR1 in particular is more sensitising 
than, for example, SUR2A (Babenko & Bryan, 2001). Whilst I did not see a 
significant inhibition beyond baseline on application of tolbutamide in wild-type 
atrial cardiomyocytes, this was administered alongside diazoxide and not in 
isolation, and in HEK293 cells overexpressing Kir6.2/SUR1 KATP channels there 
was always a degree of run-up of current at baseline during dialysis of pipette 
solution (see representative trace in figure 3.4). This run-up was seen to a 
lesser degree in murine atrial cardiomyocytes (see figure 3.17). The data 
suggest there is at least a small population of KATP channels open under basal 
conditions in these atrial cardiomyocytes, contributing to setting of the resting 
membrane potential, and Kir6.2 deletion removes this. An alternative 
explanation is that there is an indirect effect through other ion channel 
remodelling but this was not investigated. There were other consistencies, not 
least that the tolbutamide-sensitive current was abolished with Kir6.2 deletion. 
Kir6.2-deleted atrial cardiomyocytes were not hyperpolarised on application of 
diazoxide in comparison to wild type and Kir6.1-gKO cells. Similarly, unlike 
control cells, diazoxide failed to shorten the APD in Kir6.2-gKO atrial 
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cardiomyocytes. Kir6.2 is crucial to the sarcolemmal KATP current in murine 
atrial cardiomyocytes and this is consistent with the existing literature. 
 
What is interesting is the increase in tolbutamide-sensitive current in the Kir6.1-
gKO. This might be due to a replacement of Kir6.1 by Kir6.2 with its greater 
unitary conductance. The relative expression of Kir6.2 mRNA was not increased 
in the Kir6.1-gKO, but this does not alone rule out a greater expression of 
surface protein. One group has demonstrated the presence of a KATP current in 
neonatal rat atrial appendage cardiomyocytes with a single channel 
conductance of 58pS (Baron et al., 1999). This is intermediate between that of 
Kir6.1 and Kir6.2 and suggests the possibility of a heteromultimeric pore. This 
was re-enforced when the group also demonstrated a significant band for Kir6.1 
on RT-PCR of RNA extracted from these cultured cells. Another group 
recognised a differential basal activity of wild-type atrial and ventricular rat 
cardiomyocytes in the presence of 84µM intracellular ADP suggesting that there 
might be a presence of Kir6.1 (Poitry et al., 2003), and others demonstrated 
reductions in KATP current after separately electroporating pore-loop-mutated 
Kir6.1 and Kir6.2 constructs into both rat atrial and ventricular cardiomyocytes 
(van Bever et al., 2004). This all suggests there is the presence of at least some 
sarcolemmal Kir6.1 in rodent atrial cardiomyocytes and would support my 
findings. Any contribution of Kir6.1 is small, and not able to compensate for 
complete deletion of Kir6.2 as demonstrated by a failure to see a 
pharmacologically activated KATP current in these cells. Any pharmacologically 
activated current might also be very subtle if the Kir6.1 population is already 
open at baseline. Whilst it did not reach statistical significance, there was 
always a very small inhibition compared to baseline with glibenclamide in these 
cells. 
 
The tissue electrophysiology of whole heart atria is, therefore, even more 
intriguing. The ERP at baseline was prolonged in both the Kir6.1-gKO and the 
Kir6.2-gKO when compared to WT. In the latter this can be explained by the 
data pertaining to the more depolarised resting membrane potential in the 
Kir6.2-gKO, and the difference in slopes and crossover of the models for 
momentary membrane potential during the action potential between the 
knockout and wild type. Whilst the APDs were not different, ERP prolongation 
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here is almost certainly as a factor of a mechanism akin to post-repolarisation 
refractoriness (Cranefield et al., 1971; Lazzara et al., 1975; Davidenko & 
Antzelevitch, 1986). It is likely in the Kir6.2-gKO that there is a reduced 
proportion of the sodium channel population that has recovered from 
inactivation at any moment during repolarisation, particularly towards the end of 
repolarisation where the models cross at APD70. Beyond this point in the 
models, the Kir6.2-gKO has a more positive membrane potential than the WT. 
Markov models predict that the availability of sodium channels, and calcium 
channels with a longer period of recovery from inactivation, will be reduced for 
any shorter coupled extra-stimulus arriving in this critical period (O'Hara et al., 
2011). Activation of the tissue is less likely as the peak amplitude of the source 
current will be reduced, and the sink too is likely to have a higher resistance 
due to the more depolarised state of the tissue as a whole, with a reduced 
probability of activating surrounding cells whose inactivation-recovered sodium 
channel population is also depleted (Davidenko & Antzelevitch, 1986). 
 
If the unifying model for APD at any particular percentage repolarisation in the 
isolated cells (see section 3.3.6) is extrapolated using the mean measured 
values for ERP of the tissue, the ERP of the WT corresponds to ~APD50 and the 
ERP of the Kir6.2-gKO corresponds to ~APD60. Isolated myocytes were 
stimulated at 1Hz and the S1 drive train interval for programmed electrical 
stimulation of tissue was 120ms and this will incur differences in APD, but 
bearing this in mind estimates using the models can be made. For example, 
using the separate models for membrane potential at any particular percentage 
repolarisation (see section 3.3.6), at ERP in the WT the membrane potential 
approximates ~9mV and in the Kir6.2-gKO ~-3mV. There are a number of ways 
to interpret this. These of course are only approximate values from a model, 
and isolated cells are not tissue. Had monophasic action potentials or 
transmembrane action potentials been recorded from the tissue then different 
models may have been produced, and the ERPs might have fallen longer than 
a crossover point in models for membrane potential at any percentage of 
repolarisation. This would have set up a simpler explanation that the WT 
exhibited less post-repolarisation refractoriness secondary to more 
hyperpolarised membrane potentials in the critical late repolarisation zone. 
Alternatively, the values are taken on face value, and it is not inconceivable that 
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the Kir6.2-gKO tissue would need a more negative membrane potential at 
moment of stimulus to propagate activation through the tissue as a whole based 
on the concepts as previously described with regards effects of the sink 
(Cranefield et al., 1971; Lazzara et al., 1975; Davidenko & Antzelevitch, 1986). 
 
It follows that steady state conduction velocity and that at shorter coupling 
intervals, should be reduced in the Kir6.2-gKO on similar grounds to that of 
ERP prolongation. There was a trend to a reduction in Vmax of the upstroke of 
the action potential in isolated atrial cardiomyocytes of the Kir6.2-gKO mouse. 
 
It is perhaps unsurprising then that Kir6.2 deletion should lead to profound 
effects on ERP during hypoxia. Hypoxia reduces activity of all membrane 
currents in cardiomyocytes, barring the late persistent sodium current, reverse 
mode of the INa/Ca current, and of course KATP (Saint et al., 1992; Ju et al., 1996; 
Hammarström & Gage, 2002; Wang et al., 2007; Shimoda & Polak, 2011; Tang 
et al., 2012). As a result the action potential amplitude is reduced, action 
potential duration is shortened, and the resting membrane potential becomes 
more depolarised. I have shown how deletion of Kir6.2 causes a more 
depolarised resting membrane potential even under baseline conditions. 
Further compromise to this during hypoxia without compensation by deleted 
Kir6.2-containing KATP channels, would almost certainly lead to ERP 
prolongation through further post-repolarisation refractoriness. APD is also likely 
to be longer in hypoxic Kir6.2-deleted atrial cardiomyocytes, as suggested by a 
lack of APD shortening with diazoxide in this study, and demonstration of this 
previously with metabolic inhibition in cardiomyocytes (Nichols et al., 1991). 
These mechanisms are presumably at play for tolbutamide's effects in the WT 
and Kir6.1-gKO, owing to a block of the active Kir6.2-containing population. 
Ultimately, it is a purpose of KATP, to prevent complete hypoxic contractile failure 
due to failure of other membrane currents and cellular depolarisation. Action 
potential shortening also leads to reduced toxic calcium loading on the cell, both 
through reduced L-type calcium current entry, and given a localisation of KATP 
channels in the Z-groove, most probably reduced calcium-induced calcium 
release at the sarcoplasmic reticulum (Korchev et al., 2000). Kir6.2 is crucial to 
this in murine atria and the murine heart as a whole. 
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If the tolbutamide-sensitive current in isolated Kir6.1-gKO atrial myocytes is 
increased, it is paradoxical that ERP should be prolonged and the CV reduced 
in atrial tissue of these mice. Possibilities include an up-regulation of Kir6.2 only 
in isolated cells, or that there might be a subcellular localisation of Kir6.1-
containing channels that is important only in tissue. For example, KATP channels 
are known to localise to the Z-groove, and also associate with junctional 
proteins at the intercalated disk in cardiac myocytes (Korchev et al., 2000; Hong 
et al., 2012). KATP, like other potassium channels, are likely to be very important 
in modulating and improving saltatory conduction between cardiac myocytes 
through this junctional protein interaction (Vermij et al., 2017). If Kir6.1 were to 
preferentially localise to channels at the intercalated disk, deletion would be 
expected to have a significant effect on tissue conduction properties as we have 
seen in this study, and have a similar effect on tissue refractoriness to that of 
Kir6.2 deletion. An up-regulation of compensatory Kir6.2 may only be 
detectable in membranes of enzymatically-dissociated cells where the 
intercalated disk has been disrupted. An alternative explanation is that the 
electrophysiological effects of Kir6.1 deletion are indirect and occur through its 
deletion in other cellular populations. Kir6.1 is a prominent vascular smooth 
muscle cell KATP subunit and mice with global deletion of Kir6.1 exhibit coronary 
ischaemia and hypertension (Miki et al., 2002; Aziz et al., 2014). Kir6.1 has also 
been shown to be the pore-forming subunit making up the endothelial KATP 
channel and endothelial conditional knockout leads to a failure to vasodilatate 
the coronary bed during hypoxia leading to larger infarct size (Aziz et al., 2017). 
The effects of increased afterload and ischaemia in a Kir6.1 global knockout 
might lead to widespread cardiac fibrosis. Absence of a cardioprotective effect 
of Kir6.2 deletion might also lead to the same. I have as yet not looked for 
histological changes in the atria of either pore-forming knockout mice but one 
might expect to see such changes. With cellular injury fibroblasts differentiate 
into myofibroblasts, which cause a degree of cellular uncoupling and conduction 
slowing due to differences in ion channel expression and inefficiencies in 
saltatory cardiac conduction (Rohr, 2012). Where they do form gap junctions, 
they exert a depolarising effect on adjacent cardiomyocytes as they themselves 
sit at a more depolarised resting membrane potential (Nguyen et al., 2014). 
This effect would tend to produce a similar functional consequence as seen in 
the action potentials of the Kir6.2-gKO isolated atrial cardioyocytes and may 
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well offer another reasonable explanation behind the changes in tissue 
electrophysiology seen in the Kir6.1-gKO. 
 
In keeping with the critical mass hypothesis, in that a threshold size of tissue 
would be required to sustain a re-entrant arrhythmia, early thoughts were the 
mouse heart, and in particular murine atria, would be too small to fibrillate 
(Garrey, 1914; 1924). This has been subsequently challenged by various 
models of AF in the mouse (Riley et al., 2012). The ratio of murine atrial 
circumference to atrial wavefront path length is also not dissimilar to that of 
larger mammals (Kaese & Verheule, 2012). 
 
However, whilst the consensus for the duration of a sustained arrhythmia in the 
human is defined as 30 seconds, there is no such consensus for the mouse. 
The multitude of published models of murine AF display a variety of cut-offs for 
duration of sustained arrhythmia, and they also demonstrate a variety of 
methods to induce arrhythmia including both programmed electrical stimulation 
and burst pacing (Riley et al., 2012). Arguments could be made then that the 
exact arrhythmogenic mechanism being explored actually differs between these 
studies, re-entrant vs triggered. In general, certainly clinically in humans, 
arrhythmias induced to programmed electrical stimulation are thought to 
represent re-entrant activity. In attempting, then, to explore the effects of 
wavefront path length on re-entrant arrhythmia inducibility, I used programmed 
electrical stimulation to induce arrhythmia. Utilising the existing literature, I used 
a conservative cut-off of 500ms or longer for an arrhythmia to be considered 
sustained. 
 
Kir6.2-gKO atria displayed an absence of arrhythmia inducibility to programmed 
electrical stimulation through the hypoxia/washout 20-minute protocol. This was 
not observed in the Kir6.1-gKO. A natural explanation for this is the absence of 
minimum wavefront path length shortening in the Kir6.2-gKO compared to the 
WT and Kir6.1-gKO mice, such that re-entrant activity is favoured in the WT and 
Kir6.1-gKO. The effects of tolbutamide administration on PES-induced 
arrhythmia inducibility in hypoxic WT and Kir6.1-gKO murine atria was also 
compared. Whilst sustained arrhythmias were seen in the atria of untreated 
hearts, none were seen in tolbutamide-treated hearts though this did not reach 
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statistical significance. Small numbers, though, might have led to an 
inappropriately powered study in this aspect.  
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4.4 KATP channel activation organises rotational wavefronts to 
straight uniform wavefronts, and slows automaticity 
 
The finding of this project that potassium channel activation can lead to 
organisation of rotational wavefronts is very intriguing. The classic theories 
behind re-entry, either functional or around an anatomical obstacle, revolve 
around the notion of a critical mass of tissue required to set up the wavefronts 
(Garrey, 1914; Rensma et al., 1988; Kim et al., 1997). This critical mass is in 
part dependent on the minimum wavefront path length required to set up a re-
entrant wave, and this is defined by the product of conduction velocity and 
effective refractory period of the tissue (Allessie et al., 1977). Any intervention 
that leads to prolongation of ERP, would lead to WFPL prolongation and a 
reduced likelihood of re-entrant waves sustaining themselves. On this basis the 
mode of action of anti-arrhythmic drugs is thought mainly to be driven by ERP 
prolongation, though more recently, reduction of tissue excitability by sodium 
channel blockade has been apportioned to the anti-arrhythmic effects of 
flecainide on spiral waves, through reducing the angle of curvature at the centre 
of the rotor and increasing the excitable gap (Coronel et al., 2012; Pandit & 
Jalife, 2013; Osadchii, 2017). This too can be expected to increase the WFPL 
and for a given tissue mass reduce the likelihood of multiple re-entrant waves. 
However, pharmacological intervention, or invasive catheter ablation of AF are 
not always met with success. The basic premise of catheter ablation is isolation 
of the pulmonary veins from the body of the left atrium to eliminate drivers from 
the pulmonary veins (Haïssaguerre et al., 1998). Techniques evolved to 
demonstrate that wide antral circumferential ablation was superior to ostial 
pulmonary vein isolation (Proietti et al., 2014). This was deemed due to not only 
eliminating exit of drivers from the pulmonary veins, but also debulking the left 
atrium in general and reducing the volume of tissue that could sustain re-entry. 
 
The opening of KATP channels leads to faster repolarisation and a shorter QT 
interval on the surface ECG, a marker of the activation-recovery interval 
(Kubota et al., 1993; Lu et al., 2008). In turn this gives a reduced effective 
refractory period, which in principle can predispose to re-entrant circuits and a 
pro-fibrillatory state. Pro-fibrillatory effects of KATP openers have been shown in 
the ventricle in numerous animal models and a major factor in this is likely to 
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involve heterogeneous dispersion of APD effects both in an interventricular, and 
intraventricular manner between layers of the myocardium (Wolleben et al., 
1989; Chi et al., 1990; Furukawa et al., 1991; Di Diego & Antzelevitch, 1993; 
Wolk et al., 1999; Uchida et al., 1999; Quintanilla et al., 2013). 
 
The corollary is that blocking KATP would be anti-arrhythmic. Studies in rat and 
canine models have looked at ventricular fibrillatory potential in the context of 
ischaemia and shown that this is reduced in the presence of KATP blocking 
drugs (Wolleben et al., 1989; Kantor et al., 1990; Billman et al., 1998). This has 
been replicated in a Langendorff-perfused explanted cardiomyopathic human 
heart model (Farid et al., 2011).  
 
Studies have also investigated arrhythmia inducibility in atrial preparations. In a 
rat model isoproterenol-induced metabolic stress led to a reduced intracellular 
ATP concentration and an increased atrial tachyarrhythmia inducible state that 
was reversed with the KATP inhibitor glibenclamide (Kim et al., 2012). In a 
murine model with salt-induced hypertension, atrial KATP upregulation was seen 
coinciding with shortened APD and ERP and increased atrial arrhythmia 
inducibility (Lader et al., 2011). In human hearts obtained at transplantation, 
KCOs were seen to increase atrial arrhythmia inducibility that was then 
terminated with a KATP inhibitor (Fedorov et al., 2011). 
 
It has also been demonstrated, however, that AF initiation is dependent on 
other factors such as APD and CV restitution at shorter coupling intervals, 
where steeper restitution slopes (>1) are associated with enhanced wavebreak 
and fibrillatory conduction (Qu et al., 1999; Weiss et al., 1999). The 
spatiotemporal heterogeneity of restitution is also important in causing 
wavebreak (Cao et al., 1999; Banville & Gray, 2002). More recently, it has also 
been shown that conduction slowing is important at the moment of AF initiation, 
as is a heterogeneity of conduction slowing across the atria for perseveration of 
AF (Narayan et al., 2008; Lalani et al., 2012; Krummen et al., 2012; Lim et al., 
2017; Honarbakhsh et al., 2018). Potassium channel blocking drugs such as 
sotalol demonstrate reverse use dependence with greater block at longer 
diastolic intervals and steepen the APD restitution slope (Lathrop et al., 1989; 
1990). I saw a hyperpolarisation of the resting membrane potential with KATP 
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activation in HL-1 cells. Potassium channel activation, by hyperpolarising the 
membrane potential, could actually serve to increase conduction velocity by 
increasing sodium channel availability. Atria are less thick than the ventricles 
and the degree of transmural and spatial heterogeneity of KATP expression 
across the atria has not been described like it has in the ventricle. The effects of 
KATP opening in the HL-1 syncytia might be a uniform phenomenon and serve to 
homogenise conduction velocity across the tissue sheet. Increasing conduction 
velocity should serve to increase the minimum wavefront path length and 
reduce the likelihood of re-entrant activation. KATP opening may also reduce 
APD and CV restitution slopes, or at least shift them leftwards to shorter 
coupling intervals, and in a uniform manner if there is no significant gradient of 
ion channel expression, like what might be expected in the HL-1 syncytia. This 
would need to be explored further to prove but might explain the organisation of 
rotational activity seen. 
 
Whilst channel opening might open up tissue to the increased likelihood of re-
entry, in the case of abnormal automaticity or triggered activity, it is also 
possible that hyperpolarisation of the membrane will lead to the arrhythmia 
being extinguished. Effects of KATP modulation on automaticity have largely 
been investigated in isolated nodal cell or Purkinje fibre preparations and 
confirm that an increased outward potassium flux and membrane 
hyperpolarisation on channel opening slows spontaneous firing rate and 
suppresses automaticity (Yanagisawa & Taira, 1981; Satoh & Hashimoto, 1984; 
Imanishi et al., 1984; Lathrop et al., 1990). In my series of experiments, further 
to organising rotational wavefronts, KATP activation then silenced HL-1 syncytia 
in a dose-dependent fashion. This could be explained by further 
hyperpolarisation leading to reduced automaticity. Similarly, it may merely be an 
effect of reduced excitability of the HL-1 syncytia, that prevented curvature of 
rotational wavefronts, and organisation to a straight wavefronts. 
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4.5 Pharmacological KATP activation does not impact on sinus 
node automaticity 
 
Further to the finding that increased doses of diazoxide could silence HL-1 
syncytia, and work from our lab that a large proportion of murine SAN cells were 
diazoxide-sensitive (Aziz et al., 2018), I sought to establish whether 
pharmacological KATP activation could have an SAN slowing effect. This was not 
the case but KATP inhibition was able to blunt the SAN slowing effects of 
hypoxia. Similar effects have been shown in a Kir6.2 -/- mouse (Fukuzaki et al., 
2008). Hypoxia and metabolic inhibition are inherently potent activators of KATP 
and perhaps more so than pharmacological activation alone, especially if the 
current density for KATP is small in the sinus node compared to atria as our lab 
has demonstrated through this and a previous study (~20pA/pF vs ~130pA/pF 
in atrial cardiomyocytes) (Aziz et al., 2018). During hypoxia, the activity of the 
inward calcium currents and calcium release from the sarcoplasmic reticulum 
are reduced (Shimoda & Polak, 2011), and a reduction in circulating cAMP from 
reduced availability of ATP is likely to contribute to reduced If current. Taken 
together hyperpolarisation from hypoxia induced KATP activation is likely to slow 
diastolic depolarisation and pacemaker activity further. 
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4.6 Human cardiac KATP 
 
The data from this project suggests one major difference in the subunit 
composition of the KATP current in the human heart as compared to that of the 
mouse. SUR1 expression appeared very low in the "normal" human heart. One 
group have demonstrated a failure to shorten action potential duration on 
administration of diazoxide in non-failing human heart atria, but the opposite in 
the failing heart (Fedorov et al., 2011). Pinacidil was able to shorten action 
potentials in both scenarios. A high dose of diazoxide was used, 300µM, and 
thus this could represent SUR2B activation, or even SUR2A activation in the 
presence of a high concentration of MgADP. Another group have shown a lack 
of inhibition by tolbutamide in human right atrial cardiac myocytes (Zünkler et 
al., 1997). SUR2-specific KATP openers have also been shown to activate 
current in human atrial cardiomyocytes (Pelzmann et al., 2001; Balana et al., 
2003). Inferences on the differential cardiomyocyte composition of subunits 
other than SUR1 is difficult when utilising whole heart RNA. SUR2B is likely to 
be expressed in the endothelium and smooth muscle cell populations that make 
up the total RNA, and this probably explains a large relative expression of this 
subunit in my results given that non-myocytes in the heart constitute ~70% of 
cells, and endothelial cells alone are said to constitute >60% of this non-
myocyte population (Pinto et al., 2016). Single cell RNA quantification from 
isolated cardiomyocytes is likely to yield more meaningful information, and 
single cell electrophysiology using the pharmacological tools established in this 
project could further delineate the subunit composition of human 
cardiomyocytes. 
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4.7 Clinical implications and translational aspects 
 
In a murine model, this study has demonstrated KATP inhibition to have anti-
arrhythmic effects on the atria in the context of ischaemia. Conduction velocity 
is slowed during hypoxia, and thus inhibition of a potassium channel that is 
strongly activated by hypoxia, and shortens APD during hypoxia, will counter 
these WFPL shortening effects by prolonging the ERP. This paradigm might be 
useful in the context of ischaemia driven atrial arrhythmias during, for example, 
the peri-procedural period of cardiac surgery where there is a high burden of 
post-operative AF and potassium channel blocking drugs such as amiodarone 
already provide a benefit (Budeus et al., 2006). If an atrial selective KATP blocker 
can be developed then this might also have benefit during the peri-myocardial-
infarct period where AF burden is also high. Amiodarone is the most effective 
drug in this context but carries with it the risk of many side effects. There are 
various series commenting on the pro- and anti-arrhythmic effects of 
sulphonylureas used in diabetic patients. These were usually in the context of 
ischaemia, specifically with respect to ventricular fibrillation, and the findings are 
equivocal (Leonard et al., 2017). These series are also observational and 
naturally, therefore, heterogeneous. There are no such data pertaining to the 
prevalence of atrial arrhythmias or its burden amongst this patient cohort. 
 
The alternative paradigm raised by this study is that potassium channel 
activation can be anti-arrhythmic. Myocardial sleeves and strands extend from 
the left atrium into the pulmonary veins producing a distinct architecture 
including areas of fibrosis and conduction slowing (Saito et al., 2000; Ho et al., 
2001; Mueller-Hoecker et al., 2008). Fibroblast differentiation to myfibroblasts is 
a precursor step to the development of fibrosis and the latter are more 
depolarised at rest lacking the ionic currents required of specialised 
cardiomyocytes (Camelliti et al., 2005; Nguyen et al., 2014). This contributes to 
conduction slowing and, through electrotonic interaction, is likely to have a 
depolarising effect on adjacent pulmonary vein (PV) myocytes, and those in the 
atrial body, where a fibrotic histopathological substrate is also stipulated in the 
mechanism of chronic AF (Schotten et al., 2011; Rohr, 2012; Nguyen et al., 
2014). PV myocytes have been shown to have a more depolarised resting 
membrane potential, lower peak amplitude and shorter action potential duration 
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(Ehrlich et al., 2003). They also display automaticity with expression of 
pacemaker-like currents including ICaT and a hyperpolarisation-activated cation 
current akin to the "funny" current (Cheung, 1981a; Chen et al., 2004; Ehrlich et 
al., 2004). Enrichment of transcription factors, PITX2 and SHOX2, known to 
control the development of nodal and pacemaking regions of the heart, has 
been shown at the LA-PV junction (Yeh et al., 2013). PV myocytes have also 
displayed calcium-handling abnormalities and develop EADs and DADs that 
can give rise to triggered activity, and atrial cardiomyocytes from patients with 
chronic AF demonstrate abnormal calcium handling with enhanced SR calcium 
leak and INa/Ca function (Cheung, 1981b; Chen et al., 1999; Wit & Boyden, 2007; 
Schotten et al., 2011; Voigt et al., 2012). Whilst cholinergic activity would be 
expected to shorten APD and increase the likelihood of re-entry, M3 muscarinic 
receptors also lead to increased calcium release from SR stores via the Gq 
receptor pathway and it may be that calcium handling is an all-important factor 
here in the generation of cholinergic AF. It is conceivable, therefore, that 
potassium channel activation alone, in reducing calcium loading on the cell and 
providing an opposing current to depolarisation, reduce the likelihood of 
triggered or automatic activity that might drive AF. It might also have a 
homogenising effect on conduction velocity and APD restitution that serves to 
reduce the likelihood of wavebreak and acts to organise rotational wavefronts 
as has been seen in this study. 
 
KATP opening has cardioprotective effects not least owing to reducing the 
calcium load on the myocyte. There may be other, indirect, positive cardiac 
effects of KATP activation. Diazoxide was first explored clinically for its anti-
hypertensive effect through vascular smooth muscle relaxation (McNair et al., 
1983). In the more modern era it is used to suppress insulin secretion in 
hyperinsulinaemic hypoglycaemic patients (Nessa et al., 2016). It is a drug with 
fully established pharmacokinetics and safety characteristics with no associated 
increased risk of arrhythmias (Welters et al., 2015). 
 
It has also been shown through its pancreatic and central effects, to improve 
glycaemic control in type 1 diabetics, ameliorate beta-cell function in type 2 
diabetics, and lead to weight loss in obese patients (Qvigstad et al., 2004; 
Schreuder et al., 2005; van Boekel et al., 2008; Radtke et al., 2010). Recent 
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good evidence shows that obesity and epicardial fat have a clear association 
with promoting an AF substrate. Diazoxide could have a multi-dimensional 
action in reducing the burden of AF not only via a direct electrophysiological 
effect of KATP opening, but also by favourable metabolic effects. 
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4.8 Limitations 
 
Further to limitations previously mentioned through the discussion, attention 
must be drawn to others. 
 
The mouse model brings with it limitations with regards differences in action 
potential characteristics compared to human, owing to differences in calcium 
handling and repolarising currents. The KATP subunit composition in the murine 
heart is likely to be different from that of the human as has been alluded to. 
 
In the quantitative mRNA analysis, GAPDH was used as a sole reference gene. 
An ideal reference gene is one that has completely stable expression across 
developmental stages, disease states, different tissue/cell types and different 
tissue preparations. No commonly used reference gene can be said to truly 
exhibit this though some show more stability than others and GAPDH tends to 
be one of the more stable (Vandesompele et al., 2002; Brattelid et al., 2010). 
Knockout of the pore-forming subunits in itself may have affected GAPDH 
expression stability, though demonstration of the absence of expression of the 
pore-forming subunit in question in each of the global knockout mice is not in 
doubt given the clear and profound evidence for deletion in the quantification 
analysis. Caution must, however, be exercised when analysing expression 
differences between the other subunits. Equally we do not know the exact 
contribution of different cell types in each of the tissue samples used, though 
the mean of various preparations was taken, and the variation is accounted for 
in the statistical testing. Whilst making inferences into absolute expression 
differences and proportions would be unwise, it is reasonable to observe and 
accept the trends in differences in subunit expression, and much of the data 
pertaining to quantitative mRNA analysis in the mouse is supported by the 
electrophysiology and pharmacology also presented. The same qualms 
described above would apply to the human quantitative mRNA analysis 
Undoubtedly the purest and most ideal approach, is to use the geometric mean 
of a number, usually a minimum of three, different reference genes deemed 
most stable amongst the different cell types in the tissue preparation of interest 
(Vandesompele et al., 2002). 
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HL-1 syncytia are representative of 2D sheets of tissue and not likely to be 
more than 2 to 3 cells thick. Whole heart tissue is not a 2D sheet and cardiac 
conduction is a 3D phenomenon. A corollary to this is the measurement of 
conduction velocity in the Langendorff preparation was performed solely on the 
epicardial surface in a 2D format and does not account for wavefront paths 
passing transmurally. Whilst also there was a large drive to manually check the 
quality of electrograms, and the method used to measure conduction velocity 
has been validated previously (Finlay et al., 2014), there is always the 
possibility of error with regards electrogram quality. 
 
Arrhythmia induction protocols have already been mentioned in that they could 
be more aggressive. The definition of arrhythmia including a single ectopic 
could be seen as too sensitive, though this was a standardised approach and 
ectopy was only taken in response to programmed electrical stimulation.  
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4.9 Future directions 
 
A thorough assessment of the KATP current in isolated human cardiomyocytes is 
needed. The pharmacological tools with patch clamp demonstrated in this 
project could be used. It is my plan to perform this on isolated cardiomyocytes 
from tissue obtained from patients undergoing cardiothoracic surgery under the 
auspices of The Barts Cardiovascular Registry. I would also include an 
assessment of nicorandil in these experiments. Isolated cardiomyocyte single 
cell RNA quantification could also be compared. Atrial tissue is easier to obtain 
from a risk balance perspective, though it may also be possible to obtain 
ventricular myocardial samples from, for example, septal myectomy patients 
with hypertrophic cardiomyopathy, and also make a direct comparison of atrial 
and ventricular KATP pharmacology through patch clamp of these cells.  
 
Further assessments of the conduction velocity across the HL-1 syncytia would 
be possible through utilisation of the electrograms obtained through the MEA. 
An assessment of calcium transient characteristics under control 
circumstances, and in response to diazoxide, including peak amplitude, 
duration at half-maximum amplitude, time to peak and tau could all be assessed 
under uniform frequency by pacing through the MEA. After-depolarisations 
could also be assessed both through stimulation at high frequencies to induce 
calcium loading, or even in the presence of caffeine, and any suppression of 
diazoxide examined. This could also be performed in Langendorff preparations 
looking at ectopic and arrhythmia burden in control and knockout mouse hearts 
in response to diazoxide +/- caffeine. 
 
Given diazoxide is a fully established drug with known safety profile and 
pharmacokinetics, it is conceivable that a clinical trial be performed looking at its 
effects in patients with AF. Similarly, given nicorandil is a widely used drug in 
patients with cardiac ischaemia for improved symptoms of angina, and that it 
does not appear to have pro-arrhythmic effects in the ventricle, it too could be 
assessed for an atrial anti-arrhythmic effect. 
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